JP2016056142A - Combination of pde10a inhibitor and antipsychotic drug - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a novel schizophrenia therapeutic drug which can reduce the side effects caused by antipsychotic drugs while maintaining the efficacy, by reducing dosage of combined antipsychotic drugs.SOLUTION: The invention provides a medicament for the treatment of schizophrenia characterized by administering a compound represented by general formula (I) in combination with at least one kind of antipsychotic drug. [Ris a C1-C3 alkyl group, etc.; Ris a C1-C3 alkoxy C1-C3 alkyl group, etc.; Ris C1-C6 alkyl group, etc.; Rand Rare, each independently, a C1-C6 alkyl group which may be substituted by a hydrogen atom, a hydroxy group, etc., or an (azetidine-1-yl) carbonyl group which may be substituted by a hydroxy group etc.; and at least one of Rand the Ris a hydrogen atom.]SELECTED DRAWING: None

Description

  The present invention relates to the treatment of schizophrenia comprising a combination of a phosphodiesterase 10A inhibitor (sometimes abbreviated as PDE10A inhibitor herein) and an antipsychotic agent.

  Schizophrenia develops during adolescence or early adulthood, presents with positive symptoms such as hallucinations delusions and excitement, and negative symptoms such as emotional dullness, poverty of thought, and reduced motivation. It tends to have a progressive course and tends to recur. It is a serious and important mental illness that affects a promising youth.

  Pharmacotherapy for schizophrenia consists of first-generation antipsychotics (FGA) (also called typical antipsychotics) and second-generation antipsychotics (SGA, second-generation antipsychotics) Called). FGA is a dopamine D2 receptor antagonist introduced in the 1950s, and SGA is an antipsychotic developed with the intention of reducing the side effects of FGA. In SGA, due to the difference in its mechanism of action, SDA (serotonin dopamine antagonist) such as risperidone, MARTA (multi-acting receptor targeted antipsychotics) such as quetiapine fumarate, and aripiprazole called DSS (dopamine system stabilizer) is there. The current mainstream of pharmacotherapy is SGA, but combination therapy with FGA or SGA with different mechanism of action is also being performed (Non-patent Document 1).

  Although SGA was developed with the intention of reducing the side effects of FGA, many have serious side effects. For example, extrapyramidal symptoms that cause the body to move unconsciously, hyperprolactinemia, which is a sex hormone abnormality, cardiovascular symptoms such as decreased blood pressure and ECG abnormalities, autonomic symptoms such as dry mouth and fluency, increased blood sugar levels, and There are obesity, etc., and SGA adherence is poor and is reported to be about 40% (non-patent document 2).

  As a mechanism of action different from existing SGA, it is known that inhibition of phosphodiesterase (hereinafter sometimes referred to as PDE) 10A can improve the positive symptoms, negative symptoms and / or cognitive impairment of schizophrenia. Furthermore, it is also known that schizophrenia can be treated (for example, Patent Documents 1 to 15 and Non-Patent Documents 3 to 10).

  PDE10A inhibitors functionally antagonize dopamine D2 receptor signals in the same way as existing antipsychotics by increasing cAMP (cyclic adenosine monophosphate) levels, but PDE10A is hardly present in the periphery and is not present in the brain. Then it is localized in the striatum and nucleus accumbens. In addition, it is known that a PDE10A inhibitor increases a phosphorylated protein of a glutamate receptor through enhancement of protein kinase A (PKA) signal by increasing cAMP level (Non-patent Document 11).

WO2004 / 002484 WO2006 / 034491 WO2006 / 072828 WO2007 / 077490 WO2007 / 129183 WO2008 / 001182 WO2008 / 004117 WO2008 / 084299 WO2009 / 158393 WO2009 / 158473 WO2010 / 057121 WO2010 / 057126 WO2010 / 090737 WO2012 / 124782 WO2012 / 133607

Sperm Journal, 115 (7): 774-781, 2013 J Clin Psychiatry, 67 (10): 1542-1550, 2006 Journal of Medicinal Chemistry, 2009, 52, 5188-5196 The Journal of Pharmacology and Experimental Therapeutics, Vol.325, No.2, 681-690, 2008 European Journal of Neuroscience, Vol.21, pp.1070-1076, 2005 Journal of Neurochemistry, 2008, 105, 546-556 The Journal of Pharmacology and Experimental Therapeutics, Vol.331, No.2, 574-590, 2009 Journal of Medicinal Chemistry, 2011, 54, 7621-7638 Neuropharmacology 2012, 62: 1371-1380 Neuropharmacology 2013, 64: 215-223 J Pharmacol Exp Ther, 331: 574-590, 2009

  Under the background as described above, an object of the present invention is to provide a drug capable of reducing the dose required for the efficacy of an antipsychotic drug and reducing the side effects caused by the antipsychotic drug by combining the drugs.

  The present inventor first reduced the dose required for the efficacy of an existing antipsychotic drug by combining an existing antipsychotic drug (FGA and SGA) with a different mechanism of action and an existing antipsychotic drug, We conducted intensive research on the belief that side effects based on existing antipsychotic drugs can be reduced while maintaining their efficacy.

  The present inventor has found that PDE10A inhibitors have extremely few side effects compared to existing atypical antipsychotics, and also have an effect on negative symptoms and / or cognitive impairment as well as positive symptoms of schizophrenia. I thought it was supposed. Therefore, the combination of a selective PDE10A inhibitor and an existing antipsychotic can reduce the dose required for the efficacy of the existing antipsychotic and reduce the side effects of the existing antipsychotic while maintaining the efficacy. Thought.

  As a result, the present inventor reduces the dose required for the efficacy of the antipsychotic drug by combining the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof with an existing antipsychotic drug, The inventors have found that the side effects of antipsychotic drugs can be reduced while maintaining their medicinal effects, and have completed the present invention.

The present invention is as follows.
(1) A method for treating schizophrenia, wherein a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug are administered in combination: For medicine.

In the present invention, the following can be preferably mentioned.
(2) The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent are contained as active ingredients of different preparations at the same time or at different times. The medicament according to (1), which is administered.
(3) The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug are contained in a single preparation (1) The medicament according to 1.
(4) The medicament according to (1), which is a kit preparation comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent.
(5) From (1) to (4), intended for patients undergoing treatment with a pharmaceutical composition containing the compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient The medicament according to any one of selected.
(6) The medicament according to any one of (1) to (4), which is intended for a patient who is receiving treatment with an antipsychotic drug.
(7) R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, and R ⁴ and R ⁵ are each independently , A hydrogen atom, a C1-C3 alkyl group optionally substituted with one substituent selected from substituent group α, or one substituent selected from substituent group α. Or (azetidin-1-yl) carbonyl group, and the substituent group α is a group consisting of a hydroxy group, a C1-C3 alkoxy group, and a hydroxypyrrolidine group, provided that at least one of R ⁴ and R ⁵ is hydrogen The medicament according to any one of (1) to (6), which is an atom.
(8) R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, R ⁴ is a hydrogen atom, R ⁵ Is substituted with one C1-C3 alkyl group substituted with one hydroxy group, C1-C3 alkyl group substituted with one C1-C3 alkoxy group, or substituted with one C1-C3 alkoxy group at the 3-position The pharmaceutical according to any one of (1) to (6), which is a (azetidin-1-yl) carbonyl group.
(9) R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, and R ⁴ is one (3-hydroxy The pharmaceutical according to any one of (1) to (6), which is a C1-C3 alkyl group substituted with a pyrrolidin-1-yl) group, and R ⁵ is a hydrogen atom.
(10) A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof,
7-acetyl-N- (4-((4-hydroxypiperidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide,
7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide,
(S) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide,
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide,
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide hydrochloride,
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide p-toluenesulfonate,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride ,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide benzenesulfone Acid salt,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide methanesulfone Acid salt,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p- Toluene sulfonate,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide bromide Hydrogenates,
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide,
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide hydrochloride,
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide methanesulfonate,
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide hydrobromide,
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide,
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride,
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide methanesulfonate,
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide,
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride,
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide methanesulfonate,
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrobromide,
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p-toluenesulfonate,
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide half ethane-1,2-disulfonate,
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide,
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride, or
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrobromide The medicine according to any one of (1) to (6).
(11) A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof,
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p- Toluene sulfonate,
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride, or
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide from (1) to (6) which is hydrochloride The medicament according to any one of selected.
(12) Antipsychotic drugs
4- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -1- (4-fluorophenyl) butan-1-one,
3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -2-methyl-6,7,8,9-tetrahydro-4H -Pyrido [1,2-a] pyrimidin-4-one,
Cis-N- [4- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] butyl] cyclohexane-1,2-dicarboximide,
(9RS) -3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -9-hydroxy-2-methyl-6,7 , 8,9-Tetrahydro-4H-pyrido [1,2-a] pyrimidin-4-one,
5- [2- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] ethyl] -6-chloro-1,3-dihydro-2H-indol-2-one,
Trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz [2,3: 6,7] oxepino [4,5-c] pyrrole,
(3aR, 4S, 7R, 7aS) -2-{(1R, 2R) -2- [4- (1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl] cyclohexylmethyl} hexahydro-4, 7-methano-2H-isoindole-1,3-dione,
2- (4-ethyl-1-piperazinyl) -4- (4-fluorophenyl) -5,6,7,8,9,10-hexahydrocycloocta [b] pyridine,
2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol,
2-methyl-4- (4-methylpiperazin-1-yl) -10H-thieno [2,3-b] [1,5] benzodiazepine,
8-chloro-11- (4-methylpiperazin-1-yl) -5H-dibenzo [b, e] [1,4] diazepine,
7- [4- [4- (1-benzothiophen-4-yl) piperazin-1-yl] butoxy] quinolin-2 (1H) -one, or
7- [4- [4- (2,3-dichlorophenyl) -1-piperazinyl] butoxy] -3,4-dihydro-2 (1H) -quinolinone or a pharmaceutically acceptable salt thereof (1) to The medicament according to any one of (11), selected from (11).
(13) Antipsychotic drugs
4- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -1- (4-fluorophenyl) butan-1-one,
3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -2-methyl-6,7,8,9-tetrahydro-4H -Pyrido [1,2-a] pyrimidin-4-one,
2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol, or
7- [4- [4- (2,3-dichlorophenyl) -1-piperazinyl] butoxy] -3,4-dihydro-2 (1H) -quinolinone or a pharmaceutically acceptable salt thereof (1) to The medicament according to any one of (11), selected from (11).
(14) Antipsychotic drugs
4- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -1- (4-fluorophenyl) butan-1-one,
3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -2-methyl-6,7,8,9-tetrahydro-4H -Pyrido [1,2-a] pyrimidin-4-one,
2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol hemi-fumarate, or
7- [4- [4- (2,3-dichlorophenyl) -1-piperazinyl] butoxy] -3,4-dihydro-2 (1H) -quinolinone, any one selected from (1) to (11) The medicine according to one item.
(15) A method for treating schizophrenia, comprising administering a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof in combination with at least one antipsychotic agent: .

(Where
R ¹ is a hydrogen atom or a C1-C3 alkyl group,
R ² is a hydrogen atom, a C1-C3 alkylcarbonyl group, a hydroxy C1-C3 alkyl group or a C1-C3 alkoxy C1-C3 alkyl group,
R ³ is a C1-C6 alkyl group or a C3-C6 cycloalkyl group,
R ⁴ and R ⁵ are each independently selected from a hydrogen atom, a C1-C6 alkyl group optionally substituted with one substituent selected from substituent group α, or a substituent group α. (Azetidin-1-yl) carbonyl group optionally substituted by one substituent,
Substituent group α is a group consisting of a hydroxy group, a C1-C6 alkoxy group, a methylsulfonyl group, a hydroxypyrrolidine group, and a hydroxypiperidine group,
Provided that at least one of R ⁴ and R ⁵ is a hydrogen atom)
(16) The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one kind of antipsychotic drug are contained as active ingredients of different preparations at the same time or at different times. The method according to (15), which is administered.
(17) The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug are contained in a single preparation (15) The treatment method according to 1.
(18) The treatment method according to (15), which is a kit preparation comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug .
(19) From (15) to (18) intended for patients undergoing treatment with a pharmaceutical composition containing a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient The treatment method as described in any one selected.
(20) The treatment method according to any one of (15) to (18), which targets a patient who is receiving treatment with an antipsychotic drug.
(21) R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, R ⁴ is a hydrogen atom, R ⁵ Is substituted with one C1-C3 alkyl group substituted with one hydroxy group, C1-C3 alkyl group substituted with one C1-C3 alkoxy group, or substituted with one C1-C3 alkoxy group at the 3-position The therapeutic method according to any one of (15) to (20), which is a (azetidin-1-yl) carbonyl group.
(22) R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, and R ⁴ is one (3-hydroxy The treatment method according to any one of (15) to (20), which is a C1-C3 alkyl group substituted with a pyrrolidin-1-yl) group, and R ⁵ is a hydrogen atom.
(23) A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof,
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p- Toluene sulfonate,
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride, or
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide from (15) to (20) which is hydrochloride The treatment method as described in any one selected.
(24) Antipsychotic drugs
4- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -1- (4-fluorophenyl) butan-1-one,
3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -2-methyl-6,7,8,9-tetrahydro-4H -Pyrido [1,2-a] pyrimidin-4-one,
2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol hemi-fumarate, or
7- [4- [4- (2,3-dichlorophenyl) -1-piperazinyl] butoxy] -3,4-dihydro-2 (1H) -quinolinone, any one selected from (15) to (23) The treatment method according to one item.

  In the present specification, the “C1-Cn alkyl group” refers to a linear or branched alkyl group having 1 to n carbon atoms. Examples of the C1-C3 alkyl group include a methyl group, an ethyl group, a propyl group, and an isopropyl group. Examples of the C1-C6 alkyl group include a butyl group, isobutyl group, tert-butyl group, pentyl group, 1-ethylpropyl group, hexyl group and the like in addition to the C1-C3 alkyl group.

  In the present specification, the “C1-C3 alkylcarbonyl group” refers to a carbonyl group to which the “C1-C3 alkyl group” is bonded. Examples of the C1-C3 alkylcarbonyl group include an acetyl group, a propionyl group, and a propylcarbonyl group.

  In the present specification, the “hydroxy C1-C3 alkyl group” refers to a group in which at least one hydrogen atom of the “C1-C3 alkyl group” is substituted with a hydroxy group. Examples of the hydroxy C1-C3 alkyl group include a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, and a 1-hydroxypropyl group.

  In the present specification, the “C1-Cn alkoxy group” refers to a group in which the “C1-Cn alkyl group” is bonded to an oxygen atom. Examples of the C1-C3 alkoxy group include a methoxy group, an ethoxy group, a propoxy group, and an isopropoxy group. Examples of the C1-C6 alkoxy group include a butyloxy group and a hexyloxy group in addition to the C1-C3 alkoxy group.

  In the present specification, the “C1-C3 alkoxy C1-C3 alkyl group” refers to a group in which at least one hydrogen atom of the “C1-C3 alkyl group” is substituted with the “C1-C3 alkoxy group”. Examples of the C1-C3 alkoxy C1-C3 alkyl group include a methoxymethyl group, an ethoxymethyl group, a propoxymethyl group, and a 1-methoxyethyl group.

  In the present specification, the “C 3 -C 6 cycloalkyl group” refers to a saturated cyclic hydrocarbon group having 3 to 6 carbon atoms. Examples of the C3-C6 cycloalkyl group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.

  In the present specification, the “C1-Cn alkyl group optionally substituted with one substituent” means that one hydrogen atom of the “C1-Cn alkyl group” may be substituted with a substituent. Refers to the group.

  In the present specification, the “optionally substituted (azetidin-1-yl) carbonyl group” is a group in which one hydrogen atom of the azetidine ring may be substituted with a substituent. Say.

  As used herein, “pharmaceutically acceptable salt” refers to a salt formed by reacting a compound of the present invention with an acid or a base.

  Salts include hydrohalides such as hydrofluoride, hydrochloride, hydrobromide and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate and phosphate Methanesulfonate, trifluoromethanesulfonate, lower alkanesulfonates such as ethanesulfonate; arylsulfonates such as benzenesulfonate, p-toluenesulfonate; acetate, malate, fumarate Acid salts, succinates, citrates, ascorbates, tartrate, oxalates, maleates, and other organic acid salts; sodium, potassium, lithium, and other alkali metal salts; calcium salts, magnesium salts Alkaline earth metal salts such as: aluminum salts, metal salts such as iron salts, inorganic salts such as ammonium salts, t-octylamine salts, dibenzylamine salts, morpholine salts, Glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N, N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine Salts, amine salts such as organic salts such as N-benzylphenethylamine salt, piperazine salt, tetramethylammonium salt, tris (hydroxymethyl) aminomethane salt; glycine salt, lysine salt, arginine salt, ornithine salt, glutamate salt, aspartic acid And amino acid salts such as salts.

  The compound represented by the general formula (I) of the present invention, for example, may be left in the atmosphere to absorb moisture and be adsorbed water to form a hydrate. A solvate is also included in the compound represented by the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof.

  Since the compound of the present invention may have an asymmetric carbon atom in the molecule, a stereoisomer exists. These stereoisomers and mixtures of stereoisomers are all represented by a single formula, that is, general formula (I). Accordingly, the present invention includes all of these stereoisomers and a mixture of these stereoisomers in an arbitrary ratio. The definition of stereoisomer is as shown in “1996 IUPAC, Pure and Applied Chemistry 68, 2193-2222”.

The present invention can also include compounds in which one or more of the atoms that constitute a compound of the present invention is replaced by an isotope of that atom. There are two types of isotopes, radioactive isotopes and stable isotopes. Examples of isotopes include hydrogen isotopes ( ² H and ³ H), carbon isotopes ( ¹¹ C, ¹³ C and ¹⁴ C), nitrogen isotopes ( ¹³ N and ¹⁵ N), oxygen isotopes ( ¹⁵ O, ¹⁷ O and ¹⁸ O), fluorine isotopes ( ¹⁸ F) and the like. A composition containing a compound labeled with an isotope is useful, for example, as a therapeutic agent, prophylactic agent, research reagent, assay reagent, diagnostic agent, in vivo diagnostic imaging agent, and the like. Isotopically labeled compounds are also encompassed by the compounds of the invention, and any mixture of isotope-labeled compounds in any proportion is also encompassed by the compounds of the invention. The isotope-labeled compound of the present invention can be produced by a method known in the art, for example, by using an isotope-labeled raw material instead of the raw material in the production method of the present invention described later. .

  The invention can also include prodrugs of the compounds of the invention. A prodrug is a derivative of a compound of the present invention and refers to a compound that is enzymatically or chemically converted into the compound of the present invention in vivo.

  Prodrugs of the compounds of the present invention include compounds in which the hydroxy group in the molecule is acylated, alkylated, phosphorylated, etc. (for example, Povl Krogsgaard-Larsen et al., “Text Book of Drug Design and Development” 4th edition, CRC Press, 2009, pages 135-149). Such prodrugs can be produced from the compounds of the present invention by methods known in the art.

R ¹ is preferably a hydrogen atom, a methyl group or an ethyl group, more preferably a methyl group or an ethyl group, and even more preferably a methyl group.

R ² is preferably a hydrogen atom, acetyl group, propionyl group, hydroxymethyl group, 1-hydroxyethyl group, 1-methoxyethyl group, methoxymethyl group, ethoxymethyl group, propoxymethyl group or isopropoxymethyl group. More preferably, it is a methoxymethyl group.

R ³ is preferably a C1-C3 alkyl group or a C3-C6 cycloalkyl group, more preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a 1-ethylpropyl group, A tert-butyl group, a cyclopropyl group, a cyclobutyl group or a cyclopentyl group, and even more preferably a methyl group.

R ⁴ is preferably a hydrogen atom, a C1-C3 alkyl group which may be substituted with one substituent selected from substituent group α, or one substituent selected from substituent group α. (Azetidin-1-yl) carbonyl group optionally substituted with a group, more preferably a hydrogen atom, a methyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group, (3-hydroxypiperidin-1-yl) methyl group or (4-hydroxypiperidin-1-yl) methyl group, even more preferably a hydrogen atom, 2 -Hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group or (4-hydroxypiperidin-1-yl) methyl group.

R ⁵ is preferably a hydrogen atom, a C1-C3 alkyl group optionally substituted with one substituent selected from substituent group α, or one substituent selected from substituent group α. (Azetidin-1-yl) carbonyl group optionally substituted with a group, more preferably a hydrogen atom, a methyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxypropan-2-yl group, Methoxymethyl group, ethoxymethyl group, methylsulfonylmethyl group, (3-hydroxypyrrolidin-1-yl) methyl group, (3-hydroxyazetidin-1-yl) carbonyl group or (3-methoxyazetidin-1-yl) A carbonyl group, more preferably a hydrogen atom, a hydroxymethyl group, a methoxymethyl group, a methylsulfonylmethyl group or a (3-methoxyazetidin-1-yl) carbonyl group.

  The substitution group α is preferably a group consisting of a hydroxy group, a C1-C3 alkoxy group, a methylsulfonyl group, a hydroxypyrrolidine group and a hydroxypiperidine group, and more preferably a hydroxy group, a methoxy group, an ethoxy group, and a methylsulfonyl group. , 3-hydroxypyrrolidine group, 3-hydroxypiperidine group and 4-hydroxypiperidine group.

A preferred combination of R ¹ , R ² , R ³ , R ⁴ and R ⁵ is that R ¹ is a hydrogen atom, a methyl group or an ethyl group, and R ² is a hydrogen atom, an acetyl group, a propionyl group or a hydroxymethyl group. 1-hydroxyethyl group, 1-methoxyethyl group, methoxymethyl group, ethoxymethyl group, propoxymethyl group or isopropoxymethyl group, and R ³ is a C1-C3 alkyl group or a C3-C6 cycloalkyl group R ⁴ is a hydrogen atom, a C1-C3 alkyl group which may be substituted with one substituent selected from substituent group α, or one substituent selected from substituent group α. A C1-C3 alkyl group which is an optionally substituted (azetidin-1-yl) carbonyl group, and R ⁵ is optionally substituted with one substituent selected from a hydrogen atom and a substituent group α. Or one substituent selected from substituent group α It is an optionally substituted (azetidin-1-yl) carbonyl group, and a combination in which at least one of R ⁴ and R ⁵ is a hydrogen atom.

A more preferred combination of R ¹ , R ² , R ³ , R ⁴ and R ⁵ is that R ¹ is a hydrogen atom, methyl group or ethyl group, and R ² is a hydrogen atom, acetyl group, propionyl group, hydroxymethyl Group, 1-hydroxyethyl group, 1-methoxyethyl group, methoxymethyl group, ethoxymethyl group, propoxymethyl group or isopropoxymethyl group, R ³ is methyl group, ethyl group, propyl group, isopropyl group, butyl Group, isobutyl group, 1-ethylpropyl group, tert-butyl group, cyclopropyl group, cyclobutyl group or cyclopentyl group, and R ⁴ is a hydrogen atom, methyl group, hydroxymethyl group, 1-hydroxyethyl group, 2- Hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group, (3-hydroxypiperidin-1-yl) methyl group or (4-hydroxypiperidine-1 -Yl) methyl group, and R ⁵ is a hydrogen atom, methyl group, hydroxymethyl group, 1-hydroxyethyl group, 2-hydroxypropan-2-yl group, methoxymethyl group, ethoxymethyl group, methylsulfonylmethyl group. , (3-hydroxypyrrolidin-1-yl) methyl group, (3-hydroxyazetidin-1-yl) carbonyl group or (3-methoxyazetidin-1-yl) carbonyl group, and R ⁴ and R ⁵ A combination in which at least one is a hydrogen atom.

An even more preferred combination of R ¹ , R ² , R ³ , R ⁴ and R ⁵ is that R ¹ is a methyl group, R ² is a methoxymethyl group, R ³ is a methyl group, and R ⁴ is A hydrogen atom, 2-hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group or (4-hydroxypiperidin-1-yl) methyl group, R ⁵ is a hydrogen atom, hydroxymethyl Group, a methoxymethyl group, a methylsulfonylmethyl group or a (3-methoxyazetidin-1-yl) carbonyl group, and a combination in which at least one of R ⁴ and R ⁵ is a hydrogen atom.

A particularly preferred combination of R ¹ , R ² , R ³ , R ⁴ and R ⁵ is that R ¹ is a methyl group, R ² is a methoxymethyl group, R ³ is a methyl group, and R ⁴ is a hydrogen atom Or a combination in which R ⁵ is a hydroxymethyl group, a methoxymethyl group or a (3-methoxyazetidin-1-yl) carbonyl group, or R ¹ is a methyl group and R ² is a methoxymethyl group , R ³ is a methyl group, R ⁴ is a (R)-(3-hydroxypyrrolidin-1-yl) methyl group, and R ⁵ is a hydrogen atom.

  Increased locomotor activity in rats induced by repeated administration of phencyclidine (PCP), which has been reported as an excellent animal model of schizophrenia (Neurochem. Int., 51: 173-184, 2007) When the effect of the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof was examined, a significant inhibitory action was observed. In animal models of schizophrenia, among the existing antipsychotic drugs, FGA haloperidol, SGA risperidone, quetiapine fumarate, and aripiprazole were also confirmed to have an inhibitory effect, and the above-mentioned inhibitory action alone. It was confirmed that a combination of 1/3 of the indicated dose was effective.

  It has been clarified that the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof shows an improving effect in an animal model of schizophrenia based on PDE10A inhibitory activity. Among the existing antipsychotic drugs, haloperidol FGA, risperidone SGA, quetiapine fumarate, and aripiprazole were also found to have an inhibitory effect. Furthermore, it was found that when the compound of the present invention and these antipsychotic drugs were used in combination, it was effective at a dose of 1/3 of the minimum effective dose that showed an inhibitory action alone. Therefore, the present invention can provide a new therapeutic agent for schizophrenia.

FIG. 1 is a graph showing the inhibitory effect of oral administration of haloperidol (0.1, 0.3, 1 mg / kg) on spontaneous locomotor activity in rats induced by repeated PCP administration. Physiological saline or PCP (2 mg / kg) is subcutaneously administered once a day for 5 days. Solvent or haloperidol (0.1, 0.3, 1 mg / kg) is orally administered about 1 hour before PCP only on the fifth day. did. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (each group n = 9). *** p <0.001: Significantly different from vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 2 is a graph showing the inhibitory effect of oral administration of risperidone (0.1, 0.3, 1 mg / kg) on the spontaneous locomotor activity induced by repeated PCP administration. Saline or PCP (2 mg / kg) is subcutaneously administered once a day for 5 days, and solvent or risperidone (0.1, 0.3, 1 mg / kg) is orally administered about 1 hour before PCP on the fifth day only. did. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (each group n = 9). * p <0.05, *** p <0.001: Significantly different from the vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 3 is a graph showing the inhibitory effect of oral administration of quetiapine fumarate (10, 30, 100 mg / kg) on spontaneous locomotor activity in rats induced by repeated PCP administration. Physiological saline or PCP (2 mg / kg) was subcutaneously administered once a day for 5 days, and solvent or quetiapine fumarate (10, 30, 100 mg / kg) was administered about 1 hour before PCP only on the fifth day Was orally administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (each group n = 8-9). * p <0.05: Significantly different from the solvent + PCP administration group (Dunnett multiple comparison test). FIG. 4 is a graph showing the inhibitory effect of oral administration of aripiprazole (10, 30, 100 mg / kg) on the spontaneous motor activity increase in rats induced by repeated PCP administration. Saline or PCP (2 mg / kg) is subcutaneously administered once a day for 5 days. Solvent or aripiprazole (10, 30, 100 mg / kg) is orally administered only about 5 hours before PCP administration. did. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (each group n = 8-9). * p <0.05: Significantly different from the solvent + PCP administration group (Dunnett multiple comparison test). FIG. 5 is a graph showing the inhibitory effect of oral administration of Example 39 (3, 10, 30 mg / kg) on spontaneous locomotor activity in rats induced by repeated PCP administration. Saline or PCP (2 mg / kg) was subcutaneously administered once a day for 5 days. Solvent or Example 39 (3, 10, 30 mg / kg) was administered about 1 hour before PCP administration only on the 5th day. Orally administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (n = 6 for each group). ** p <0.01: Significantly different from the solvent + PCP administration group (Dunnett multiple comparison test). FIG. 6 is a graph showing the inhibitory effect of oral administration of Example 68 (0.3, 1, 3 mg / kg) on the spontaneous locomotor activity in rats induced by repeated PCP administration. Physiological saline or PCP (2 mg / kg) was subcutaneously administered once a day for 5 days, and solvent or Example 68 (0.3, 1, 3 mg / kg) was administered about 1 hour before PCP administration only on the 5th day. Orally administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (n = 5-6 for each group). *** p <0.001: Significantly different from vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 7 is a graph showing the inhibitory effect of oral administration of Example 77 (0.3, 1, 3 mg / kg) on the spontaneous locomotor activity in rats induced by repeated administration of PCP. Physiological saline or PCP (2 mg / kg) was subcutaneously administered once a day for 5 days, and solvent or Example 77 (0.3, 1, 3 mg / kg) was administered about 1 hour before PCP administration only on the 5th day. Orally administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (n = 5-6 for each group). ** p <0.01, *** p <0.001: Significantly different from the vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 8 is a graph showing the inhibitory effect of oral administration of Example 106 (0.3, 1, 3 mg / kg) on the spontaneous locomotor activity induced by repeated PCP administration. Saline or PCP (2 mg / kg) was subcutaneously administered once a day for 5 days, and solvent or Example 106 (0.3, 1, 3 mg / kg) was administered about 1 hour before PCP only on the fifth day. Orally administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (each group n = 9). *** p <0.001: Significantly different from vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 9 is a graph showing an inhibitory effect of the combination of an antipsychotic drug and 1/3 dose of the minimum effective dose of Example 39 on the spontaneous locomotor activity in rats induced by repeated PCP administration. Physiological saline or PCP (2 mg / kg) is subcutaneously administered once a day for 5 days, and only on the 5th day, 1/3 of the solvent or minimum effective dose of antipsychotic (haloperidol 0.3 mg / kg, risperidone 0.1 mg / kg, quetiapine fumarate 30 mg / kg, aripiprazole 30 mg / kg) and 1/3 of the minimum effective dose of Example 39 (3 mg / kg) were orally administered continuously about 1 hour before PCP administration Administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (n = 6 for each group). *** p <0.001: Significantly different from vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 10 is a graph showing the inhibitory effect of a combination of an antipsychotic drug and 1/3 dose of the minimum effective dose of Example 68 on the spontaneous locomotor activity in rats induced by repeated PCP administration. Physiological saline or PCP (2 mg / kg) is subcutaneously administered once a day for 5 days, and only on the 5th day, 1/3 of the solvent or minimum effective dose of antipsychotic (haloperidol 0.3 mg / kg, risperidone 0.1 mg / kg, quetiapine fumarate 30 mg / kg, aripiprazole 30 mg / kg) and 1/3 of the minimum effective dose of Example 68 (1 mg / kg) were orally administered continuously about 1 hour before PCP administration Administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (n = 6 for each group). *** p <0.001: Significantly different from vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 11 is a graph showing the inhibitory effect of combined use of an antipsychotic drug and 1/3 of the minimum effective dose of Example 77 on the spontaneous locomotor activity in rats induced by repeated PCP administration. Physiological saline or PCP (2 mg / kg) is subcutaneously administered once a day for 5 days, and only on the 5th day, 1/3 of the solvent or minimum effective dose of antipsychotic (haloperidol 0.3 mg / kg, risperidone 0.1 mg / kg, quetiapine fumarate 30 mg / kg, aripiprazole 30 mg / kg) and 1/3 of the minimum effective dose of Example 77 (0.3 mg / kg) were orally administered continuously about 1 hour before PCP administration Administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (n = 5-6 for each group). *** p <0.001: Significantly different from vehicle + PCP administration group (Dunnett multiple comparison test). FIG. 12 is a graph showing the inhibitory effect of a combination of an antipsychotic drug and 1/3 of the minimum effective dose of Example 106 on the spontaneous locomotor activity induced by repeated administration of PCP. Physiological saline or PCP (2 mg / kg) is subcutaneously administered once a day for 5 days, and only on the 5th day, 1/3 of the solvent or minimum effective dose of antipsychotic (haloperidol 0.3 mg / kg, risperidone 0.1 mg / kg, quetiapine fumarate 30 mg / kg, aripiprazole 30 mg / kg) and 1/3 of the minimum effective dose of Example 106 (0.3 mg / kg) were orally administered continuously approximately 1 hour before PCP administration Administered. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. The vertical axis represents the distance traveled by the rat for 60 minutes (unit: m). The results are shown as mean ± standard error (n = 6 for each group). ** p <0.01, *** p <0.001: Significantly different from the vehicle + PCP administration group (Dunnett multiple comparison test).

  The compound of the present invention can be produced, for example, by the following method.

  In the production method described below, depending on the type of functional group, it is effective in terms of production technology to replace the functional group with a suitable protecting group (a group that can be easily converted into the functional group) from the raw material to the intermediate stage. There are cases. Examples of such a functional group include an amino group, a hydroxy group, a formyl group, a carboxy group, and the like, and the protecting group is not particularly limited as long as it is a commonly used protecting group, for example, Theodora W. Protective groups described in Greene and Peter GM Wuts, Greene's Protective Groups in Organic Synthesis. Fourth Edition, John Wiley & Sons, Inc., and the like. The reaction for introducing these protecting groups and the reaction for removing the protecting groups can be carried out according to conventional methods such as the methods described in the above-mentioned documents.

The compounds of the present invention can be produced, for example, by the following method:

Can be manufactured according to. In the formula, R ¹ , R ² , R ³ , R ⁴ and R ⁵ are the same as described above.

  In this reaction, the compound (1) and the compound (2) are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction at room temperature to 80 ° C., usually for 1 hour to 7 days. Is done by doing. This reaction may be performed in the presence of a base. Examples of the solvent include, but are not limited to, dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide (hereinafter sometimes referred to as “DMF”), N, N-dimethylacetamide, and the like. The condensing agent is not particularly limited as long as it is used in the amidation reaction. For example, carbodiimides such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, carbodiimides and 1-hydroxy Combination with N-hydroxy compounds such as -7-azabenzotriazole, combination of carbodiimides and N, N-dimethyl-4-aminopyridine, 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (below , Such as “PyBOP”), O- (1H-benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate (hereinafter referred to as “HBTU”). ) And the like. Examples of the base include triethylamine, N, N-diisopropylethylamine, potassium carbonate and the like.

  Compound (2) may be a commercially available product or a known compound, or can be produced using the methods described in Reference Examples and Examples below, known methods, or modifications thereof. Compound (1) can be produced, for example, using the following method, the methods described in Reference Examples and Examples below, known methods, or modifications thereof.

Compound (1) can be prepared, for example, by the following method:

Can be manufactured according to. In the formula, X is a halogen atom, and R ¹ , R ² and R ³ are the same as described above. Compound (3) may be a commercially available product or a known compound, or can be produced using the methods described in Reference Examples and Examples below, known methods, or modifications thereof.

  The first step is a step of producing compound (4) from compound (3). In this step, compound (3) and base are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction at −78 to −40 ° C., usually for 10 minutes to 5 hours, and then DMF is added. Usually, it is carried out by stirring for 10 minutes to 5 hours. The solvent is not particularly limited, and examples thereof include tetrahydrofuran (hereinafter sometimes referred to as “THF”). Examples of the base include lithium diisopropylamide and lithium tetramethylpiperidide. Lithium diisopropylamide can be prepared by mixing N, N-diisopropylamine and n-butyllithium, and lithium tetramethylpiperidide can contain 2,2,6,6-tetramethylpiperidine and n-butyllithium. It can be prepared by mixing.

  The second step is a step of producing compound (5) from compound (4). This step is carried out by using an equivalent amount of compound (4) and an alkylating agent or an excess of one of them, and stirring in a solvent inert to the reaction at −80 ° C. to room temperature, usually for 10 minutes to 24 hours. Although it does not specifically limit as a solvent, THF, toluene, etc. are mentioned. Examples of the alkylating agent include halogenated C1-C3 alkylmagnesium (eg, methylmagnesium bromide, ethylmagnesium bromide, etc.), diC1-C3 alkylzinc (eg, diethylzinc, etc.), and the like.

  The third step is a step of producing compound (6) from compound (5). This step can be performed by Method A or Method B.

(Method A)
In this method, compound (5) and N-methylmorpholine-N-oxide are used in an equivalent amount or in excess, and in a solvent inert to the reaction, in the presence of tetrapropylammonium perruthenate, 0 to 50 ° C. And is usually carried out by stirring for 10 minutes to 3 hours. The solvent is not particularly limited, and examples thereof include acetonitrile.

(Method B)
In this method, compound (5) and sodium hypochlorite are used in an equivalent amount or in excess, and in a solvent inert to the reaction, 2-azaadamantane-N-oxyl, potassium bromide, tetrabutylammonium bromide and It is carried out by stirring in the presence of a saturated aqueous sodium hydrogen carbonate solution at −20 ° C. to room temperature, usually 30 minutes to 6 hours. Although it does not specifically limit as a solvent, A dichloromethane etc. are mentioned.

  The fourth step is a step of producing compound (7) from compound (4) or compound (6). In this step, compound (4) or compound (6) and ethyl thioglycolate are used in an equivalent amount or in excess, and in a solvent inert to the reaction, in the presence of a base at 0 to 50 ° C., usually 1 Performed by stirring for -24 hours. The solvent is not particularly limited, and examples thereof include DMF. Examples of the base include potassium carbonate and 1,8-diazabicyclo [5.4.0] -7-undecene.

  The fifth step is a step of producing compound (8) from compound (7). This step can be performed by Method C, Method D, or Method E.

(Method C)
This method can be carried out by Step A and Step B.
(Process A)
In this step, compound (7) and (1-ethoxyvinyl) tributyltin are used in an equivalent amount or in excess of one and in a solvent inert to the reaction in the presence of a catalyst at 60 to 150 ° C., usually 1 to 48. This is done by stirring for a period of time. This step is preferably performed in an inert gas atmosphere. Although it does not specifically limit as a solvent, Toluene etc. are mentioned. Examples of the catalyst include dichlorobis (triphenylphosphine) palladium (II). Examples of the inert gas include argon and nitrogen.
(Process B)
It is carried out by using the compound obtained in step A and hydrochloric acid in an equivalent amount or one of them in excess, and stirring in a solvent inert to the reaction at 0 to 50 ° C., usually for 1 to 48 hours. Although it does not specifically limit as a solvent, Toluene, ethanol, THF, etc. are mentioned.

(Method D)
This method can be performed by Step C and Step D.
(Process C)
In this step, compound (7) and trimethylsilylacetylene are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction in the presence of a catalyst at 50 to 120 ° C., usually for 1 to 48 hours. Done. This step is preferably performed in an inert gas atmosphere. The solvent is not particularly limited, and examples include triethylamine, a mixed solvent of triethylamine and THF, and the like. Examples of the catalyst include copper (I) iodide, copper (I) bromide, dichlorobis (triphenylphosphine) palladium (II), tetrakis (triphenylphosphine) palladium (0), and the like. Examples of the inert gas include argon and nitrogen.
(Process D)
In this step, the compound obtained in Step C and p-toluenesulfonic acid monohydrate are used in an equivalent amount or in excess, and in a solvent inert to the reaction, at 50 to 120 ° C., usually for 1 to 48 hours. This is done by stirring. Although it does not specifically limit as a solvent, Acetic acid, chloroform, etc. are mentioned.

(Method E)
In this method, compound (7) and isopropyl magnesium chloride are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction at −78 to −40 ° C., usually for 10 minutes to 3 hours. It is carried out by adding I) and lithium chloride and usually stirring for 10 minutes to 3 hours, and then adding C ₁ -C ₆ alkylcarbonyl halide or C ₃ -C ₆ cycloalkylcarbonyl halide and usually stirring for 30 minutes to 6 hours. The solvent is not particularly limited, and examples thereof include THF.

  The sixth step is a step of producing compound (1) from compound (8). This step is carried out by using an equivalent amount of compound (8) and base or an excess of one, and stirring in a solvent inert to the reaction at 0 to 80 ° C., usually for 1 to 24 hours, and then adding an acid. . Examples of the solvent include, but are not limited to, a single solvent such as water, ethanol, methanol, THF, 1,4-dioxane, a mixed solvent thereof, and the like. Examples of the base include sodium hydroxide and lithium hydroxide. Examples of the acid include hydrochloric acid.

  The compound of the present invention can be produced using the above-mentioned method, and can be easily produced from a known compound according to Reference Examples and Examples described later.

  As the antipsychotic agent in the present invention, for example, a first generation or second generation antipsychotic agent can be used. Examples of the first generation antipsychotics include phenothiazine derivatives, butyrophenone derivatives, benzamide derivatives, and the like. Examples of the phenothiazine derivative include chlorpromazine hydrochloride, levomepromazine, fluphenazine and the like, and preferably chlorpromazine hydrochloride is used. Examples of the butyrophenone derivative include haloperidol, haloperidol decanoate, bromoperidol, and preferably haloperidol is used. Examples of the benzamide derivative include sulpiride, sultopride hydrochloride, thiopride hydrochloride, etc., and preferably sulpiride is used. Examples of second generation antipsychotics include serotonin dopamine blockers (SDA), multi-receptor targeted drugs (MARTA), dopamine stabilizers (DSS), and the like. Examples of serotonin dopamine blockers include risperidone, perospirone hydrochloride hydrate, paliperidone, ziprasidone, asenapine, lurasidone, blonanserin and the like, and risperidone is preferably used. Examples of MARTA include quetiapine fumarate, olanzapine, and clozapine, and quetiapine fumarate is preferably used. DSS includes, for example, aripiprazole and is preferably used. An example of a dopamine D3 / D2 receptor partial agonist is cariprazine. An example of a dopamine D2 / 5-HT1A receptor partial agonist is brexpiprazole.

  Haloperidol is 4- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -1- (4-fluorophenyl) butan-1-one.

  Risperidone is 3- {2- [4- (6-fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -2-methyl-6,7,8,9 -Tetrahydro-4H-pyrido [1,2-a] pyrimidin-4-one.

  Perospirone is cis-N- [4- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] butyl] cyclohexane-1,2-dicarboximide.

  Paliperidone is (9RS) -3- {2- [4- (6-fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -9-hydroxy-2-methyl -6,7,8,9-tetrahydro-4H-pyrido [1,2-a] pyrimidin-4-one.

  Ziprasidone is 5- [2- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] ethyl] -6-chloro-1,3-dihydro-2H-indol-2-one It is.

  Asenapine is trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz [2,3: 6,7] oxepino [4,5-c] pyrrole.

  Lurasidone is (3aR, 4S, 7R, 7aS) -2-{(1R, 2R) -2- [4- (1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl] cyclohexylmethyl} Hexahydro-4,7-methano-2H-isoindole-1,3-dione.

  Blonanserin is 2- (4-ethyl-1-piperazinyl) -4- (4-fluorophenyl) -5,6,7,8,9,10-hexahydrocycloocta [b] pyridine.

  Quetiapine is 2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol.

  Olanzapine is 2-methyl-4- (4-methylpiperazin-1-yl) -10H-thieno [2,3-b] [1,5] benzodiazepine.

  Clozapine is 8-chloro-11- (4-methylpiperazin-1-yl) -5H-dibenzo [b, e] [1,4] diazepine.

  Blexpiprazole is 7- [4- [4- (1-benzothiophen-4-yl) piperazin-1-yl] butoxy] quinolin-2 (1H) -one.

  Aripiprazole is 7- [4- [4- (2,3-dichlorophenyl) -1-piperazinyl] butoxy] -3,4-dihydro-2 (1H) -quinolinone.

  In the present invention, the antipsychotic agent is, for example, water, acetic acid, acetone, anisole, 1-butanol, 2-butanol, n-butyl acetate, t-butyl methyl ether, dimethyl sulfoxide, ethanol, ethyl acetate, diethyl ether, formic acid. Ethyl, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2- A solvate can be formed by contacting with a solvent such as propanol or propyl acetate or a mixed solvent containing them, or by performing recrystallization using these solvents, and such a solvate can also be formed. To the antipsychotic or pharmaceutically acceptable salt of the present invention It is free. Preferred is a hydrate.

  For cis-N- [4- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] butyl] cyclohexane-1,2-dicarboximide, hydrochloride and dihydrate are preferable.

  For 5- [2- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] ethyl] -6-chloro-1,3-dihydro-2H-indol-2-one, Salt / hydrate or mesylate / trihydrate is preferred.

  For trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz [2,3: 6,7] oxepino [4,5-c] pyrrole, the maleate salt is preferred.

  (3aR, 4S, 7R, 7aS) -2-{(1R, 2R) -2- [4- (1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl] cyclohexylmethyl} hexahydro-4, For 7-methano-2H-isoindole-1,3-dione, the hydrochloride salt is preferred.

  For 2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol, the half fumarate is preferred.

  As shown in Test Example 1, the inhibitory effect on the spontaneous locomotor activity induced by repeated PCP administration was examined. Increased locomotor activity in rats and mice induced by PCP has been widely used as a method for evaluating the activity of novel therapeutic agents for positive symptoms of schizophrenia. The reason for this is that PCP causes psychiatric symptoms such as hallucinations and delusions in humans (Am J Psychiatry, 148 (10): 1301-1308, 1991), and increases locomotor activity in rats and mice. This is because it is suppressed by existing antipsychotic drugs (Neuropharmacology, 23: 175-181, 1984). In addition, repeated administration of PCP causes not only behavioral abnormalities similar to schizophrenia but also neuropathological changes observed in schizophrenic patients. Therefore, rats that have been repeatedly administered PCP are considered to be model animals that are closer to human pathology than single doses (Neurochem. Int., 51: 173-184, 2007). In this animal model, haloperidol (haloperidol injection, Dainippon Sumitomo Pharma Co., Ltd.) (1 mg / kg), risperidone (risperidone oral solution, Janssen Pharma Co., Ltd.) (0.3, 1 mg / kg), an antipsychotic drug, Quetiapine fumarate (LKT Laboratories, Inc.) (100 mg / kg), aripiprazole (Abilify powder 1%, Otsuka Pharmaceutical Co., Ltd.) (100 mg / kg) showed a significant inhibitory effect, and Example 39 (10 , 30 mg / kg), Example 68 (3 mg / kg), Example 77 (1, 3 mg / kg), and Example 106 (1, 3 mg / kg). This indicates that Example 39, Example 68, Example 77, and Example 106 have an improving effect on patients with schizophrenia.

  As shown in Test Example 2, the inhibitory effect on the spontaneous locomotor activity of rats induced by repeated administration of PCP when a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and an antipsychotic drug are used in combination It was investigated. In combination, 1/3 of the lowest effective dose, each of which showed inhibitory action alone, was used. That is, haloperidol (0.3 mg / kg), risperidone (0.1 mg / kg), quetiapine fumarate (30 mg / kg) or aripiprazole (30 mg / kg) in combination with Example 39 (3 mg / kg), In combination with Example 68 (1 mg / kg), in combination with Example 77 (0.3 mg / kg), or in combination with Example 106 (0.3 mg / kg) Increased locomotor activity was significantly suppressed. This means that FGA haloperidol, SGA risperidone, quetiapine fumarate, 1/3 of the minimum effective dose of aripiprazole, a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof This indicates that the combination of 1/3 of the minimum effective dose has an improving effect on schizophrenic patients.

  In the present invention, a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug are administered in combination "treatment of schizophrenia, “Medicament for” refers to a compound of the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent administered in combination for the treatment of schizophrenia. It is a medicine that is supposed to be.

  In the present invention, “administered in combination” with a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent means that the subject to be administered for a certain period of time. Means that the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug are taken into the body. A preparation containing the compound represented by formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent in a single preparation may be administered, and each preparation is prepared separately. And may be administered separately. When formulated separately, the timing of administration is not particularly limited, and may be administered at the same time, and may be administered at different times or on different days. When the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic are administered at different times or days, the order of administration is not particularly limited. Usually, since each formulation is administered according to each administration method, the administration may be the same number of times or may be different times. Moreover, when each is formulated separately, the administration method (administration route) of each formulation may be the same, and may be administered by different administration methods (administration route). Further, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug do not need to be present in the body at the same time, and preferably for a certain period (for example, one month, preferably May be taken into the body during a week, more preferably several days, even more preferably one day), and the other active ingredient may disappear from the body at any time of administration.

  Examples of dosage forms of the medicament of the present invention include, for example, 1) administration of a single preparation comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug 2) Simultaneous administration by the same route of administration of two types of preparations obtained by separately formulating the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent separately 3) Time difference in the same administration route of two types of preparations obtained by separately formulating the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent separately 4) Different administration routes of two preparations obtained by separately formulating the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent separately 5) General formula (I) Including administration at a compound or time different administration routes of two kinds of preparations pharmaceutically obtained by separate formulation of the antipsychotic least one and acceptable salt thereof and the like.

  In this invention, when it is set as 2 types of different preparations, it can also be set as the kit containing them.

  A pharmaceutical composition containing the compound of the present invention or a pharmaceutically acceptable salt thereof and / or an antipsychotic as an active ingredient is administered to a mammal (eg, human, horse, cow, pig, etc., preferably human). If so, it can be administered systemically or locally, orally or parenterally.

  The pharmaceutical composition of the present invention can be prepared by selecting an appropriate form according to the administration method and preparing various preparations that are usually used.

  Examples of the form of the oral pharmaceutical composition include tablets, pills, powders, granules, capsules, solutions, suspensions, emulsions, syrups, elixirs and the like. The preparation of such a pharmaceutical composition includes excipients, binders, disintegrants, lubricants, swelling agents, swelling aids, coating agents, plasticizers, stabilizers, antiseptics, anti-fouling agents, ordinarily used as additives. An oxidizing agent, a coloring agent, a solubilizing agent, a suspending agent, an emulsifying agent, a sweetening agent, a preservative, a buffering agent, a diluent, a wetting agent and the like are appropriately selected as necessary, and can be produced according to a conventional method.

  The forms of parenteral pharmaceutical compositions include injections, ointments, gels, creams, poultices, patches, sprays, inhalants, sprays, eye drops, nasal drops, suppositories, and inhalations. Agents and the like. Preparation of the pharmaceutical composition in such a form involves the use of stabilizers, preservatives, solubilizers, moisturizers, preservatives, antioxidants, flavoring agents, gelling agents, neutralizing agents, buffers, which are usually used as additives. Agents, isotonic agents, surfactants, colorants, buffering agents, thickeners, wetting agents, fillers, absorption enhancers, suspending agents, binders, etc. Can be manufactured according to

  The dose of the compound of the present invention or a pharmaceutically acceptable salt thereof varies depending on symptoms, age, body weight, etc., but in the case of oral administration, 1 to several times a day, once per adult, in terms of compound The amount is 0.01 to 1000 mg, preferably 0.1 to 500 mg. In the case of parenteral administration, the amount is 0.005 to 500 mg, preferably 0.05 to 250 mg, in terms of compound per adult once or several times a day.

  EXAMPLES Hereinafter, although this invention is demonstrated concretely along an Example, a test example, etc., the scope of the present invention is not limited to these Examples.

The fractions containing the target product in Reference Examples and Examples were detected by observation by TLC (Thin Layer Chromatography) or analysis by LC / MS (Liquid Chromatograph / Mass Spectrometry). “Room temperature” in Reference Examples and Examples usually indicates about 10 ° C. to about 35 ° C. Proton NMR spectra that cannot be confirmed broadly, such as OH and NH protons, are not described in the data.
In the following, the following abbreviations are used.
DMSO: Dimethyl sulfoxide
TIPS: Triisopropylsilyl
TBS: tert-butyldimethylsilyl
Boc: tert-butoxycarbonyl
ESI: Electrospray ionization method
FAB: Fast atom bombardment ionization method
[M + H] ⁺ : Molecular ion peak

(Reference Example 1) 1- (3,6-Dibromo-2-fluorophenyl) ethanol
A solution of 3,6-dibromo-2-fluorobenzaldehyde (34.56 g) in THF (400 mL) was cooled to −78 ° C. under a nitrogen stream, and methylmagnesium bromide (0.97 M THF solution, 190 mL) was added dropwise. The mixture was stirred for 10 minutes and then at room temperature for 1 hour. The reaction mixture was cooled to 0 ° C., saturated aqueous ammonium chloride solution (105 mL) and water (63 mL) were added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated to give the title compound (36.77 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.22-7.37 (m, 2H), 5.29-5.41 (m, 1H), 2.42 (m, 1H), 1.62 (dd, J = 6.9, 1.2 Hz, 3H).

Reference Example 2 1- (3,6-Dibromo-2-fluorophenyl) ethanone To a solution of the compound obtained in Reference Example 1 (36.77 g) in acetonitrile (700 mL) at room temperature with N-methylmorpholine-N-oxide (21.69 g) and tetrapropylammonium perruthenate (4.34 g) were added, and the mixture was stirred at the same temperature for 20 minutes. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 to 90:10) to give the title compound (35.49 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.46 (dd, J = 8.5, 6.9 Hz, 1H), 7.27-7.31 (m, 1H), 2.59 (d, J = 1.2 Hz, 3H).

(Reference Example 3) Ethyl 4,7-dibromo-3-methylbenzo [b] thiophene-2-carboxylate DMF (670 mL) suspension of compound (30.49 g) obtained in Reference Example 2 and potassium carbonate (42.72 g) To the mixture was added ethyl thioglycolate (5.65 mL) at room temperature, and the mixture was stirred at the same temperature for 2 hours. Ethyl thioglycolate (5.65 mL) was added to the reaction mixture at room temperature, and the mixture was stirred at the same temperature for 6 hr. Ethyl thioglycolate (1.13 mL) was added to the reaction mixture at room temperature, and the mixture was stirred at the same temperature for 16 hr. Ethyl iodide (16.5 mL) was added to the reaction mixture at room temperature, and the mixture was stirred at the same temperature for 23 hours. The reaction mixture was cooled to 0 ° C., water (760 mL) was added dropwise, the mixture was stirred at the same temperature for 2 hours, the precipitated solid was collected by filtration, washed successively with a DMF-water mixture, water and hexane to give the title compound ( 35.15 g) was obtained.
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.47-7.51 (m, 1H), 7.35-7.41 (m, 1H), 4.41 (q, J = 6.9 Hz, 2H), 3.11 (s, 3H) , 1.43 (t, J = 7.1 Hz, 3H).

(Reference Example 4) Ethyl 4,7-diacetyl-3-methylbenzo [b] thiophene-2-carboxylate Compound (11.19 g) obtained in Reference Example 3 and dichlorobis (triphenylphosphine) palladium (II) (2.08 g) A solution of (1-ethoxyvinyl) tributyltin (26.73 g) in toluene (82 mL) was added to a toluene (500 mL) solution, and the mixture was stirred at 110 ° C. for 28 hours under an argon atmosphere. The reaction mixture was cooled to room temperature and then filtered, and the filtrate was concentrated. Ethanol (100 mL) and 2N hydrochloric acid (33 mL) were added to the residue, and the mixture was stirred at room temperature for 3.5 hours. To the reaction mixture was added saturated brine (224 mL), and the mixture was extracted with ethyl acetate (560 mL). The organic layer was washed successively with saturated brine, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane / chloroform (1: 1) mixture: ethyl acetate = 100: 0 to 80:20), and the obtained solid was washed with hexane to obtain the title compound (8.256 g). .
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.12 (d, J = 7.7 Hz, 1H), 7.43 (d, J = 7.3 Hz, 1H), 4.42 (q, J = 6.9 Hz, 2H), 2.79 (s, 3H), 2.73 (s, 3H), 2.69 (s, 3H), 1.44 (t, J = 7.1 Hz, 3H).

(Reference Example 5) 4,7-Diacetyl-3-methylbenzo [b] thiophene-2-carboxylic acid To a suspension of the compound (8.255 g) obtained in Reference Example 4 in methanol (40 mL) was added 2N aqueous sodium hydroxide solution (27.1 mL) was added, and the mixture was stirred at 40 ° C. for 3 hours and 20 minutes. The reaction mixture was cooled to room temperature, 2N hydrochloric acid (29.8 mL) was added dropwise, and the mixture was cooled to 0 ° C. The precipitated solid was collected by filtration and washed with a methanol-water (1: 2) mixture to obtain the title compound (7.457 g).
¹ H NMR (DMSO, 400MHz): δ (ppm) 13.58 (s, 1H), 8.41 (d, J = 7.7 Hz, 1H), 7.77 (d, J = 7.7 Hz, 1H), 2.78 (s, 3H) , 2.77 (s, 3H), 2.55 (s, 3H).

Reference Example 6 2- (2-Chloroquinolin-4-yl) propan-2-ol Methylmagnesium bromide (mixture of 100 mL of 0.97 M THF solution and 800 mL of 0.93 M THF solution) was cooled to 0 ° C. Then, a solution of methyl 2-chloroquinoline-4-carboxylate (46.60 g) in THF (383 mL) was added dropwise, and the mixture was stirred at the same temperature for 2.5 hours. A saturated aqueous ammonium chloride solution (433 mL) and water (260 mL) were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated. Ethyl acetate (39 mL) was added to the residue and heated to 75 ° C., hexane (89 mL) was added, and the mixture was cooled to 0 ° C. The precipitated solid was collected by filtration and washed with a mixed solution of hexane-ethyl acetate (5: 1) to obtain the title compound (34.79 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.65 (dd, J = 8.7, 1.0 Hz, 1H), 8.05 (dd, J = 8.3, 1.4 Hz, 1H), 7.71 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.53-7.61 (m, 1H), 7.50 (s, 1H), 2.05 (s, 1H), 1.86 (s, 6H).

Reference Example 7 2- (2-((4-methoxybenzyl) amino) quinolin-4-yl) propan-2-ol The compound (34.79 g) obtained in Reference Example 6 and 4-methoxybenzylamine (86.15) g) was stirred at 120 ° C. for 33 hours. After the reaction mixture was cooled to room temperature, ethyl acetate (410 mL) and water (690 mL) were added, and carbon dioxide was blown into the mixture. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated. Diisopropyl ether was added to the residue, and the precipitated solid was filtered and washed with diisopropyl ether to obtain the title compound (46.65 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.36 (dd, J = 8.5, 1.2 Hz, 1H), 7.76 (dd, J = 8.1, 1.2 Hz, 1H), 7.52 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.31-7.39 (m, 2H), 7.23 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 6.84-6.92 (m, 2H), 6.75 (s, 1H), 4.89 (br. s., 1H), 4.66 (d, J = 5.3 Hz, 2H), 3.81 (s, 3H), 1.98 (s, 1H), 1.78 (s, 6H).

Reference Example 8 2- (2-Aminoquinolin-4-yl) propan-2-ol A solution of the compound (10.00 g) obtained in Reference Example 7 in dichloromethane (21.1 mL) was added to trifluoroacetic acid (hereinafter referred to as `` TFA (21.0 mL) was added and stirred at room temperature for 86 hours. The reaction mixture was concentrated, chloroform (50 mL) and 8N aqueous sodium hydroxide solution (13 mL) were added to the residue, and hexane (79 mL) and chloroform (23 mL) were added. The organic layer was dried over anhydrous magnesium sulfate and concentrated. Chloroform (73 mL) was added to the residue and heated to 60 ° C., hexane (29 mL) was added, and the mixture was cooled to 0 ° C. The precipitated solid was collected by filtration and washed with a mixed solution of hexane-chloroform (1: 1) to obtain the title compound (6.344 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.40 (d, J = 8.5 Hz, 1H), 7.72 (dd, J = 8.5, 1.2 Hz, 1H), 7.56 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H), 7.30 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H), 6.91 (s, 1H), 5.19 (br. S., 2H), 2.07 (br. S., 1H), 1.83 (s, 6H).

(Reference Example 9) 1- (3,6-dibromo-2-fluorophenyl) propan-1-ol
A toluene (1 mL) solution of 3,6-dibromo-2-fluorobenzaldehyde (282 mg) and tetraisopropyl titanate (6.4 μL) was cooled to 0 ° C., and diethylzinc (0.99 M hexane solution, 1.22 mL) was added. For 23 hours. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-60: 40) to give the title compound (119 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.31-7.36 (m, 1H), 7.23-7.26 (m, 1H), 5.05-5.12 (m, 1H), 2.34-2.41 (m, 1H), 1.86-2.04 (m, 2H), 1.00 (t, J = 7.3 Hz, 3H).

(Reference Example 10) 1- (3,6-dibromo-2-fluorophenyl) propan-1-one The compound obtained in Reference Example 9 (62.4 mg), acetonitrile (1 mL), N-methylmorpholine-N-oxide ( 35.1 mg) and tetrapropylammonium perruthenate (7.0 mg) were used in the same manner as in Reference Example 2 to obtain the title compound (54.0 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.42-7.48 (m, 1H), 7.25-7.29 (m, 1H), 2.81-2.89 (m, 2H), 1.23 (t, J = 7.3 Hz, 3H)
MS (ESI ^<+> ) m / z: 311 [M + H] ^< +>.

(Reference Example 11) Ethyl 4,7-dibromo-3-ethylbenzo [b] thiophene-2-carboxylate To a suspension of the compound obtained in Reference Example 10 (810 mg) and potassium carbonate (721 mg) in DMF (10 mL), Ethyl thioglycolate (0.371 mL) was added at 0 ° C., and the mixture was stirred at the same temperature for 1 hour, stirred at room temperature for 18 hours, stirred at 40 ° C. for 5 hours, and stirred at 50 ° C. for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-80: 20) to give the title compound (842 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.49-7.51 (m, 1H), 7.39 (d, J = 8.1 Hz, 1H), 4.41 (q, J = 7.2 Hz, 2H), 3.65 (q , J = 7.4 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H), 1.32 (t, J = 7.5 Hz, 3H).

(Reference Example 12) Ethyl 4,7-diacetyl-3-ethylbenzo [b] thiophene-2-carboxylate Toluene of the compound (800 mg) obtained in Reference Example 11 and dichlorobis (triphenylphosphine) palladium (II) (344 mg) (1-Ethoxyvinyl) tributyltin (4.13 mL) was added to the (10 mL) solution, and the mixture was stirred at 110 ° C. for 22 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and then filtered, and the filtrate was concentrated. THF (15 mL) and 6N hydrochloric acid (5 mL) were added to the residue, and the mixture was stirred at room temperature for 60 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified successively by silica gel column chromatography (hexane: ethyl acetate = 90: 10-50: 50) and basic silica gel column chromatography (hexane: ethyl acetate = 70: 30-30: 70) to give the title compound (505 mg )
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.11 (d, J = 7.7 Hz, 1H), 7.38 (d, J = 7.7 Hz, 1H), 4.41 (q, J = 7.2 Hz, 2H), 3.18 (q, J = 7.3 Hz, 2H), 2.78 (s, 3H), 2.74 (s, 3H), 1.43 (t, J = 7.3 Hz, 3H), 1.17 (t, J = 7.3 Hz, 3H)
MS (ESI ^<+> ) m / z: 319 [M + H] ^< +>.

(Reference Example 13) 4,7-Diacetyl-3-ethylbenzo [b] thiophene-2-carboxylic acid The compound (500 mg) obtained in Reference Example 12 was mixed with methanol-THF (1: 1) (15 mL) and 2N hydroxylated. Aqueous sodium solution (15 mL) was added, and the mixture was stirred at room temperature for 22 hours. 6N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (451 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 13.52 (br. S., 1H), 8.40 (d, J = 7.5 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 3.08 (q , J = 7.4 Hz, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 1.06 (t, J = 7.4 Hz, 3H)
MS (ESI ⁺ ) m / z: 291 [M + H] ⁺ .

(Reference Example 14) Ethyl 4,7-dibromobenzo [b] thiophene-2-carboxylate Add ethyl thioglycolate (600 μL) to a DMSO (20 mL) suspension of sodium hydride (60% oil suspension, 300 mg). And stirred at room temperature for 15 minutes. To the reaction mixture, a DMSO solution of 3,6-dibromo-2-fluorobenzaldehyde (1.4 g) was added, stirred at room temperature for 1 hour, and then stirred at 80 ° C. for 3 hours. Ethyl acetate and water were added to the reaction mixture, and the obtained organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: dichloromethane = 90: 10-80: 20) to give the title compound (1000 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.25 (s, 1H), 7.43-7.49 (m, 2H), 4.44 (q, J = 6.9 Hz, 2H), 1.44 (t, J = 7.1 Hz , 3H).

(Reference Example 15) Ethyl 4,7-diacetylbenzo [b] thiophene-2-carboxylate Compound (1000 mg) obtained in Reference Example 14, dichlorobis (triphenylphosphine) palladium (II) (450 mg), toluene (50 mL) , (1-ethoxyvinyl) tributyltin (5.57 mL) was used in the same manner as in Reference Example 12 to give the titled compound (700 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.91 (s, 1H), 8.17 (d, J = 7.7 Hz, 1H), 8.03 (d, J = 7.7 Hz, 1H), 4.44 (q, J = 7.3 Hz, 2H), 2.82 (s, 3H), 2.78 (s, 3H), 1.41-1.47 (m, 3H)
MS (ESI ⁺ ) m / z: 291 [M + H] ⁺ .

(Reference Example 16) 4,7-Diacetylbenzo [b] thiophene-2-carboxylic acid To a solution of the compound obtained in Reference Example 15 (700 mg) in methanol (50 mL) was added 2N aqueous sodium hydroxide solution (50 mL), and at room temperature. Stir for 2 hours. The reaction mixture was acidified with hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (250 mg).

Reference Example 17 1-Bromo-4- (dimethoxymethyl) -2-fluorobenzene
Concentrated sulfuric acid (41 μL) was added to a solution of 4-bromo-3-fluorobenzaldehyde (7.540 g) and trimethyl orthoformate (5.3 mL) in methanol (14 mL), and the mixture was stirred at 80 ° C. for 3.5 hours. Trimethyl orthoformate (2.3 mL) was added to the reaction mixture, and the mixture was stirred at 80 ° C. for 20 hours. The reaction mixture was cooled to 0 ° C., sodium methoxide (28% methanol solution, 840 μL) was added, and the mixture was concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 1: 0-12: 1) to give the title compound (9.190 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.54 (dd, J = 8.3, 7.1 Hz, 1H), 7.23-7.26 (m, 1H), 7.12 (dd, J = 8.1, 2.0 Hz, 1H) , 5.36 (s, 1H), 3.31 (s, 6H).

Reference Example 18 3-Bromo-6- (dimethoxymethyl) -2-fluorobenzaldehyde A solution of lithium diisopropylamide (1.1M THF / ethylbenzene / heptane solution, 96 mL) in THF (300 mL) was cooled to -78 ° C., and argon A THF (100 mL) solution of the compound (25.0 g) obtained in Reference Example 17 was added dropwise under an atmosphere, and the mixture was stirred at −78 ° C. for 1 hour. A solution of DMF (8.2 mL) in THF (20 mL) was added dropwise to the reaction mixture, and the mixture was stirred at the same temperature for 30 minutes. Acetic acid (20 mL) was added to the reaction mixture, the temperature was raised to 0 ° C., water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 to 70:30) to obtain the title compound (25.1 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 10.47 (s, 1H), 7.76 (dd, J = 8.4, 6.7 Hz, 1H), 7.43-7.47 (m, 1H), 5.92 (s, 1H) , 3.41 (s, 6H).

(Reference Example 19) 1- (3-Bromo-6- (dimethoxymethyl) -2-fluorophenyl) ethanol A solution of the compound (23.5 g) obtained in Reference Example 18 in THF (300 mL) was heated to 0 ° C. under an argon stream. After cooling, methylmagnesium bromide (0.97M THF solution, 130 mL) was added dropwise and stirred at the same temperature for 3 hours. To the reaction mixture was added saturated brine (100 mL), and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 to 70:30) to obtain the title compound (15.4 g).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.45 (dd, J = 8.3, 6.8 Hz, 1H), 7.25-7.28 (m, 1H), 5.59 (s, 1H), 3.37 (s, 3H) 3.28 (s, 3H), 2.64 (dd, J = 8.2, 3.9 Hz, 1H), 1.59 (dd, J = 6.8, 1.5 Hz, 3H).

Reference Example 20 1- (3-Bromo-6- (dimethoxymethyl) -2-fluorophenyl) ethanone Compound obtained in Reference Example 19 (15.1 g), acetonitrile (300 mL), N-methylmorpholine-N-oxide (9.0 g) and tetrapropylammonium perruthenate (1.8 g) were used in the same manner as in Reference Example 2 to give the titled compound (13.2 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.56 (dd, J = 8.3, 7.0 Hz, 1H), 7.24-7.26 (m, 1H), 5.48 (s, 1H), 3.34 (s, 6H) , 2.54 (d, J = 1.8 Hz, 3H).

(Reference Example 21) Ethyl 7-bromo-4- (dimethoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylate To a DMF (300 mL) solution of the compound obtained in Reference Example 20 (12.1 g), thioglycol Ethyl acid (10.0 g) and potassium carbonate (22.8 g) were added, and the mixture was stirred at 85 ° C. for 8 hours. The reaction mixture was cooled to 0 ° C., saturated brine (300 mL) was added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 to 70:30) to obtain the title compound (6.97 g).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.63-7.66 (m, 1H), 7.58-7.61 (m, 1H), 6.07 (s, 1H), 4.40 (q, J = 7.0 Hz, 2H) , 3.35 (s, 6H), 3.04 (s, 3H), 1.42 (t, J = 7.2 Hz, 3H).

(Reference Example 22) Ethyl 7-bromo-4-formyl-3-methylbenzo [b] thiophene-2-carboxylate To a THF (30 mL) solution of the compound (1.61 g) obtained in Reference Example 21, 1N hydrochloric acid (30 mL) was added. The mixture was further stirred at room temperature for 2 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (1.35 g).
MS (FAB ^<+> ) m / z: 327 [M + H] ^< +>.

Reference Example 23 Ethyl 7-bromo-4- (1-hydroxyethyl) -3-methylbenzo [b] thiophene-2-carboxylate A solution of the compound (255 mg) obtained in Reference Example 22 in THF (30 mL) was -78. The mixture was cooled to 0 ° C., and methylmagnesium bromide (0.96 M THF solution, 974 μL) was added dropwise under a nitrogen atmosphere, followed by stirring at the same temperature for 15 minutes and then at room temperature for 10 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 80: 20-10: 90) to give the title compound (270 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.58-7.63 (m, 2H), 5.87-5.94 (m, 1H), 4.40 (q, J = 7.0 Hz, 2H), 3.01 (s, 3H) 1.90 (d, J = 3.7 Hz, 1H), 1.59 (d, J = 6.5 Hz, 3H), 1.41-1.45 (m, 3H).

(Reference Example 24) 7-acetyl-4- (1-hydroxyethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Compound (700 mg) obtained in Reference Example 23, dichlorobis (triphenylphosphine) palladium (II ) (168 mg) and a solution of (1-ethoxyvinyl) tributyltin (2 mL) in toluene (100 mL) was stirred at 110 ° C. for 10 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, 2N hydrochloric acid was added, and the mixture was stirred for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was sequentially purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30 to 0: 100) and basic silica gel column chromatography (ethyl acetate) to give 7-acetyl-4- (1-hydroxyethyl) -3. -Ethyl benzo [b] thiophene-2-carboxylate was obtained.
To a solution of ethyl 7-acetyl-4- (1-hydroxyethyl) -3-methylbenzo [b] thiophene-2-carboxylate obtained above in methanol (20 mL) was added 2N aqueous sodium hydroxide solution (20 mL) at room temperature. Stir for 3 hours. The reaction mixture was acidified with hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (450 mg).

Reference Example 25 Ethyl 7-bromo-4- (1-hydroxypropyl) -3-methylbenzo [b] thiophene-2-carboxylate Compound obtained in Reference Example 22 (700 mg), THF (100 mL), ethyl bromide The title compound (380 mg) was obtained in the same manner as in Reference Example 23 using magnesium (1M THF solution, 2.8 mL).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.54-7.64 (m, 2H), 5.62-5.69 (m, 1H), 4.40 (q, J = 7.3 Hz, 2H), 2.99 (s, 3H) , 1.84-1.95 (m, 2H), 1.71-1.80 (m, 1H), 1.42 (t, J = 7.1 Hz, 3H), 1.08 (t, J = 7.3 Hz, 3H).

(Reference Example 26) Ethyl 7-acetyl-4- (1-hydroxypropyl) -3-methylbenzo [b] thiophene-2-carboxylate The compound (380 mg) obtained in Reference Example 25, dichlorobis (triphenylphosphine) palladium ( II) (100 mg) and a solution of (1-ethoxyvinyl) tributyltin (1.2 mL) in toluene (30 mL) were stirred at 110 ° C. for 10 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, 2N hydrochloric acid was added, and the mixture was stirred for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified successively by basic silica gel column chromatography (hexane: ethyl acetate = 80: 20-20: 80) and silica gel column chromatography (hexane: ethyl acetate = 80: 20-40: 60) to give the title compound (260 mg )

Reference Example 27 Ethyl 7-acetyl-3-methyl-4-propionylbenzo [b] thiophene-2-carboxylate The compound obtained in Reference Example 26 (130 mg), acetonitrile (25 mL), N-methylmorpholine-N— The title compound (120 mg) was obtained in the same manner as in Reference Example 2 using oxide (71 mg) and tetrapropylammonium perruthenate (15 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.10 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 4.41 (q, J = 7.3 Hz, 2H), 2.98 (q, J = 7.3 Hz, 2H), 2.78 (s, 3H), 2.64 (s, 3H), 1.43 (t, J = 7.1 Hz, 3H), 1.30 (t, J = 7.3 Hz, 3H).

(Reference Example 28) 7-acetyl-3-methyl-4-propionylbenzo [b] thiophene-2-carboxylic acid To a solution of the compound (120 mg) obtained in Reference Example 27 in methanol (10 mL) was added 2N aqueous sodium hydroxide (10 mL). ) And stirred at room temperature for 1 hour. The reaction mixture was acidified with hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound.

(Reference Example 29) 4-Methoxyquinolin-2-amine
A suspension of 2-aminoquinolin-4-ol (500 mg), methyl iodide (214 μL) and potassium carbonate (648 mg) in DMF (20 mL) was stirred at room temperature for 24 hours. The reaction mixture was concentrated, and the residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 85:15) to give the title compound (160 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.98 (dd, J = 8.3, 1.4 Hz, 1H), 7.60-7.64 (m, 1H), 7.53-7.59 (m, 1H), 7.22-7.28 ( m, 1H), 6.12 (s, 1H), 5.27 (br. s., 2H), 4.00 (s, 3H).

(Reference Example 30) N-benzyl-2- (benzylamino) quinoline-4-carboxamide
A mixture of methyl 2-chloroquinoline-4-carboxylate (20.000 g) and benzylamine (48.247 g) was stirred at 135 ° C. for 2.5 hours. The reaction mixture was cooled to 70 ° C., chloroform (100 mL) was added, cooled to room temperature, water (100 mL) was added, and then cooled to 0 ° C. The precipitated solid was collected by filtration and washed successively with a hexane-chloroform (1: 1) mixture and water to obtain the title compound (21.253 g).

(Reference Example 31) Methyl 2-aminoquinoline-4-carboxylate 47% hydrobromic acid (1020 mL) and acetic acid (1020 mL) were added to the compound obtained in Reference Example 30 (178.400 g), and the mixture was stirred at 125 ° C. for 37.5 hours. did. The reaction mixture was concentrated, water (580 mL) was added and cooled to 0 ° C. To the reaction mixture were added 4N aqueous sodium hydroxide solution (650 mL), 6N hydrochloric acid (10 mL), water (100 mL) and ethyl acetate (380 mL), and the mixture was warmed to room temperature. The precipitated solid was collected by filtration and washed successively with water and ethyl acetate. A solution of the obtained solid (115.15 g) in methanol (920 mL) was cooled to 0 ° C., concentrated sulfuric acid (55.6 mL) was added, and the mixture was stirred at 90 ° C. for 45 hours. The reaction mixture was cooled to room temperature, concentrated and the residue was washed with methanol (100 mL). Water (700 mL) and saturated aqueous sodium hydrogen carbonate solution (475 mL) were added to the obtained solid, and the precipitated solid was collected by filtration and washed with water to give the title compound (94.32 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.49 (dd, J = 8.5, 0.8 Hz, 1H), 7.72 (dd, J = 8.5, 0.8 Hz, 1H), 7.58-7.65 (m, 1H) 7.33-7.40 (m, 1H), 7.28 (s, 1H), 5.00 (br. S., 2H), 4.02 (s, 3H).

(Reference Example 32) Methyl 2-((tert-butoxycarbonyl) amino) quinoline-4-carboxylate To a solution of the compound (20.0 g) obtained in Reference Example 31 in DMF (100 mL), di-tert-butyl dicarbonate (138 mL) ) In dichloromethane (100 mL) was added and cooled to 0 ° C. Triethylamine (55.1 mL) was added dropwise to the reaction mixture, and the mixture was stirred at room temperature for 7 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 0-5: 1) to give the title compound (22.4 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.70 (s, 1H), 8.62 (dd, J = 8.5, 1.2 Hz, 1H), 7.84 (dd, J = 8.5, 0.8 Hz, 1H), 7.65 -7.73 (m, 2H), 7.48-7.54 (m, 1H), 4.03 (s, 3H), 1.55 (s, 9H).

(Reference Example 33) 2-((tert-butoxycarbonyl) amino) quinoline-4-carboxylic acid A mixture of the compound obtained in Reference Example 32 (1 g), 1N aqueous sodium hydroxide solution (9.9 mL) and ethanol (9.9 mL) Was stirred at room temperature for 2 hours. 1N Hydrochloric acid (9.9 mL) was added to the reaction mixture, and the precipitated solid was collected by filtration and dried to give the title compound (965 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 10.33 (s, 1H), 8.57 (d, J = 7.7 Hz, 1H), 8.53 (s, 1H), 7.81-7.85 (m, 1H), 7.73 ( ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.54 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 1.50 (s, 9H).

(Reference Example 34) tert-butyl (4- (methoxy (methyl) carbamoyl) quinolin-2-yl) carbamate Compound (200 mg) obtained in Reference Example 33, N, O-dimethylhydroxylamine hydrochloride (74 mg), 1 A mixture of -ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (146 mg), 1-hydroxy-7-azabenzotriazole (103 mg), N, N-diisopropylethylamine (98 mg) and DMF (3 mL) at room temperature For 2 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 3: 1-2: 1) to give the title compound (202 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.26 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.63-7.70 (m , 1H), 7.61 (s, 1H), 7.41-7.48 (m, 1H), 3.48 (s, 3H), 2.96 (s, 3H), 1.54 (s, 9H).

(Reference Example 35) tert-Butyl (4-acetylquinolin-2-yl) carbamate A THF (2.5 mL) solution of the compound (202 mg) obtained in Reference Example 34 was cooled to -78 ° C, and methylmagnesium bromide (1M (THF solution, 730 μL) was added dropwise, and the mixture was stirred at the same temperature for 2 hours and then stirred at room temperature overnight. The reaction mixture was cooled to 0 ° C. and methylmagnesium bromide (1M THF solution, 6 mL) was added dropwise and stirred. The reaction mixture was poured into ice water, saturated aqueous ammonium chloride solution was added, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 3: 1) to give the title compound (144 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.53 (s, 1H), 8.31-8.35 (m, 1H), 7.80-7.84 (m, 1H), 7.67 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H), 7.56 (br. S., 1H), 7.48 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 2.77 (s, 3H), 1.56 (s, 9H).

Reference Example 36 1- (2-Aminoquinolin-4-yl) ethanone A mixture of the compound obtained in Reference Example 35 (634 mg), dichloromethane (1 mL) and TFA (1 mL) was stirred at room temperature overnight. The reaction mixture was concentrated, and the residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 96: 4) to give the title compound (302 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.12 (dd, J = 8.1, 1.2 Hz, 1H), 7.71 (dd, J = 8.5, 0.8 Hz, 1H), 7.57-7.63 (m, 1H) , 7.33 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 6.92 (s, 1H), 4.85 (br. S., 2H), 2.69 (s, 3H).

Reference Example 37 1- (2-Aminoquinolin-4-yl) ethanol A mixture of the compound obtained in Reference Example 36 (302 mg), methanol (8.6 mL), and sodium borohydride (92 mg) was stirred at room temperature. The reaction mixture was concentrated, and the residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 99: 1 to 95: 5) to give the title compound (281 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.76 (dd, J = 8.1, 1.2 Hz, 1H), 7.68 (dd, J = 8.5, 0.8 Hz, 1H), 7.52-7.57 (m, 1H) , 7.23-7.29 (m, 1H), 6.93 (s, 1H), 5.52 (q, J = 6.4 Hz, 1H), 4.75 (br.s., 2H), 3.49 (s, 1H), 1.61 (d, J = 6.5 Hz, 3H).

(Reference Example 38) tert-butyl (4- (hydroxymethyl) quinolin-2-yl) carbamate A mixture of the compound obtained in Reference Example 32 (500 mg), ethanol (30 mL), sodium borohydride (180 mg) at 80 ° C. For 6 hours. The reaction mixture was concentrated, and the residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 100: 0-50: 50) to give the title compound (320 mg).
MS (ESI ^<+> ) m / z: 275 [M + H] ^< +>.

Reference Example 39 (2-Aminoquinolin-4-yl) methanol A mixture of the compound obtained in Reference Example 38 (320 mg), dichloromethane (5 mL) and TFA (5 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to give the title compound (62 mg).
MS (ESI ^<+> ) m / z: 175 [M + H] ^< +>.

(Reference Example 40) N-((2-aminoquinolin-4-yl) methyl) -N-methylacetamide The compound obtained in Reference Example 38 (600 mg), 1,2-dichloroethane (10 mL), triethylamine (365 μL) and A mixture of methanesulfonyl chloride (203 μL) was stirred at room temperature for 2 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Methylamine (2M THF solution, 20 mL) was added to the residue, and the mixture was stirred at room temperature for 2 hours, and then the reaction mixture was concentrated. To the residue, THF (10 mL), triethylamine (446 μL) and acetyl chloride (220 μL) were added, and the mixture was stirred at room temperature for 10 minutes. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. To the residue were added dichloromethane (5 mL) and TFA (5 mL), and the mixture was stirred at room temperature for 20 hours. The reaction mixture was concentrated, and the residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 92: 8) to give the title compound (320 mg).
MS (ESI ^<+> ) m / z: 230 [M + H] ^< +>.

(Reference Example 41) 2-Fluoro-3-iodobenzaldehyde
A solution of N, N-diisopropylamine (14.2 mL) in THF (180 mL) was cooled to 0 ° C., n-butyllithium (1.59 M hexane solution, 75.5 mL) was added, and the mixture was stirred for 10 min. The reaction mixture was cooled to −78 ° C., 1-fluoro-2-iodobenzene (11.77 mL) was added dropwise, and the mixture was stirred for 1 hour. To the reaction mixture was added DMF (20.4 mL), and the mixture was stirred for 5 minutes, then acetic acid (9 mL) and water were added successively, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-80: 20) to give the title compound (10.7 g).

(Reference Example 42) 1- (2-Fluoro-3-iodophenyl) ethanol Using the compound obtained in Reference Example 41 (10.6 g), THF (70 mL) and methylmagnesium bromide (0.9 M THF solution, 71 mL), In the same manner as in Reference Example 1, the title compound (10.0 g) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.65 (ddd, J = 7.7, 6.1, 1.6 Hz, 1H), 7.45-7.50 (m, 1H), 6.92 (t, J = 7.7 Hz, 1H) , 5.15-5.23 (m, 1H), 1.50 (d, J = 6.5 Hz, 3H).

(Reference Example 43) 1- (2-Fluoro-3-iodophenyl) ethanone The compound (5.00 g), acetonitrile (100 mL), N-methylmorpholine-N-oxide (3.30 g) and perruthenium obtained in Reference Example 42 The title compound (4.26 g) was obtained in the same manner as in Reference Example 2 using tetrapropylammonium acid (661 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.93 (ddd, J = 7.7, 5.9, 1.8 Hz, 1H), 7.79-7.84 (m, 1H), 7.00 (t, J = 7.7 Hz, 1H) , 2.65 (d, J = 4.9 Hz, 3H)
MS (ESI ^<+> ) m / z: 265 [M + H] ^< +>.

(Reference Example 44) Ethyl 7-iodo-3-methylbenzo [b] thiophene-2-carboxylate To a suspension of the compound (2.90 g) obtained in Reference Example 43 and potassium carbonate (4.56 g) in acetonitrile (20 mL), Ethyl thioglycolate (1.81 mL) was added, and the mixture was stirred at 80 ° C. for 4 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-80: 20) to give the title compound (2.70 g).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.79-7.84 (m, 2H), 7.12-7.17 (m, 1H), 4.40 (q, J = 6.9 Hz, 2H), 2.73 (s, 3H) , 1.43 (t, J = 7.1 Hz, 3H)
MS (ESI ^<+> ) m / z: 347 [M + H] ^< +>.

(Reference Example 45) Ethyl 3-methyl-7-propionylbenzo [b] thiophene-2-carboxylate Compound (346 mg) obtained in Reference Example 44, propionic anhydride (386 μL), tris (dibenzylideneacetone) dipalladium A mixture of (0) (23 mg), N, N-diisopropylethylamine (344 μL), lithium chloride (297 mg) and DMF (6 mL) was stirred at 140 ° C. for 3.5 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-80: 20) to give the title compound (75 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.14-8.17 (m, 1H), 8.06-8.09 (m, 1H), 7.52-7.57 (m, 1H), 4.40 (q, J = 7.0 Hz, 2H), 3.18 (q, J = 7.3 Hz, 2H), 2.80 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H), 1.32 (t, J = 7.3 Hz, 3H)
MS (ESI ^<+> ) m / z: 277 [M + H] ^< +>.

Reference Example 46 3-Methyl-7-propionylbenzo [b] thiophene-2-carboxylic acid Compound obtained in Reference Example 45 (70 mg), THF (4 mL), methanol (4 mL) and 2N aqueous sodium hydroxide solution (4 mL ) Was stirred at room temperature for 60 hours. 6N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (80 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 8.39 (dd, J = 7.4, 0.9 Hz, 1H), 8.27 (dd, J = 8.0, 1.0 Hz, 1H), 7.66-7.71 (m, 1H), 3.24 (q, J = 7.3 Hz, 2H), 2.75 (s, 3H), 1.17 (t, J = 7.2 Hz, 3H)
MS (ESI ^<+> ) m / z: 249 [M + H] ^< +>.

(Reference Example 47) Ethyl 7-butyryl-3-methylbenzo [b] thiophene-2-carboxylate A solution of the compound obtained in Reference Example 44 (346 mg) in THF (4 mL) was cooled to −78 ° C., and isopropylmagnesium chloride ( 2.0M THF solution, 0.7 mL) was added and stirred for 30 minutes. Copper (I) iodide (229 mg) and lithium chloride (102 mg) were added to the reaction mixture, and the mixture was stirred for 20 minutes, butyryl chloride (345 μL) was added, and the mixture was stirred at room temperature for 2 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-80: 20) to give the title compound (166 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.14-8.18 (m, 1H), 8.06-8.10 (m, 1H), 7.53-7.58 (m, 1H), 4.40 (q, J = 7.0 Hz, 2H), 3.12 (t, J = 7.3 Hz, 2H), 2.81 (s, 3H), 1.82-1.92 (m, 2H), 1.40-1.45 (m, 3H), 1.05 (t, J = 7.5 Hz, 3H )
MS (ESI ^<+> ) m / z: 291 [M + H] ^< +>.

(Reference Example 48) 7-butyryl-3-methylbenzo [b] thiophene-2-carboxylic acid Compound (150 mg) obtained in Reference Example 47, methanol-THF (1: 1) mixture (5 mL) and 2N aqueous sodium hydroxide solution (5 mL) was stirred at room temperature for 2.5 days. 6N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (132 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 13.36 (br. S., 1H), 8.40 (dd, J = 7.5, 1.0 Hz, 1H), 8.27 (dd, J = 8.0, 1.0 Hz, 1H) , 7.65-7.70 (m, 1H), 3.18 (t, J = 7.3 Hz, 2H), 2.74 (s, 3H), 1.67-1.77 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H)
MS (ESI ^<+> ) m / z: 263 [M + H] ^< +>.

(Reference Example 49) Ethyl 7-isobutyryl-3-methylbenzo [b] thiophene-2-carboxylate Compound (346 mg) obtained in Reference Example 44, THF (4 mL), isopropylmagnesium chloride (2.0 M THF solution, 0.7 mL) , Copper iodide (I) (229 mg), lithium chloride (102 mg) and isobutyryl chloride (346 μL) were used in the same manner as in Reference Example 47 to obtain the title compound (137 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.16-8.19 (m, 1H), 8.07-8.10 (m, 1H), 7.54-7.59 (m, 1H), 4.40 (q, J = 7.3 Hz, 2H), 3.70-3.82 (m, 1H), 2.81 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H), 1.31 (d, J = 6.9 Hz, 6H)
MS (ESI ^<+> ) m / z: 291 [M + H] ^< +>.

(Reference Example 50) 7-isobutyryl-3-methylbenzo [b] thiophene-2-carboxylic acid Compound (125 mg) obtained in Reference Example 49, methanol-THF (1: 1) mixture (5 mL), and 2N aqueous sodium hydroxide solution A mixture of (5 mL) was stirred at room temperature for 20 hours. 6N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (120 mg).

(Reference Example 51) Ethyl 7- (cyclopropylcarbonyl) -3-methylbenzo [b] thiophene-2-carboxylate Compound (346 mg) obtained in Reference Example 44, THF (4 mL), isopropylmagnesium chloride (2.0 M THF solution) , 0.7 mL), copper (I) iodide (229 mg), lithium chloride (102 mg) and cyclopropanecarbonyl chloride (299 μL) were obtained in the same manner as in Reference Example 47 to give the title compound (130 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.33-8.36 (m, 1H), 8.08-8.11 (m, 1H), 7.57-7.62 (m, 1H), 4.39 (q, J = 7.3 Hz, 2H), 2.82-2.89 (m, 1H), 1.41 (t, J = 7.2 Hz, 3H), 1.35-1.39 (m, 2H), 1.10-1.15 (m, 2H)
MS (ESI ^<+> ) m / z: 289 [M + H] ^< +>.

Reference Example 52 7- (Cyclopropylcarbonyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Compound (120 mg) obtained in Reference Example 51, methanol-THF (1: 1) mixture (5 mL) and 2N A mixture of aqueous sodium hydroxide (5 mL) was stirred at room temperature for 15 hours. 6N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (108 mg).

(Reference Example 53) Ethyl 3-methyl-7-pentanoylbenzo [b] thiophene-2-carboxylate The compound obtained in Reference Example 44 (346 mg), THF (4 mL), isopropylmagnesium chloride (2.0 M THF solution, 0.7 mL), copper (I) iodide (229 mg), lithium chloride (102 mg) and valeryl chloride (392 μL) were used in the same manner as in Reference Example 47 to obtain the title compound (265 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.15-8.18 (m, 1H), 8.07-8.10 (m, 1H), 7.53-7.58 (m, 1H), 4.40 (q, J = 7.3 Hz, 2H), 3.14 (t, J = 7.3 Hz, 2H), 2.81 (s, 3H), 1.77-1.87 (m, 2H), 1.40-1.51 (m, 5H), 0.98 (t, J = 7.3 Hz, 3H )
MS (ESI ^<+> ) m / z: 305 [M + H] ^< +>.

Reference Example 54 3-Methyl-7-pentanoylbenzo [b] thiophene-2-carboxylic acid Compound obtained in Reference Example 53 (120 mg), methanol-THF (1: 1) mixture (5 mL) and 2N hydroxylation The title compound (222 mg) was obtained in the same manner as in Reference Example 52 using aqueous sodium solution (5 mL).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 13.32 (br. S., 1H), 8.40 (dd, J = 7.5, 0.8 Hz, 1H), 8.26 (dd, J = 8.0, 1.0 Hz, 1H) , 7.65-7.70 (m, 1H), 3.20 (t, J = 7.4 Hz, 2H), 2.74 (s, 3H), 1.63-1.72 (m, 2H), 1.33-1.44 (m, 2H), 0.93 (t , J = 7.4 Hz, 3H)
MS (ESI ^<+> ) m / z: 277 [M + H] ^< +>.

Reference Example 55 Ethyl 7- (cyclobutylcarbonyl) -3-methylbenzo [b] thiophene-2-carboxylate Compound (346 mg) obtained in Reference Example 44, THF (4 mL), isopropylmagnesium chloride (2.0 M THF solution) , 0.7 mL), copper (I) iodide (229 mg), lithium chloride (102 mg) and cyclobutanecarbonyl chloride (377 μL) were obtained in the same manner as in Reference Example 47 to give the title compound (300 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.02-8.05 (m, 1H), 7.95-7.98 (m, 1H), 7.48-7.53 (m, 1H), 4.40 (q, J = 7.2 Hz, 2H ), 4.11-4.21 (m, 1H), 2.79 (s, 3H), 2.47-2.58 (m, 2H), 2.31-2.42 (m, 2H), 2.07-2.20 (m, 1H), 1.91-2.02 (m , 1H), 1.43 (t, J = 7.1 Hz, 3H)
MS (ESI ^<+> ) m / z: 303 [M + H] ^< +>.

Reference Example 56 7- (Cyclobutylcarbonyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Compound (390 mg) obtained in Reference Example 55, methanol-THF (1: 1) mixture (5 mL) and 2N The title compound (320 mg) was obtained in the same manner as in Reference Example 52 using aqueous sodium hydroxide solution (5 mL).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 13.35 (br. S., 1H), 8.26 (dd, J = 8.0, 1.0 Hz, 1H), 8.20 (dd, J = 7.5, 0.8 Hz, 1H) , 7.63-7.68 (m, 1H), 4.29-4.38 (m, 1H), 2.74 (s, 3H), 2.29-2.38 (m, 4H), 2.02-2.15 (m, 1H), 1.79-1.89 (m, 1H)
MS (ESI ^<+> ) m / z: 275 [M + H] ^< +>.

(Reference Example 57) Ethyl 3-methyl-7-pivaloylbenzo [b] thiophene-2-carboxylate Compound obtained in Reference Example 44 (346 mg), THF (4 mL), isopropylmagnesium chloride (2.0 M THF solution, 0.7 mL) , Copper iodide (I) (229 mg), lithium chloride (102 mg) and pivaloyl chloride (406 μL) were used in the same manner as in Reference Example 47 to give the title compound (166 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.28-8.32 (m, 1H), 8.02-8.05 (m, 1H), 7.49-7.54 (m, 1H), 4.39 (q, J = 7.3 Hz, 2H), 2.80 (s, 3H), 1.51 (s, 9H), 1.42 (t, J = 7.1 Hz, 3H)
MS (ESI ^<+> ) m / z: 305 [M + H] ^< +>.

(Reference Example 58) 3-Methyl-7-pivaloylbenzo [b] thiophene-2-carboxylic acid Compound (160 mg) obtained in Reference Example 57, methanol-THF (1: 1) mixture (5 mL), and 2N aqueous sodium hydroxide solution A mixture of (5 mL) was stirred at room temperature for 36 hours. 6N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (144 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 13.34 (br.s., 1H), 8.47 (dd, J = 7.7, 0.9 Hz, 1H), 8.22 (dd, J = 8.0, 1.0 Hz, 1H) , 7.62-7.67 (m, 1H), 2.74 (s, 3H), 1.43 (s, 9H)
MS (ESI ^<+> ) m / z: 277 [M + H] ^< +>.

Reference Example 59 Ethyl 3-methyl-7- (3-methylbutanoyl) benzo [b] thiophene-2-carboxylate Compound (346 mg) obtained in Reference Example 44, THF (4 mL), isopropylmagnesium chloride (2.0 M THF solution, 0.7 mL), copper (I) iodide (229 mg), lithium chloride (102 mg) and isovaleryl chloride (402 μL) were used in the same manner as in Reference Example 47 to give the title compound (188 mg). It was.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.13-8.16 (m, 1H), 8.07-8.10 (m, 1H), 7.53-7.58 (m, 1H), 4.40 (q, J = 7.3 Hz, 2H), 3.00 (d, J = 6.9 Hz, 2H), 2.81 (s, 3H), 2.35-2.46 (m, 1H), 1.43 (t, J = 7.1 Hz, 3H), 1.04 (d, J = 6.9 Hz, 6H)
MS (ESI ^<+> ) m / z: 305 [M + H] ^< +>.

(Reference Example 60) 3-Methyl-7- (3-methylbutanoyl) benzo [b] thiophene-2-carboxylic acid Compound (180 mg) obtained in Reference Example 59 and methanol-THF (1: 1) mixed solution (5 mL ) And 2N aqueous sodium hydroxide (5 mL) were stirred at room temperature for 36 hours. 6N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (166 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 13.36 (br.s., 1H), 8.40 (dd, J = 7.5, 0.8 Hz, 1H), 8.27 (dd, J = 8.0, 1.0 Hz, 1H) , 7.65-7.70 (m, 1H), 3.07 (d, J = 7.0 Hz, 2H), 2.74 (s, 3H), 2.18-2.29 (m, 1H), 0.97 (d, J = 6.8 Hz, 6H)
MS (ESI ^<+> ) m / z: 277 [M + H] ^< +>.

(Reference Example 61) Ethyl 7- (2-ethylbutanoyl) -3-methylbenzo [b] thiophene-2-carboxylate The compound obtained in Reference Example 44 (346 mg), THF (4 mL), isopropylmagnesium chloride (2.0 M The title compound (271 mg) was prepared in the same manner as in Reference Example 47 using THF solution (0.7 mL), copper (I) iodide (229 mg), lithium chloride (102 mg) and 2-ethylbutyryl chloride (452 μL). Obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.16-8.20 (m, 1H), 8.08-8.12 (m, 1H), 7.55-7.60 (m, 1H), 4.40 (q, J = 7.0 Hz, 2H), 3.43-3.53 (m, 1H), 2.82 (s, 3H), 1.83-1.95 (m, 2H), 1.60-1.72 (m, 2H), 1.42 (t, J = 7.5 Hz, 3H), 0.89 (t, J = 7.5 Hz, 6H)
MS (ESI ^<+> ) m / z: 319 [M + H] ^< +>.

(Reference Example 62) 7- (2-Ethylbutanoyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Compound (250 mg) obtained in Reference Example 61, methanol-THF (1: 1) mixed solution (5 mL) And a mixture of 2N aqueous sodium hydroxide (5 mL) was stirred at room temperature for 36 hours. 6N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (215 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 13.36 (br.s., 1H), 8.46 (d, J = 7.0 Hz, 1H), 8.29 (dd, J = 7.9, 0.9 Hz, 1H), 7.68 -7.72 (m, 1H), 3.63-3.71 (m, 1H), 2.75 (s, 3H), 1.68-1.80 (m, 2H), 1.51-1.62 (m, 2H), 0.81 (t, J = 7.4 Hz , 6H)
MS (ESI ^<+> ) m / z: 291 [M + H] ^< +>.

(Reference Example 63) Ethyl 7- (cyclopentylcarbonyl) -3-methylbenzo [b] thiophene-2-carboxylate Compound (346 mg) obtained in Reference Example 44, THF (4 mL), isopropylmagnesium chloride (2.0 M THF solution, 0.7 mL), copper (I) iodide (229 mg), lithium chloride (102 mg) and cyclopentanecarbonyl chloride (401 μL) were used in the same manner as in Reference Example 47 to obtain the title compound (180 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.17-8.20 (m, 1H), 8.06-8.09 (m, 1H), 7.54-7.59 (m, 1H), 4.39 (q, J = 7.3 Hz, 2H), 3.86-3.95 (m, 1H), 2.81 (s, 3H), 1.98-2.06 (m, 4H), 1.65-1.85 (m, 4H), 1.42 (t, J = 7.1 Hz, 3H)
MS (ESI ^<+> ) m / z: 317 [M + H] ^< +>.

(Reference Example 64) 7- (Cyclopentylcarbonyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Compound (170 mg) obtained in Reference Example 63, methanol-THF (1: 1) mixture (5 mL) and 2N water The title compound (155 mg) was obtained in the same manner as in Reference Example 62 using aqueous sodium oxide solution (5 mL).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 13.35 (br. S., 1H), 8.43 (d, J = 7.0 Hz, 1H), 8.27 (dd, J = 8.0, 1.0 Hz, 1H), 7.66 -7.71 (m, 1H), 4.00-4.09 (m, 1H), 2.75 (s, 3H), 1.93-2.03 (m, 2H), 1.76-1.87 (m, 2H), 1.62-1.70 (m, 4H)
MS (ESI ^<+> ) m / z: 289 [M + H] ^< +>.

(Reference Example 65) (4-Bromo-3-fluorophenyl) methanol
A solution of 4-bromo-3-fluorobenzoic acid (39.422 g) in THF (240 mL) was cooled to 0 ° C. under a nitrogen atmosphere, and borane-tetrahydrofuran complex (0.9 M THF solution, 400 mL) was added dropwise and stirred for 2 hours. Thereafter, the mixture was stirred at room temperature for 20 hours. The reaction mixture was cooled to 0 ° C. and water (40 mL) was added dropwise. The reaction mixture was concentrated, water (200 mL), ethyl acetate (100 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL) were sequentially added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated to give the title compound (36.71 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.53 (dd, J = 8.1, 7.3 Hz, 1H), 7.14-7.19 (m, 1H), 7.00-7.06 (m, 1H), 4.68 (d, J = 5.7 Hz, 2H), 1.75 (t, J = 5.9 Hz, 1H).

Reference Example 66 4-Bromo-3-fluorobenzylmethanesulfonate A solution of the compound (30.0 g) obtained in Reference Example 65 and triethylamine (22.4 mL) in dichloromethane (300 mL) was cooled to 0 ° C., and methanesulfonyl chloride ( 12.5 mL) was added dropwise, and the mixture was stirred at the same temperature for 1.5 hours. The reaction mixture was washed with a saturated aqueous sodium hydrogen carbonate-water (1: 3) mixture (300 mL) and saturated brine (300 mL), dried over anhydrous sodium sulfate, and concentrated to give the title compound (40.7 g). .
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.57-7.62 (m, 1H), 7.18-7.22 (m, 1H), 7.07-7.11 (m, 1H), 5.18 (s, 2H), 3.00 ( s, 3H).

(Reference Example 67) 1-Bromo-2-fluoro-4- (methoxymethyl) benzene Sodium methoxide (5.0 M methanol solution, 150 mL) was added to a solution of the compound (40.7 g) obtained in Reference Example 66 in methanol (150 mL). The solution was added dropwise and stirred at room temperature for 1 hour. A saturated aqueous ammonium chloride solution (150 mL) and water (150 mL) were added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give the title compound (31.0 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.48-7.53 (m, 1H), 7.10-7.14 (m, 1H), 6.97-7.01 (m, 1H), 4.41 (s, 2H), 3.39 ( s, 3H).

(Reference Example 68) 3-Bromo-2-fluoro-6- (methoxymethyl) benzaldehyde
A solution of 2,2,6,6-tetramethylpiperidine (232.70 g) in THF (2543 mL) was cooled to −72 ° C. under an argon stream, and n-butyllithium (1.5 M hexane solution, 925 mL) was added dropwise. Stir at temperature for 1 hour. To the reaction mixture was added dropwise a solution of the compound (305.15 g) obtained in Reference Example 67 in THF (1272 mL), and the mixture was stirred at the same temperature for 1 hour. A solution of DMF (117.6 mL) in THF (255 mL) was added dropwise to the reaction mixture, and the mixture was stirred at the same temperature for 1 hour. Acetic acid (255 mL) was added to the reaction mixture, the temperature was raised to room temperature, water (3360 mL) was added, and the mixture was extracted with ethyl acetate (1850 mL). The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate solution (1540 mL) and saturated brine (1540 mL), dried over anhydrous magnesium sulfate, and concentrated. Hexane (2000 mL) was added to the residue, and the mixture was stirred at room temperature for 16 hours, cooled to 0 ° C. and collected by filtration. The obtained solid was washed with hexane (100 mL) to give the title compound (231.4 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 10.48 (d, J = 0.8 Hz, 1H), 7.78 (dd, J = 8.3, 7.0 Hz, 1H), 7.42-7.47 (m, 1H), 4.79 (s, 2H), 3.49 (s, 3H).

Reference Example 69 1- (3-Bromo-2-fluoro-6- (methoxymethyl) phenyl) ethanol Methylmagnesium bromide (3500 mL of a 0.99 M THF solution and 800 mL of a 1.12 M THF solution) in THF ( The solution (1100 mL) was cooled to 0 ° C. under a nitrogen stream, and a solution of the compound (652.99 g) obtained in Reference Example 68 in THF (4570 mL) was added dropwise, and the mixture was stirred at 10 ° C. for 1.5 hours. A saturated aqueous ammonium chloride solution (3450 mL) was added dropwise to the reaction mixture, water (3450 mL) was added, and the mixture was extracted with ethyl acetate (6900 mL). The organic layer was washed with a water-saturated brine (1: 1) mixture (4400 mL), dried over anhydrous magnesium sulfate, and concentrated to give the title compound (703.00 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.42 (dd, J = 8.3, 6.8 Hz, 1H), 6.99 (dd, J = 8.2, 1.1 Hz, 1H), 5.19-5.28 (m, 1H) 4.49-4.63 (m, 2H), 3.39 (s, 3H), 2.92 (dd, J = 7.8, 3.0 Hz, 1H), 1.58-1.61 (m, 3H).

Reference Example 70 1- (3-Bromo-2-fluoro-6- (methoxymethyl) phenyl) ethanone To a solution of the compound obtained in Reference Example 69 (800 g) in dichloromethane (8000 mL), 2-azaadamantane-N-oxyl (0.463 g) was added, and then a mixture of potassium bromide (36.18 g), tetrabutylammonium bromide (49.01 g) and saturated aqueous sodium hydrogen carbonate solution (4165 mL) was added, and the mixture was cooled to 0 ° C. and stirred. To the reaction mixture, a mixture of sodium hypochlorite aqueous solution (manufactured by Nacalai Tesque, 8.5-13.5% as effective chlorine, 2880 mL) and saturated aqueous sodium hydrogen carbonate solution (4000 mL) was added dropwise and stirred at the same temperature for 2 hours. Hexane (8800 mL) was added to the reaction mixture, and the temperature was raised to room temperature. The organic layer was washed with a mixture of sodium thiosulfate (239 g), water (2280 mL) and saturated brine (2280 mL), then washed successively with water and saturated brine, and concentrated to give the title compound (783 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.56 (dd, J = 8.2, 6.9 Hz, 1H), 7.11 (dd, J = 8.3, 1.0 Hz, 1H), 4.43 (s, 2H), 3.35 (s, 3H), 2.57 (d, J = 2.8 Hz, 3H).

Reference Example 71 Ethyl 7-bromo-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylate 1,8 in a DMF (11.00 L) solution of the compound (1000 g) obtained in Reference Example 70 -Diazabicyclo [5.4.0] -7-undecene (1720 mL) was added and cooled to 10 ° C. A solution of ethyl thioglycolate (440 mL) in DMF (390 mL) was added dropwise to the reaction mixture, and the mixture was stirred at room temperature for 22 hours. The reaction mixture was cooled to 0 ° C., water (11.72 L) was added dropwise, and the precipitated solid was collected by filtration, washed with water, and dried to give the title compound (1103 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.55 (d, J = 7.8 Hz, 1H), 7.26 (d, J = 7.8 Hz, 1H), 4.82 (s, 2H), 4.40 (q, J = 7.0 Hz, 2H), 3.45 (s, 3H), 3.01 (s, 3H), 1.42 (t, J = 7.2 Hz, 3H).

Reference Example 72 Ethyl 4- (methoxymethyl) -3-methyl-7-((trimethylsilyl) ethynyl) benzo [b] thiophene-2-carboxylate Compound (100.00 g) obtained in Reference Example 71, copper iodide A mixture of (I) (1.110 g), dichlorobis (triphenylphosphine) palladium (II) (4.090 g), trimethylsilylacetylene (66.7 mL) and triethylamine (1000 mL) was stirred at 70 ° C. for 29.5 hours under an argon atmosphere. The reaction mixture was cooled to room temperature and concentrated. The residue was purified by silica gel column chromatography (hexane: chloroform = 1: 1). Ethanol (525 mL) was added to the obtained solid, heated to 75 ° C., and then cooled to 0 ° C. The precipitated solid was collected by filtration and washed with ethanol to obtain the title compound (97.60 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.50 (d, J = 7.5 Hz, 1H), 7.33 (d, J = 7.5 Hz, 1H), 4.85 (s, 2H), 4.41 (q, J = 7.1 Hz, 2H), 3.44 (s, 3H), 3.01 (s, 3H), 1.43 (t, J = 7.2 Hz, 3H), 0.32 (s, 9H).

(Reference Example 73) Ethyl 7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylate Compound (25.00 g) obtained in Reference Example 72, p-toluenesulfonic acid monohydrate A mixture of (32.97 g) and acetic acid (250 mL) was stirred at 65 ° C. for 6 hours. The reaction mixture was cooled to room temperature, water (250 mL) was added dropwise, and then cooled to 0 ° C. The precipitated solid was collected by filtration and washed with a water-ethanol (1: 2) mixture. The obtained solid was purified by silica gel column chromatography (chloroform). Toluene (102 mL) was added to the obtained solid, heated to 75 ° C., and then cooled to 0 ° C. The precipitated solid was collected by filtration and washed with a hexane-toluene (1: 1) mixed solution to obtain the title compound (18.01 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.07 (d, J = 7.5 Hz, 1H), 7.58 (d, J = 7.5 Hz, 1H), 4.99 (s, 2H), 4.40 (q, J = 7.0 Hz, 2H), 3.51 (s, 3H), 3.03 (s, 3H), 2.75 (s, 3H), 1.43 (t, J = 7.2 Hz, 3H).

Reference Example 74 7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid The compound obtained in Reference Example 73 (18.01 g), 4N aqueous sodium hydroxide solution (29.4 mL) and A mixture of ethanol (201 mL) was stirred at 60 ° C. for 3 hours. The reaction mixture was cooled to room temperature, water (96.7 mL) and 2N hydrochloric acid (64.7 mL) were added, and the mixture was cooled to 0 ° C. The precipitated solid was collected by filtration and washed with a mixed solution of ethanol-water (2: 1) to obtain the title compound (16.037 g).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 13.36 (br.s., 1H), 8.31 (d, J = 7.8 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 5.00 (s , 2H), 3.40 (s, 3H), 2.96 (s, 3H), 2.74 (s, 3H)
MS (ESI ^<+> ) m / z: 279 [M + H] ^< +>.

(Reference Example 75) Ethyl 7-acetyl-4- (dimethoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylate Compound (11.680 g) obtained in Reference Example 21, dichlorobis (triphenylphosphine) palladium (II ) (1.779 g), and a solution of (1-ethoxyvinyl) tributyltin (31.1 mL) in toluene (350 mL) was stirred at 100 ° C. for 18 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, 2N hydrochloric acid (175 mL) was added, and the mixture was stirred for 8 hr. The reaction mixture was filtered through Hyflo Super Cel (manufactured by Nacalai Tesque), and the high flow super cell was washed with toluene (150 mL) to obtain an organic layer from the filtrate. The obtained organic layer was washed successively with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 1: 0 to 4: 1) to obtain a solid containing the title compound. Hexane (300 mL) was added to the obtained solid and heated to 70 ° C., and then cooled to 0 ° C., and the precipitated solid was collected by filtration. The obtained solid was washed with hexane to obtain the title compound (7.787 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.11 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 7.7 Hz, 1H), 6.20 (s, 1H), 4.41 (q, J = 7.3 Hz, 2H), 3.38 (s, 6H), 3.08 (s, 3H), 2.77 (s, 3H), 1.43 (t, J = 7.3 Hz, 3H).

Reference Example 76 Ethyl 7-acetyl-4-formyl-3-methylbenzo [b] thiophene-2-carboxylate To a solution of the compound (4.0 g) obtained in Reference Example 75 in THF (60 mL) was added 2N hydrochloric acid (30 mL). The mixture was further stirred at room temperature for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (3.5 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 11.05 (s, 1H), 8.18 (d, J = 7.8 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 4.44 (q, J = 7.0 Hz, 2H), 3.05 (s, 3H), 2.81 (s, 3H), 1.45 (t, J = 7.2 Hz, 3H).

(Reference Example 77) Ethyl 7-acetyl-4- (hydroxymethyl) -3-methylbenzo [b] thiophene-2-carboxylate A solution of the compound obtained in Reference Example 76 (3.0 g) in dichloromethane (100 mL) was trihydrated. After adding sodium acetoxyboron (10.9 g), acetic acid (2.4 mL) was added, and the mixture was stirred at 40 ° C. for 4 days. Saturated aqueous ammonium chloride solution (70 mL) and water (70 mL) were added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (3.0 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.09 (d, J = 7.5 Hz, 1H), 7.65 (d, J = 7.5 Hz, 1H), 5.31 (d, J = 5.8 Hz, 2H), 4.40 (q, J = 7.0 Hz, 2H), 3.05 (s, 3H), 2.76 (s, 3H), 1.92 (t, J = 5.8 Hz, 1H), 1.43 (t, J = 7.2 Hz, 3H).

(Reference Example 78) 7-acetyl-4- (ethoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid A suspension of the compound (146 mg) obtained in Reference Example 77 in ethanol (10 mL) was concentrated at room temperature. Sulfuric acid (5 mL) was added dropwise, and the mixture was stirred at 60 ° C. for 22 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was dissolved in a THF-methanol (2: 1) mixture (7.5 mL), 4N aqueous sodium hydroxide solution (2.5 mL) was added, and the mixture was stirred at room temperature for 4 hr. The reaction mixture was acidified with 6N hydrochloric acid and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound.
MS (ESI ^<+> ) m / z: 293 [M + H] ^< +>.

(Reference Example 79) 7-acetyl-3-methyl-4- (propoxymethyl) benzo [b] thiophene-2-carboxylic acid To a suspension of the compound obtained in Reference Example 77 (146 mg) in 1-propanol (10 mL) Concentrated sulfuric acid (5 mL) was added dropwise at room temperature, and the mixture was stirred at 60 ° C. for 3 days. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was dissolved in a THF-methanol (2: 1) mixture (7.5 mL), 4N aqueous sodium hydroxide solution (2.5 mL) was added, and the mixture was stirred at room temperature for 20 hr. The reaction mixture was acidified with 6N hydrochloric acid and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound.
MS (ESI ^<+> ) m / z: 307 [M + H] ^< +>.

(Reference Example 80) 7-acetyl-4- (isopropoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid To a suspension of the compound obtained in Reference Example 77 (146 mg) in 2-propanol (10 mL) Concentrated sulfuric acid (5 mL) was added dropwise at room temperature, and the mixture was stirred at 60 ° C. for 3 days. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was dissolved in a THF-methanol (2: 1) mixture (7.5 mL), 4N aqueous sodium hydroxide solution (2.5 mL) was added, and the mixture was stirred at room temperature for 20 hr. The reaction mixture was acidified with 6N hydrochloric acid and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound.
MS (ESI ^<+> ) m / z: 307 [M + H] ^< +>.

(Reference Example 81) Ethyl 7-acetyl-4- (1-hydroxyethyl) -3-methylbenzo [b] thiophene-2-carboxylate A solution of the compound (350 mg) obtained in Reference Example 76 in THF (20 mL) was added to a nitrogen atmosphere. Under cooling to −78 ° C., methylmagnesium bromide (0.96M THF solution, 2.5 mL) was added dropwise, and the mixture was stirred at room temperature for 6 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 85: 15-50: 50) to give the title compound (230 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.22 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 7.7 Hz, 1H), 5.95-6.02 (m, 1H), 4.37-4.45 ( m, 2H), 3.03 (s, 3H), 2.77 (s, 3H), 1.57 (d, J = 5.7 Hz, 3H), 1.44 (t, J = 7.1 Hz, 3H)
MS (ESI ^<+> ) m / z: 307 [M + H] ^< +>.

(Reference Example 82) Ethyl 7-acetyl-4- (1-methoxyethyl) -3-methylbenzo [b] thiophene-2-carboxylate Compound obtained in Reference Example 81 (90 mg), p-toluenesulfonic acid (14 mg) And a mixture of methanol (25 mL) was stirred at 70 ° C. for 2 days. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (hexane: ethyl acetate = 90: 10-60: 40) to give the title compound (100 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.14 (d, J = 7.7 Hz, 1H), 7.79 (d, J = 7.7 Hz, 1H), 5.42-5.52 (m, 1H), 4.41 (q , J = 6.9 Hz, 2H), 3.31 (s, 3H), 3.28-3.36 (m, 3H), 3.03 (s, 3H), 2.76 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H) , 1.38-1.47 (m, 3H).

(Reference Example 83) 7-acetyl-4- (1-methoxyethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Compound (100 mg), methanol (10 mL) and 2N sodium hydroxide obtained in Reference Example 82 A mixture of aqueous solution (10 mL) was stirred at room temperature for 3 hours. The reaction mixture was acidified with hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (60 mg).
MS (ESI ^<+> ) m / z: 293 [M + H] ^< +>.

(Reference Example 84) (2-((tert-Butoxycarbonyl) amino) quinolin-4-yl) methyl methanesulfonate Solution of compound (3.00 g) obtained in Reference Example 38 and triethylamine (1.68 mL) in dichloromethane (50 mL) Was cooled to 0 ° C., methanesulfonyl chloride (929 μL) was added, and the mixture was stirred at the same temperature for 1 hour. To the reaction mixture was added a saturated aqueous sodium hydrogen carbonate-water (1: 3) mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (3.90 g).
MS (ESI ^<+> ) m / z: 353 [M + H] ^< +>.

Reference Example 85 2-(((2-Aminoquinolin-4-yl) methyl) (methyl) amino) ethanol The compound obtained in Reference Example 84 (2.71 g), 2- (methylamino) ethanol (693 mg), A mixture of N, N-diisopropylethylamine (1.49 g) and DMF (8 mL) was stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was dissolved in dichloromethane (4.86 mL), TFA (4.86 mL) was added, and the mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated, and the residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 98: 2-92: 8) to give the title compound (1.29 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.91-7.95 (m, 1H), 7.68-7.72 (m, 1H), 7.54-7.59 (m, 1H), 7.27-7.32 (m, 1H), 6.79 (s, 1H), 5.00 (br. S., 2H), 3.89 (s, 2H), 3.65-3.70 (m, 2H), 2.68-2.73 (m, 2H), 2.32 (s, 3H).

Reference Example 86 1-((2-Aminoquinolin-4-yl) methyl) pyrrolidin-3-ol A solution of the compound obtained in Reference Example 38 (700 mg) and triethylamine (426 μL) in 1,2-dichloroethane (15 mL) To the mixture was added methanesulfonyl chloride (237 μL), and the mixture was stirred at room temperature for 2 hours. To the reaction mixture was added aqueous sodium hydrogen carbonate solution, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. To the residue were added THF (15 mL) and DL-3-pyrrolidinol (1 mL), and the mixture was stirred for 24 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 80:20), and tert-butyl (4-((3-hydroxypyrrolidin-1-yl) methyl) quinoline- 2-yl) carbamate was obtained. Dichloromethane (10 mL) and TFA (6 mL) were added to the obtained compound, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to give the title compound (500 mg).
MS (ESI ^<+> ) m / z: 244 [M + H] ^< +>.

Reference Example 87 1-((2-Aminoquinolin-4-yl) methyl) piperidin-4-ol A mixture of the compound obtained in Reference Example 84 (282 mg), 4-hydroxypiperidine (243 mg) and THF (4 mL) Was stirred at 50 ° C. for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Dichloromethane (5 mL) and TFA (1 mL) were added to the residue, and the mixture was stirred at room temperature for 14 hours. 2N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to obtain the title compound (183 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.96-8.00 (m, 1H), 7.66-7.69 (m, 1H), 7.53-7.58 (m, 1H), 7.27-7.29 (m, 1H), 7.24-7.26 (m, 1H), 6.82 (s, 1H), 4.74 (br. S., 2H), 3.81 (s, 2H), 3.72-3.80 (m, 1H), 2.79-2.88 (m, 2H) , 2.23-2.32 (m, 2H), 1.88-1.96 (m, 2H), 1.58-1.68 (m, 2H)
MS (ESI ^<+> ) m / z: 258 [M + H] ^< +>.

Reference Example 88 1-((2-Aminoquinolin-4-yl) methyl) piperidin-3-ol A mixture of the compound obtained in Reference Example 84 (282 mg), 3-hydroxypiperidine (243 mg) and THF (4 mL) Was stirred at 50 ° C. for 5.5 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Dichloromethane (5 mL) and TFA (1 mL) were added to the residue, and the mixture was stirred at room temperature for 18 hours. 2N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 85:15) to obtain the title compound (178 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.94-7.97 (m, 1H), 7.66-7.69 (m, 1H), 7.53-7.58 (m, 1H), 7.25-7.29 (m, 1H), 6.75 (s, 1H), 4.73 (br. S., 2H), 3.78-3.89 (m, 3H), 2.27-2.71 (m, 5H), 1.48-1.92 (m, 3H)
MS (ESI ^<+> ) m / z: 258 [M + H] ^< +>.

(Reference Example 89) (S) -1-((2-Aminoquinolin-4-yl) methyl) pyrrolidin-3-ol The compound obtained in Reference Example 84 (160 mg), (S) -3-pyrrolidinol (110 μL) And a mixture of THF (2 mL) was stirred at 50 ° C. for 6 h. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Dichloromethane (5 mL) and TFA (1 mL) were added to the residue, and the mixture was stirred at room temperature for 18 hours. 2N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to obtain the title compound (102 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.94 (dd, J = 8.5, 1.2 Hz, 1H), 7.68 (dd, J = 8.7, 1.0 Hz, 1H), 7.52-7.58 (m, 1H) , 7.25-7.29 (m, 1H), 6.81 (s, 1H), 4.75 (br. S., 2H), 4.35-4.41 (m, 1H), 3.96 (s, 2H), 2.94-3.02 (m, 1H ), 2.76-2.83 (m, 1H), 2.58-2.65 (m, 1H), 2.37-2.46 (m, 1H), 2.17-2.28 (m, 1H), 1.75-1.85 (m, 1H)
MS (ESI ^<+> ) m / z: 244 [M + H] ^< +>.

(Reference Example 90) (R) -1-((2-Aminoquinolin-4-yl) methyl) pyrrolidin-3-ol Compound (160 mg) obtained in Reference Example 84, (R) -3-pyrrolidinol (110 μL) And a mixture of THF (2 mL) was stirred at 50 ° C. for 7 h. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Dichloromethane (5 mL) and TFA (1 mL) were added to the residue, and the mixture was stirred at room temperature for 18 hours. 2N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to obtain the title compound (103 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.94 (dd, J = 8.3, 1.4 Hz, 1H), 7.68 (dd, J = 8.5, 1.2 Hz, 1H), 7.53-7.58 (m, 1H) , 7.25-7.30 (m, 1H), 6.81 (s, 1H), 4.74 (br. S., 2H), 4.35-4.42 (m, 1H), 3.97 (s, 2H), 2.94-3.02 (m, 1H ), 2.77-2.82 (m, 1H), 2.59-2.66 (m, 1H), 2.37-2.45 (m, 1H), 2.17-2.29 (m, 1H), 1.76-1.84 (m, 1H)
MS (ESI ^<+> ) m / z: 244 [M + H] ^< +>.

Reference Example 91 1- (3-Bromo-2-fluoro-6- (methoxymethyl) phenyl) propan-1-ol Ethylmagnesium bromide (1M THF solution, 76 mL) was cooled to 0 ° C. A solution of the compound obtained in 68 (12.6 g) in THF (200 mL) was added dropwise, and the mixture was stirred at room temperature for 3 hours. A saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 50: 1 to 1: 1) to give the title compound (10.1 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.41 (dd, J = 8.1, 6.9 Hz, 1H), 6.99-7.03 (m, 1H), 4.92 (dd, J = 8.1, 6.1 Hz, 1H) , 4.55-4.60 (m, 1H), 4.46-4.51 (m, 1H), 3.38 (s, 3H), 1.77-1.99 (m, 2H), 0.97 (t, J = 7.5 Hz, 3H).

Reference Example 92 1- (3-Bromo-2-fluoro-6- (methoxymethyl) phenyl) propan-1-one N-methyl was added to a solution of the compound (10.1 g) obtained in Reference Example 91 in acetonitrile (100 mL). Morpholine-N-oxide (6.40 g) and tetrapropylammonium perruthenate (1.281 g) were added, and the mixture was stirred at room temperature for 10 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-3: 1) to give the title compound (7.2 g).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.51-7.56 (m, 1H), 7.05-7.09 (m, 1H), 4.39 (s, 2H), 3.32-3.34 (m, 3H), 2.82- 2.90 (m, 2H), 1.17-1.22 (m, 3H).

(Reference Example 93) Ethyl 7-bromo-3-ethyl-4- (methoxymethyl) benzo [b] thiophene-2-carboxylate Into a DMF (100 mL) solution of the compound (7.2 g) obtained in Reference Example 92, 8-Diazabicyclo [5.4.0] -7-undecene (11.83 mL) and ethyl thioglycolate (3.16 mL) were added, and the mixture was stirred at room temperature for 8 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-80: 20) to give the title compound (7.3 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.57 (d, J = 7.7 Hz, 1H), 7.30 (d, J = 7.7 Hz, 1H), 4.82 (s, 2H), 4.39-4.44 (m , 2H), 3.44 (s, 3H), 3.41-3.48 (m, 2H), 1.43 (t, J = 7.1 Hz, 3H), 1.28-1.35 (m, 3H).

(Reference Example 94) Ethyl 3-ethyl-4- (methoxymethyl) -7-((trimethylsilyl) ethynyl) benzo [b] thiophene-2-carboxylate THF (100 mL of the compound (4.33 g) obtained in Reference Example 93 ) Solution was added trimethylsilylacetylene (2.89 mL), tetrakis (triphenylphosphine) palladium (0) (0.420 g), copper (I) bromide (0.174 g) and triethylamine (3.38 mL), and 80 Stir at 12 ° C. for 12 hours. The reaction mixture was cooled to room temperature and filtered, and then the filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 to 1: 1) to obtain the title compound (3.70 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.51 (d, J = 7.7 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 4.84 (s, 2H), 4.41 (q, J = 7.0 Hz, 2H), 3.42-3.49 (m, 2H), 3.44 (s, 3H), 1.43 (t, J = 7.1 Hz, 3H), 1.27-1.34 (m, 3H), 0.32 (s, 9H) .

(Reference Example 95) Ethyl 7-acetyl-3-ethyl-4- (methoxymethyl) benzo [b] thiophene-2-carboxylate Compound (3.70 g) obtained in Reference Example 94, p-toluenesulfonic acid monohydrate Product (15.03 g) and chloroform (10 mL) were stirred at 80 ° C. for 10 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 1 to 1: 1) to obtain the title compound (1.80 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.08 (d, J = 7.7 Hz, 1H), 7.62 (d, J = 7.7 Hz, 1H), 4.98 (s, 2H), 4.40 (q, J = 6.9 Hz, 2H), 3.51 (s, 3H), 3.47 (q, J = 7.4 Hz, 2H), 2.76 (s, 3H), 1.43 (t, J = 7.1 Hz, 3H), 1.32 (t, J = 7.5 Hz, 3H).

Reference Example 96 7-Acetyl-3-ethyl-4- (methoxymethyl) benzo [b] thiophene-2-carboxylic acid An aqueous sodium solution (28.1 mL) was added dropwise, and the mixture was stirred at room temperature for 12 hours. 4N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (1.64 g).

(Reference Example 97) 4- (Pyrrolidin-1-ylmethyl) quinolin-2-amine
Pyrrolidine (334 μL) was added to a solution of 4- (bromomethyl) -2-chloroquinoline (1.03 g) and triethylamine (669 μL) in acetonitrile (10 mL), and the mixture was stirred at room temperature for 3 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. 4-methoxybenzylamine (2.61 mL) was added to the residue, and the mixture was stirred at 110 ° C. for 18 hours under an argon atmosphere. The reaction mixture was dissolved in dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. Toluene (1.30 mL) and methanesulfonic acid (1.30 mL) were added to the residue, and the mixture was stirred at 80 ° C. for 16 hours. 4N sodium hydroxide was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10), and the resulting solid was washed with a mixed solution of ethyl acetate-hexane (1: 3) to give the title compound (432 mg). Obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.95 (dd, J = 8.5, 1.2 Hz, 1H), 7.67 (dd, J = 8.7, 1.0 Hz, 1H), 7.51-7.57 (m, 1H) , 7.24-7.29 (m, 1H), 6.84 (s, 1H), 4.74 (br. S., 2H), 3.95 (d, J = 1.2 Hz, 2H), 2.59-2.65 (m, 4H), 1.79- 1.87 (m, 4H)
MS (ESI ^<+> ) m / z: 228 [M + H] ^< +>.

(Reference Example 98) 4- (morpholinomethyl) quinolin-2-amine
Morpholine (350 μL) was added to a solution of 4- (bromomethyl) -2-chloroquinoline (1.03 g) and triethylamine (669 μL) in acetonitrile (10 mL), and the mixture was stirred at room temperature for 3 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. 4-methoxybenzylamine (2.61 mL) was added to the residue, and the mixture was stirred at 110 ° C. for 18 hours under an argon atmosphere. The reaction mixture was dissolved in dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. Toluene (1.30 mL) and methanesulfonic acid (1.30 mL) were added to the residue, and the mixture was stirred at 80 ° C. for 16 hours. 4N sodium hydroxide was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10), and the obtained solid was washed with a mixed solution of ethyl acetate-hexane (1: 3) to give the title compound (348 mg). Obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.00 (dd, J = 8.3, 1.0 Hz, 1H), 7.68 (dd, J = 8.7, 1.0 Hz, 1H), 7.53-7.58 (m, 1H) , 7.25-7.30 (m, 1H), 6.81 (s, 1H), 4.76 (br. S., 2H), 3.80 (d, J = 0.8 Hz, 2H), 3.71-3.75 (m, 4H), 2.51- 2.56 (m, 4H)
MS (ESI ^<+> ) m / z: 244 [M + H] ^< +>.

Reference Example 99 (R) -4-((3-Fluoropyrrolidin-1-yl) methyl) quinolin-2-amine
A suspension of 4- (bromomethyl) -2-chloroquinoline (1.946 g), potassium carbonate (2.306 g) and sodium iodide (3.87 g) in DMF (30 mL) was stirred for 30 minutes, and (R) -3-fluoro Pyrrolidine hydrochloride (1.00 g) was added and stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. 2,4-Dimethoxybenzylamine (0.990 mL) was added to the residue, and the mixture was stirred at 120 ° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10), and (R) -N- (2,4-dimethoxybenzyl) -4-((3- Fluoropyrrolidin-1-yl) methyl) quinolin-2-amine was obtained. Dichloromethane (10 mL) and TFA (1.752 mL) were added to the obtained compound, and the mixture was stirred at 50 ° C. for 1 hr. The reaction mixture was cooled to room temperature, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 70:30) to give the title compound (1.20 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.93 (dd, J = 8.1, 1.2 Hz, 1H), 7.70 (dd, J = 8.5, 0.8 Hz, 1H), 7.57 (ddd, J = 8.4, 7.0, 1.6 Hz, 1H), 7.29 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H), 6.88 (s, 1H), 5.09-5.30 (m, 3H), 3.99-4.03 (m, 2H), 2.79 -3.04 (m, 3H), 2.55-2.62 (m, 1H), 2.04-2.27 (m, 2H)
MS (ESI ^<+> ) m / z: 246 [M + H] ^< +>.

Reference Example 100 4-((4-Fluoropiperidin-1-yl) methyl) quinolin-2-amine
A mixture of 4- (bromomethyl) -2-chloroquinoline (436 mg), triethylamine (1 mL), water (0.5 mL), acetonitrile (2 mL) and 4-fluoropiperidine hydrochloride (237 mg) was stirred at room temperature for 1.5 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. 4-methoxybenzylamine (2.2 mL) was added to the residue, and the mixture was stirred at 100 ° C. overnight. The reaction mixture was dissolved in dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. Toluene (1.1 mL) and methanesulfonic acid (1.1 mL) were added to the residue, and the mixture was stirred at 100 ° C. for 3 hours. 4N sodium hydroxide was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to obtain the title compound (104 mg).
MS (ESI ⁺ ) m / z: 260 [M + H] ⁺ .

Reference Example 101 1-((2-Aminoquinolin-4-yl) methyl) azetidin-3-ol
A mixture of 4- (bromomethyl) -2-chloroquinoline (1.28 g), triethylamine (2 mL), water (1 mL), acetonitrile (4 mL) and 3-hydroxyazetidine hydrochloride (548 mg) was stirred at room temperature for 1.5 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. 4-methoxybenzylamine (3.27 mL) was added to the residue, and the mixture was stirred at 75 ° C. for 15 hr. The reaction mixture was dissolved in dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. Toluene (1.6 mL) and methanesulfonic acid (1.6 mL) were added to the residue, and the mixture was stirred at 60 ° C. for 15 hours. A 4N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to give the title compound (23 mg).
MS (ESI ^<+> ) m / z: 230 [M + H] ^< +>.

(Reference Example 102) 7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide To a solution of the compound (2.00 g) obtained in Reference Example 74 in N, N-dimethylacetamide (20 mL) HBTU (3.27 g) and N, N-diisopropylethylamine (1.11 g) were added under a nitrogen atmosphere and stirred for 30 minutes. A mixture of ammonium acetate (1.66 g) and N, N-diisopropylethylamine (2.78 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with ethyl acetate, washed successively with water, 0.05N hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was washed with an ethyl acetate-heptane mixture to give the title compound (1.36 g).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 8.26 (d, J = 7.6 Hz, 1H), 7.90 (brs, 1H), 7.67 (brs, 1H), 7.63 (d, J = 7.6 Hz, 1H) , 4.97 (s, 2H), 3.39 (s, 3H), 2.77 (s, 3H), 2.74 (s, 3H).

(Reference Example 103) 2-Chloro-4-((3,3-difluoropyrrolidin-1-yl) methyl) quinoline
A suspension of 4- (bromomethyl) -2-chloroquinoline (447 mg), potassium carbonate (505 mg) and sodium iodide (861 mg) in DMF (10 mL) was stirred at room temperature for 30 minutes, and 3,3-difluoropyrrolidine hydrochloride (250 mg) was added and stirred at room temperature for 5 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (480 mg).

Reference Example 104 (R)-(2-Chloroquinolin-4-yl) (3-hydroxypyrrolidin-1-yl) methanone
A mixture of 2-chloroquinoline-4-carboxylic acid (623 mg), thionyl chloride (2.19 mL) and chloroform (10 mL) was refluxed overnight and the reaction mixture was concentrated. Triethylamine (502 μL) and chloroform (8 mL) were added to the residue, cooled to 0 ° C., a solution of (R) -pyrrolidinol in chloroform (2 mL) was added dropwise, and the mixture was stirred at the same temperature for 1 hour. Water and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was washed with a dichloromethane-hexane (1: 3) mixture to obtain the title compound (720 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.04-8.09 (m, 1H), 7.82-7.86 (m, 1H), 7.75-7.81 (m, 1H), 7.58-7.63 (m, 1H), 7.37 (d, J = 7.7 Hz, 1H), 4.43-4.70 (m, 1H), 3.79-3.98 (m, 2H), 3.10-3.50 (m, 2H), 1.94-2.20 (m, 2H)
MS (ESI ^<+> ) m / z: 277 [M + H] ^< +>.

Reference Example 105 (R)-(2-Aminoquinolin-4-yl) (3-hydroxypyrrolidin-1-yl) methanone The compound (166 mg) obtained in Reference Example 104 and 4-methoxybenzylamine (785 mg) The mixture was stirred at 80 ° C. overnight. The reaction mixture was dissolved in dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. Toluene (0.4 mL) and methanesulfonic acid (0.389 mL) were added to the residue, and the mixture was stirred at 60 ° C. overnight. A 4N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 85:15) to obtain the title compound (26 mg).
MS (ESI ^<+> ) m / z: 258 [M + H] ^< +>.

(Reference Example 106) N ⁴ , N ⁴ -dimethylquinoline-2,4-diamine
A mixture of 2-amino-4-chloroquinoline (43 mg) and 50% aqueous dimethylamine (2 mL) was stirred at 150 ° C. for 30 minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated to give the title compound (43 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.88 (dd, J = 8.4, 1.3 Hz, 1H), 7.62 (dd, J = 8.6, 1.0 Hz, 1H), 7.46-7.52 (m, 1H) , 7.18-7.23 (m, 1H), 6.10 (s, 1H), 4.69 (brs, 2H), 2.97 (s, 6H).

(Reference Example 107) 7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid 2,4,6-trimethylbenzoic anhydride Compound obtained in Reference Example 74 (27.8 g) 2,4,6-trimethylbenzoyl chloride (21.6 mL) was added dropwise to a chloroform (300 mL) solution of triethylamine (19.0 mL) and stirred at room temperature for 3 hours. The reaction mixture was concentrated, water and saturated aqueous ammonium chloride solution were added, and the mixture was extracted with toluene. The organic layer was washed with a saturated aqueous ammonium chloride-water (1: 1) mixture, dried over anhydrous sodium sulfate, and concentrated. The residue was washed with diisopropyl ether to give the title compound (39.0 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.12 (d, J = 7.7 Hz, 1H), 7.62 (d, J = 7.7 Hz, 1H), 6.93 (s, 2H), 4.99 (s, 2H ), 3.52 (s, 3H), 3.09 (s, 3H), 2.75 (s, 3H), 2.51 (s, 6H), 2.33 (s, 3H).

Reference Example 108 4- (Methoxymethyl) -3-methyl-7-pivaloylbenzo [b] thiophene-2-carboxylic acid Compound (306 mg) obtained in Reference Example 73 and methyl iodide (498 μL) in DMSO (3 mL) The solution was warmed to 50 ° C., potassium hydroxide (1122 mg) and DMSO (3 mL) were added, and the mixture was stirred at the same temperature for 1.5 hours. Methyl iodide (498 μL) was added to the reaction mixture and stirred for 30 minutes. The reaction mixture was poured into a mixture of 1N hydrochloric acid and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: dichloromethane = 30: 70-0: 100). To the obtained compound, THF (2 mL), methanol (1 mL) and 2N aqueous sodium hydroxide solution (1 mL) were added, and the mixture was stirred at room temperature for 2 hours. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (81 mg).
MS (ESI ^<+> ) m / z: 321 [M + H] ^< +>.

(Reference Example 109) 7-isobutyryl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Compound obtained in Reference Example 73 in a mixture of potassium hydroxide (2244 mg) and DMSO (10 mL) ( 612 mg) and methyl iodide (996 μL) were added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into a mixture of 1N hydrochloric acid and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. To the residue were added THF (8 mL), methanol (4 mL) and 2N aqueous sodium hydroxide solution (4 mL), and the mixture was stirred at room temperature for 1 hour. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated, and the resulting solid was washed with a hexane-ethyl acetate (1: 1) mixture to obtain the title compound (344 mg).
MS (ESI ^<+> ) m / z: 307 [M + H] ^< +>.

(Reference Example 110) Methyl 2-chloroquinoline-5-carboxylate
Add a solution of methyl iodide (8.20 g) in DMF (20 mL) to a suspension of 2-chloroquinoline-5-carboxylic acid (8.00 g) and potassium carbonate (15.98 g) in DMF (20 mL), and stir at room temperature for 3 hours did. Saturated brine and water were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated to give the title compound (8.28 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.35 (dd, J = 9.3, 0.8 Hz, 1H), 8.31 (dd, J = 7.5, 1.3 Hz, 1H), 8.22 (dt, J = 8.5, 1.0 Hz, 1H), 7.77 (dd, J = 8.4, 7.4 Hz, 1H), 7.51 (d, J = 9.3 Hz, 1H), 4.01 (s, 3H)
MS (ESI ^<+> ) m / z: 222 [M + H] ^< +> _.

(Reference Example 111) (2-Chloroquinolin-5-yl) methanol Sodium borohydride (3.414 g) was added to a THF (67 mL) solution of the compound (5.000 g) obtained in Reference Example 110, and methanol (22 mL) was added. The solution was added dropwise and stirred at 55 ° C. for 30 minutes. The reaction mixture was cooled to room temperature, water (125 mL) was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated to give the title compound (4.355 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.49 (dd, J = 8.8, 0.8 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.70 (dd, J = 8.5, 7.0 Hz , 1H), 7.57 (dd, J = 7.0, 1.0 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 5.13 (br.s., 2H), 1.82 (br.s., 1H)
MS (ESI ^<+> ) m / z: 194 [M + H] ^< +>.

(Reference Example 112) (2-Chloroquinolin-5-yl) methyl methanesulfonate A solution of the compound obtained in Reference Example 111 (465 mg) and triethylamine (502 μL) in dichloromethane (15 mL) was cooled to 0 ° C., and methanesulfonyl chloride was (232 μL) was added and stirred at the same temperature for 2 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1 to 1: 2) to give the title compound (577 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.42 (d, J = 8.9 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.72-7.79 (m, 1H), 7.66 (d , J = 6.9 Hz, 1H), 7.52 (d, J = 8.9 Hz, 1H), 5.66 (s, 2H), 2.92 (s, 3H)
MS (ESI ^<+> ) m / z: 272 [M + H] ^< +>.

(Reference Example 113) (R) -2-Chloro-5-((3-fluoropyrrolidin-1-yl) methyl) quinoline Compound (500 mg) obtained in Reference Example 112, (R) -3-fluoropyrrolidine hydrochloride A solution of (277 mg) and triethylamine (465 mg) in N, N-dimethylacetamide (5 mL) was stirred at 70 ° C. for 2 hours. The reaction mixture was diluted with ethyl acetate, washed successively with water, saturated sodium hydrogen carbonate and saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to obtain the title compound (484 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.66 (d, J = 8.9 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 8.5 Hz, 1H), 7.48 (d, J = 6.9 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 5.06-5.27 (m, 1H), 3.97-4.10 (m, 2H), 2.70-2.92 (m, 3H) , 2.42-2.51 (m, 1H), 1.94-2.23 (m, 2H).

Reference Example 114 4-((2-chloroquinolin-5-yl) methyl) morpholine Reference was made using the compound obtained in Reference Example 112 (300 mg), morpholine (116 mg), triethylamine (146 mg) and THF (5 mL). In the same manner as in Example 113, the title compound (261 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.69 (d, J = 9.1 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 7.2, 8.5 Hz, 1H ), 7.45 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 3.87 (s, 2H), 3.60-3.70 (m, 4H), 2.41-2.50 (m, 4H) .

(Reference Example 115) 1- (2-chloroquinolin-5-yl) -N, N-dimethylmethanamine THF (1 mL) of the compound (108 mg) obtained in Reference Example 112 and dimethylamine (2M THF solution, 0.8 mL) ) The solution was stirred at room temperature overnight, dimethylamine (2M THF solution, 0.8 mL) was added and stirred at 60 ° C for 1 hour, dimethylamine (2M THF solution, 0.8 mL) was added and stirred at 60 ° C for 2 hours. . The reaction mixture was diluted with ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate: methanol = 10: 10: 1) to give the title compound (53 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.63-8.66 (m, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.65 (dd, J = 7.2, 8.5 Hz, 1H), 7.41 -7.47 (m, 1H), 7.40 (d, J = 8.8 Hz, 1H), 3.80 (s, 2H), 2.27 (s, 6H).

(Reference Example 116) (S) -1-((2-Chloroquinolin-5-yl) methyl) pyrrolidin-3-ol Compound obtained in Reference Example 112 (140 mg), (S) -3-hydroxypyrrolidine (54 mg ) And triethylamine (79 mg) in THF (5 mL) was refluxed overnight. The reaction mixture was diluted with ethyl acetate, washed successively with saturated sodium bicarbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate: methanol = 10: 10: 1) to give the title compound (129 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.62-8.64 (m, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.65 (dd, J = 7.1, 8.4 Hz, 1H), 7.47 (d, J = 8.9 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 4.30-4.36 (m, 1H), 3.98-4.06 (m, 2H), 2.80-2.90 (m, 1H), 2.64-2.70 (m, 1H), 2.54-2.61 (m, 1H), 2.30-2.40 (m, 1H), 2.13-2.22 (m, 1H), 1.69-1.84 (m, 2H).

(Reference Example 117) (R) -1-((2-Chloroquinolin-5-yl) methyl) pyrrolidin-3-ol To a solution of the compound (2.943 g) obtained in Reference Example 112 in chloroform (40 mL) was added triethylamine (2.19). mL) was added and cooled to 0 ° C., and then a solution of (R) -3-hydroxypyrrolidine (1.175 g) in chloroform (5 mL) was added and stirred at room temperature for 20 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 1 to 90:10) to obtain the title compound (2.544 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.62-8.69 (m, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.65 (dd, J = 8.5, 7.3 Hz, 1H), 7.47 (d, J = 6.5 Hz, 1H), 7.40 (d, J = 8.9 Hz, 1H), 4.29-4.37 (m, 1H), 4.01 (s, 2H), 2.80-2.88 (m, 1H), 2.63- 2.68 (m, 1H), 2.55-2.61 (m, 1H), 2.29-2.43 (m, 1H), 2.14-2.24 (m, 1H), 1.69-1.77 (m, 1H).

Reference Example 118 (R) -1-((2-((4-Methoxybenzyl) amino) quinolin-5-yl) methyl) pyrrolidin-3-ol The compound (2.45 g) obtained in Reference Example 117 and 4 A mixture of -methoxybenzylamine (7.31 mL) was stirred at 140 ° C. for 8 hours. The reaction mixture was cooled to room temperature, diluted with dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 97: 3-84: 16) to obtain the title compound (2.744 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.30 (d, J = 9.7 Hz, 1H), 7.62-7.66 (m, 1H), 7.44 (dd, J = 8.5, 7.3 Hz, 1H), 7.31 -7.36 (m, 2H), 7.11-7.15 (m, 1H), 6.85-6.90 (m, 2H), 6.63 (d, J = 9.3 Hz, 1H), 4.94 (br. S., 1H), 4.64 ( d, J = 5.7 Hz, 2H), 4.29 (br.s., 1H), 3.90-3.93 (m, 2H), 3.80 (s, 3H), 2.81-2.88 (m, 1H), 2.64-2.69 (m , 1H), 2.53 (dd, J = 10.1, 4.9 Hz, 1H), 2.27-2.35 (m, 1H), 2.11-2.21 (m, 1H), 1.66-1.76 (m, 1H)
MS (ESI ^<+> ) m / z: 364 [M + H] ^< +>.

Reference Example 119 (R) -1-((2-Aminoquinolin-5-yl) methyl) pyrrolidin-3-ol A mixture of the compound (2.744 g) obtained in Reference Example 118 and TFA (11.6 mL) was 70. Stir at 0 ° C. for 10 hours. The reaction mixture was cooled to room temperature and concentrated. Chloroform and 2N aqueous sodium hydroxide solution were added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 98.5: 1.5 to 93: 7) to obtain the title compound (1.411 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.38 (d, J = 9.7 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.46 (dd, J = 8.5, 6.9 Hz, 1H ), 7.15-7.19 (m, 1H), 6.73 (d, J = 9.3 Hz, 1H), 4.71 (br.s., 2H), 4.26-4.33 (m, 1H), 3.89-3.97 (m, 2H) , 2.82-2.88 (m, 1H), 2.64-2.69 (m, 1H), 2.54 (dd, J = 9.9, 5.1 Hz, 1H), 2.29-2.36 (m, 1H), 2.12-2.22 (m, 1H) , 1.68-1.76 (m, 1H).

(Reference Example 120) (2-((4-Methoxybenzyl) amino) quinolin-5-yl) methanol A mixture of the compound obtained in Reference Example 111 (700 mg) and 4-methoxybenzylamine (2.83 mL) at 140 ° C. Stir for 4 hours. The reaction mixture was cooled to room temperature, diluted with dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 97: 3-91: 9) to give the title compound (910 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.19 (d, J = 9.7 Hz, 1H), 7.66-7.69 (m, 1H), 7.42-7.52 (m, 1H), 7.30-7.35 (m, 2H), 7.19-7.24 (m, 1H), 6.85-6.90 (m, 2H), 6.67 (d, J = 8.9 Hz, 1H), 5.01 (s, 2H), 4.97 (br.s., 1H), 4.62-4.66 (m, 2H), 3.80 (s, 3H)
MS (ESI ⁺ ) m / z: 295 [M + H] ⁺ .

(Reference Example 121) (2-Aminoquinolin-5-yl) methanol A mixture of the compound obtained in Reference Example 120 (910 mg), TFA (4.8 mL) and dichloromethane (2 mL) was stirred at room temperature overnight, and then at 60 ° C. Stir for 3 hours. The reaction mixture was cooled to room temperature and concentrated. A 2N aqueous sodium hydroxide solution and methanol were added to the residue, and the mixture was refluxed for 30 minutes. The reaction mixture was cooled to room temperature and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was washed with a mixed solution of ethyl acetate-hexane (2: 1) to obtain the title compound (214 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.27 (d, J = 9.3 Hz, 1H), 7.61-7.66 (m, 1H), 7.49-7.55 (m, 1H), 7.26-7.27 (m, 1H), 6.78 (d, J = 8.9 Hz, 1H), 5.04 (s, 2H), 4.75 (br.s., 2H)
MS (ESI ^<+> ) m / z: 175 [M + H] ^< +>.

Reference Example 122 5- (Chloromethyl) quinolin-2-amine A mixture of the compound obtained in Reference Example 121 (214 mg), thionyl chloride (107.5 μL), acetonitrile (5 mL) and chloroform (2.5 mL) at 50 ° C. Stir for 3 hours. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (223 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.23 (d, J = 8.9 Hz, 1H), 7.65-7.69 (m, 1H), 7.47-7.53 (m, 1H), 7.27-7.30 (m, 1H), 6.82 (d, J = 9.3 Hz, 1H), 4.93 (s, 2H), 4.80 (br. S., 2H)
MS (ESI ^<+> ) m / z: 193 [M + H] ^< +>.

Reference Example 123 1-((2-Aminoquinolin-5-yl) methyl) azetidin-3-ol The compound obtained in Reference Example 122 (120 mg), 3-hydroxyazetidine hydrochloride (82 mg), acetonitrile (3 mL ), Water (0.75 mL) and triethylamine (0.75 mL) were stirred at 45 ° C. for 12 hours. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (99 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 8.13 (d, J = 8.9 Hz, 1H), 7.33-7.37 (m, 2H), 7.02-7.05 (m, 1H), 6.74 (d, J = 8.9 Hz, 1H), 6.35 (s, 2H), 5.28 (d, J = 6.5 Hz, 1H), 4.12-4.20 (m, 1H), 3.82 (s, 2H), 3.42-3.47 (m, 2H), 2.75 -2.81 (m, 2H)
MS (ESI ^<+> ) m / z: 230 [M + H] ^< +>.

(Reference Example 124) 5-((3-methoxyazetidin-1-yl) methyl) quinolin-2-amine The compound (105 mg) obtained in Reference Example 122, 3-methoxyazetidine hydrochloride (81 mg), acetonitrile ( 3 mL), water (0.75 mL) and triethylamine (0.75 mL) were stirred at 45 ° C. for 2 hours. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 99: 1 to 95: 5) to obtain the title compound (95 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.27-8.31 (m, 1H), 7.57-7.61 (m, 1H), 7.45-7.49 (m, 1H), 7.15-7.18 (m, 1H), 6.74 (d, J = 8.9 Hz, 1H), 4.71 (br. S., 2H), 4.00-4.08 (m, 1H), 3.94 (s, 2H), 3.56-3.61 (m, 2H), 3.24 (s , 3H), 2.95-3.00 (m, 2H)
MS (ESI ^<+> ) m / z: 244 [M + H] ^< +>.

(Reference Example 125) 2-Chloro-5- (methoxymethyl) quinoline Methyl iodide (3.36 mL) was added to a DMSO (13 mL) solution of the compound (4.348 g) obtained in Reference Example 111, and potassium hydroxide (2.90 g) was added. ) Was added and stirred at room temperature for 30 minutes. The reaction mixture was cooled to 0 ° C. and water (21.3 mL) was added dropwise. The precipitated solid was collected by filtration, washed with water (52 mL), and dried to give the title compound (4.439 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.44 (dd, J = 8.8, 0.8 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.68 (dd, J = 8.5, 7.0 Hz , 1H), 7.53 (dd, J = 7.0, 1.0 Hz, 1H), 7.43 (d, J = 8.8 Hz, 1H), 4.86 (s, 2H), 3.42 (s, 3H)
MS (ESI ^<+> ) m / z: 208 [M + H] ^< +>.

(Reference Example 126) 2-hydrazinyl-5- (methoxymethyl) quinoline To the compound (4.438 g) obtained in Reference Example 125, hydrazine monohydrate (22 mL) and 1,4-dioxane (22 mL) were added, and the mixture was heated to 80 ° C. For 66 hours. The reaction mixture was cooled to room temperature, water (45 mL) was added and cooled to 0 ° C. The precipitated solid was collected by filtration, washed with water, and dried to give the title compound (3.644 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.20 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 8.3 Hz, 1H), 7.47-7.55 (m, 1H), 7.21-7.28 (m, 1H), 6.82 (d, J = 9.0 Hz, 1H), 5.95 (br. s., 1H), 4.79 (s, 2H), 4.11 (br. s., 2H), 3.40 (s, 3H )
MS (ESI ^<+> ) m / z: 204 [M + H] ^< +>.

(Reference Example 127) 5- (methoxymethyl) quinolin-2-amine To the compound (3.643 g) obtained in Reference Example 126, Raney nickel (R-200 manufactured by Nikko Rica, 4.6 mL) and methanol (92 mL) were added, and a hydrogen atmosphere Under stirring at room temperature for 40.5 hours. The reaction mixture was filtered and the filtrate was concentrated to obtain the title compound (3.292 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.22 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.50 (dd, J = 8.5, 7.0 Hz, 1H ), 7.21-7.25 (m, 1H), 6.76 (d, J = 9.0 Hz, 1H), 4.79 (s, 2H), 4.72 (br. S., 2H), 3.40 (s, 3H)
MS (ESI ^<+> ) m / z: 189 [M + H] ^< +>.

Reference Example 128 5- (Ethoxymethyl) quinolin-2-amine Ethyl iodide (0.386 mL) was added to a solution of the compound (387 mg) obtained in Reference Example 111 in DMSO (2 mL), and potassium hydroxide (258 mg) was added. In addition, the mixture was stirred at room temperature for 30 minutes. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. To the residue were added 1,4-dioxane (2 mL), water (1 mL) and hydrazine monohydrate (1.94 mL), and the mixture was stirred at 70 ° C. for 3 days and then at 80 ° C. for 2 days. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Methanol (10 mL) and Raney nickel (Raney 2400 from WR Grace and Co., 1 mL) were added to the residue, and the mixture was stirred at room temperature for 20 hours under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (289 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.25 (dd, J = 9.0, 0.8 Hz, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.47-7.52 (m, 1H), 7.24 (dd, J = 7.0, 1.0 Hz, 1H), 6.76 (d, J = 9.0 Hz, 1H), 4.83 (s, 2H), 4.75 (br. s., 2H), 3.57 (q, J = 7.0 Hz , 2H), 1.24 (t, J = 7.0 Hz, 3H)
MS (ESI ^<+> ) m / z: 203 [M + H] ^< +>.

Reference Example 129 2-chloro-5-((2-methoxyethoxy) methyl) quinoline A solution of the compound obtained in Reference Example 111 (97 mg) and 2-methoxyethyl bromide (0.286 mL) in DMF (2 mL) was added at 0 ° C. To the mixture was added sodium hydride (60% oil suspension, 24 mg), and the mixture was stirred at 0 ° C. for 3 hours and stirred at room temperature overnight. The reaction mixture was cooled to 0 ° C., sodium hydride (60% oil suspension, 24 mg) was added, and the mixture was stirred at the same temperature for 1 hr. Water and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 80: 20) to give the title compound (97 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.51 (dd, J = 8.8, 0.8 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.65-7.70 (m, 1H), 7.53 (dd, J = 7.0, 1.3 Hz, 1H), 7.43 (d, J = 9.0 Hz, 1H), 4.97 (s, 2H), 3.64-3.67 (m, 2H), 3.54-3.57 (m, 2H), 3.38 (s, 3H)
MS (ESI ^<+> ) m / z: 252 [M + H] ^< +>.

Reference Example 130 5-((2-Methoxyethoxy) methyl) quinolin-2-amine Hydrazine monohydrate (0.183) was added to a solution of the compound obtained in Reference Example 129 (95 mg) in 1,4-dioxane (1.5 mL). mL) was added and stirred at 80 ° C. overnight. Hydrazine monohydrate (0.183 mL) was added to the reaction mixture, and the mixture was stirred at 80 ° C. overnight. The reaction mixture was dried over anhydrous sodium sulfate, diluted with dichloromethane, filtered, and the filtrate was concentrated. Methanol (2 mL) and Raney nickel (Raney 2400 from WR Grace and Co., 0.1 mL) were added to the residue, and the mixture was stirred overnight at room temperature under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 50: 50-10: 90) to give the title compound (53 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.29 (dd, J = 9.0, 0.8 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.49 (dd, J = 8.5, 7.0 Hz , 1H), 7.23 (dd, J = 7.0, 1.3 Hz, 1H), 6.76 (d, J = 9.0 Hz, 1H), 4.90 (s, 2H), 4.76 (br.s., 2H), 3.60-3.64 (m, 2H), 3.52-3.56 (m, 2H), 3.38 (s, 3H)
MS (ESI ^<+> ) m / z: 233 [M + H] ^< +>.

(Reference Example 131) 5-((2-((tert-butyldimethylsilyl) oxy) ethoxy) methyl) -2-chloroquinoline The compound (194 mg) obtained in Reference Example 111 and (2-bromoethoxy) (tert- A solution of (butyl) dimethylsilane (0.751 mL) in DMF (4 mL) was cooled to 0 ° C., sodium hydride (60% oil suspension, 60 mg) was added, and the mixture was stirred at 0 ° C. for 2 hours. Water and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 95: 5) to give the title compound (81 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.52 (dd, J = 8.8, 0.8 Hz, 1H), 7.98 (d, J = 8.5 Hz, 1H), 7.67 (dd, J = 8.5, 7.0 Hz , 1H), 7.51-7.56 (m, 1H), 7.41 (d, J = 9.0 Hz, 1H), 4.97 (s, 2H), 3.78-3.82 (m, 2H), 3.59-3.63 (m, 2H), 0.89 (s, 9H), 0.05 (s, 6H)
MS (ESI ⁺ ) m / z: 352 [M + H] ⁺ .

(Reference Example 132) 5-((2-((tert-butyldimethylsilyl) oxy) ethoxy) methyl) quinolin-2-amine Compound (115 mg) of 1,4-dioxane (1.5 mL) obtained in Reference Example 131 Hydrazine monohydrate (0.476 mL) was added to the solution, and the mixture was stirred at 80 ° C. overnight. Hydrazine monohydrate (0.238 mL) was added to the reaction mixture, and the mixture was stirred at 80 ° C. overnight. The reaction mixture was dried over anhydrous sodium sulfate, diluted with dichloromethane, collected by filtration, and the filtrate was concentrated. Methanol (2 mL) and Raney nickel (Raney 2400 from WR Grace and Co., 0.1 mL) were added to the residue, and the mixture was stirred overnight at room temperature under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 65: 35-30: 70) to give the title compound (59 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.29 (d, J = 9.0 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.49 (dd, J = 8.5, 7.0 Hz, 1H ), 7.22-7.25 (m, 1H), 6.74 (d, J = 9.0 Hz, 1H), 4.89 (s, 2H), 4.76 (br.s., 2H), 3.77-3.81 (m, 2H), 3.57 -3.60 (m, 2H), 0.89 (s, 9H), 0.05 (s, 6H)
MS (ESI ^<+> ) m / z: 333 [M + H] ^< +>.

(Reference Example 133) 7-acetyl-N- (5-((2-((tert-butyldimethylsilyl) oxy) ethoxy) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [ b] Thiophene-2-carboxamide Triethylamine (0.042 mL) was added to a mixture of the compound obtained in Reference Example 132 (33.3 mg), the compound obtained in Reference Example 74 (30.6 mg), HBTU (45.5 mg) and dichloromethane (1 mL). The mixture was further stirred at room temperature for 18 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 60: 40-40: 60) to give the title compound (56.4 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (s, 1H), 8.50-8.61 (m, 2H), 8.09 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 8.0 Hz , 1H), 7.59-7.66 (m, 2H), 7.46 (d, J = 6.8 Hz, 1H), 5.01 (s, 2H), 5.00 (s, 2H), 3.80-3.84 (m, 2H), 3.61- 3.65 (m, 2H), 3.52 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 0.91 (s, 9H), 0.07 (s, 6H)
MS (ESI ^<+> ) m / z: 593 [M + H] ^< +>.

Reference Example 134 2-Chloro-5-((difluoromethoxy) methyl) quinoline Compound obtained in Reference Example 111 (265 mg), anhydrous sodium sulfate (117 mg), 2- (fluorosulfonyl) difluoroacetic acid (488 mg) and acetonitrile A mixture of (10 mL) was stirred at 50 ° C. for 2 hours. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 1-6: 1) to give the title compound (32 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.35-8.37 (m, 1H), 8.06 (d, J = 8.8 Hz, 1H), 7.72 (dd, J = 7.2, 8.8 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 6.35 (d, J = 74.0 Hz, 1H), 5.30 (s, 2H).

Reference Example 135 2- (2-Chloroquinolin-5-yl) propan-2-ol A solution of the compound (600 mg) obtained in Reference Example 110 in THF (10 mL) was cooled to 0 ° C., and methylmagnesium bromide ( 1.12 M THF solution, 5.32 mL) was added dropwise, and the mixture was stirred at the same temperature for 40 minutes. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 95: 5) to obtain the title compound (361 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.27 (d, J = 8.9 Hz, 1H), 7.93-7.97 (m, 1H), 7.61-7.66 (m, 1H), 7.55-7.59 (m, 1H), 7.38 (d, J = 8.9 Hz, 1H), 1.83 (s, 6H)
MS (ESI ^<+> ) m / z: 222 [M + H] ^< +>.

(Reference Example 136) 1- (2-Aminoquinolin-5-yl) ethanone
A solution of 5-bromoquinolin-2-amine (1.0 g), dichlorobis (triphenylphosphine) palladium (II) (315 mg) and (1-ethoxyvinyl) tributyltin (3.06 mL) in toluene (30 mL) under a nitrogen atmosphere Reflux for hours. The reaction mixture was cooled to 0 ° C., 6N hydrochloric acid (20 mL) was added, and the mixture was stirred at room temperature for 2 hr. 2N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 97.5: 2.5) and basic silica gel column chromatography (dichloromethane: methanol = 98.75: 1.25) to obtain the title compound (468 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.90-8.94 (m, 1H), 7.82 (dt, J = 8.2, 1.0 Hz, 1H), 7.77 (dd, J = 7.4, 1.1 Hz, 1H) , 7.58 (dd, J = 8.4, 7.4 Hz, 1H), 6.82 (d, J = 9.3 Hz, 1H), 4.77 (br. S., 2H), 2.72 (s, 3H)
MS (ESI ^<+> ) m / z: 187 [M + H] ^< +>.

(Reference Example 137) 1- (2-Aminoquinolin-5-yl) ethanol Ethanol (2 mL) and THF (2 mL) were added to the compound (326 mg) obtained in Reference Example 136, cooled to 0 ° C., and then hydrogenated. Sodium boron (132 mg) was added and stirred at the same temperature for 30 minutes. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and chloroform and methanol were further added. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (chloroform: methanol = 98: 2) to obtain the title compound (113 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.29-8.33 (m, 1H), 7.58-7.62 (m, 1H), 7.51-7.56 (m, 1H), 7.37-7.41 (m, 1H), 6.75 (d, J = 9.0 Hz, 1H), 5.49 (q, J = 6.7 Hz, 1H), 4.72 (br. S., 2H), 1.65 (d, J = 6.5 Hz, 3H)
MS (ESI ^<+> ) m / z: 189 [M + H] ^< +>.

Reference Example 138 5-(((tert-butyldimethylsilyl) oxy) methyl) -2-chloroquinoline DMF (85 mL) of the compound (17.54 g) obtained in Reference Example 111 and tert-butyldimethylchlorosilane (20.48 g) ) A solution of imidazole (18.50 g) in DMF (20 mL) was added to the solution, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was diluted with ethyl acetate, washed successively with saturated brine, water and saturated brine, dried over anhydrous magnesium sulfate and concentrated to give the title compound (28.42 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.41 (dd, J = 8.8, 0.8 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.68 (dd, J = 8.4, 7.2 Hz , 1H), 7.56 (dd, J = 7.2, 1.1 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 5.12 (s, 2H), 0.92 (s, 9H), 0.10 (s, 6H)
MS (ESI ^<+> ) m / z: 308 [M + H] ^< +>.

Reference Example 139 5-(((tert-butyldimethylsilyl) oxy) methyl) -2-hydrazinylquinoline The compound (28.42 g) obtained in Reference Example 138, hydrazine monohydrate (134 mL) and 1, A mixture of 4-dioxane (134 mL) was stirred at 80 ° C. for 48 hours. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with chloroform. The organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated to give the title compound (27.27g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.19 (dd, J = 9.3, 0.8 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.52 (dd, J = 8.3, 7.0 Hz , 1H), 7.29 (dd, J = 7.2, 1.1 Hz, 1H), 6.84 (d, J = 9.0 Hz, 1H), 5.06 (s, 2H), 0.91 (s, 9H), 0.08 (s, 6H)
MS (ESI ^<+> ) m / z: 304 [M + H] ^< +>.

(Reference Example 140) 5-(((tert-Butyldimethylsilyl) oxy) methyl) quinolin-2-amine To the compound (27.27 g) obtained in Reference Example 139, Raney Nickel (R-200, Nikko Rica, 36 mL) and methanol (715 mL) was added, and the mixture was stirred at room temperature for 48 hours under a hydrogen atmosphere. The reaction mixture was filtered through Hyflo Super Cel (manufactured by Nacalai Tesque), and the filtrate was concentrated to obtain the title compound (24.92 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.20 (d, J = 9.0 Hz, 1H), 7.58-7.63 (m, 1H), 7.48-7.54 (m, 1H), 7.26-7.29 (m, 1H), 6.74 (d, J = 9.0 Hz, 1H), 5.06 (s, 2H), 4.77 (br. S., 2H), 0.91 (s, 9H), 0.08 (s, 6H)
MS (ESI ^<+> ) m / z: 289 [M + H] ^< +>.

(Reference Example 141) 7-acetyl-N- (5-(((tert-butyldimethylsilyl) oxy) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2 -Carboxamide Compound (5.56 g) obtained in Reference Example 74, Compound (5.76 g) obtained in Reference Example 140 and HBTU (11.36 g) in dichloromethane (106 mL) suspension in N, N-diisopropylethylamine (10.44 mL) And stirred at room temperature for 68.5 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: ethyl acetate = 100: 0 to 90:10), and the obtained solid was washed with 2-propanol to give the title compound (8.906 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (br. S., 1H), 8.48-8.56 (m, 2H), 8.10 (d, J = 7.8 Hz, 1H), 7.77-7.83 (m , 1H), 7.63 (d, J = 7.8 Hz, 2H), 7.50 (d, J = 7.3 Hz, 1H), 5.16 (s, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 0.94 (s, 9H), 0.12 (s, 6H)
MS (ESI ^<+> ) m / z: 549 [M + H] ^< +>.

(Reference Example 142) (S)-(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl-2-((tert- (Butoxycarbonyl) amino) -3-methylbutanoate The compound obtained in Example 79 (150 mg), N- (tert-butoxycarbonyl) -L-valine (90 mg) and N, N-dimethyl-4-aminopyridine ( A solution of 93 mg) in DMF (4 mL) was cooled to 0 ° C., 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (79 mg) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30-50: 50) to give the title compound (188 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (s, 1H), 8.59 (d, J = 9.0 Hz, 1H), 8.42 (d, J = 9.0 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.62-7.68 (m, 2H), 7.51-7.55 (m, 1H), 5.52-5.70 (m, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.05-2.15 (m, 1H), 1.55 (s, 9H), 1.44 (s, 6H)
MS (ESI ^<+> ) m / z: 634 [M + H] ^< +>.

(Reference Example 143) (2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophen-2-carboxamido) quinolin-5-yl) methyl-2-((tert-butoxycarbonyl) amino ) Acetate 1 in a DMF (4 mL) solution of the compound obtained in Example 79 (120 mg), N- (tert-butoxycarbonyl) -glycine (58.1 mg) and N, N-dimethyl-4-aminopyridine (74.2 mg). -Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (63.5 mg) was added and stirred at room temperature overnight. The reaction mixture was diluted with chloroform and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 60: 40-40: 60) to give the title compound (151 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (br. S., 1H), 8.58 (d, J = 9.0 Hz, 1H), 8.42 (d, J = 9.3 Hz, 1H), 8.10 ( d, J = 7.8 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.62-7.68 (m, 2H), 7.53 (d, J = 6.8 Hz, 1H), 5.63 (s, 2H), 5.01 (s, 2H), 3.93-3.98 (m, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.44 (s, 9H)
MS (ESI ^<+> ) m / z: 592 [M + H] ^< +>.

(Reference Example 144) (S)-(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl-2-((tert- (Butoxycarbonyl) amino) propanoate DMF of the compound obtained in Example 79 (120 mg), N- (tert-butoxycarbonyl) -L-alanine (62.7 mg) and N, N-dimethyl-4-aminopyridine (74.2 mg) To the (4 mL) solution was added 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (63.5 mg), and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 55: 45-35: 65) to give the title compound (159 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (s, 1H), 8.59 (d, J = 9.3 Hz, 1H), 8.41 (d, J = 9.0 Hz, 1H), 8.10 (d, J = 7.5 Hz, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.62-7.68 (m, 2H), 7.53 (d, J = 5.5 Hz, 1H), 5.53-5.69 (m, 2H), 5.01 (s, 2H), 4.36 (br. s., 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.43 (s, 9H), 1.36 (d, J = (7.0 Hz, 3H)
MS (ESI ^<+> ) m / z: 606 [M + H] ^< +>.

Reference Example 145 (2- (7-Acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyldi-tert-butyl phosphate Obtained in Example 79 1H-tetrazole (70.9 mg) and di-tert-butyl N, N-diisopropyl phosphoramidite (183 μL) were added to a DMF (5 mL) solution of the compound (200 mg), and the mixture was stirred at room temperature overnight. To the reaction mixture were added 1H-tetrazole (70.9 mg) and di-tert-butyl N, N-diisopropyl phosphoramidite (183 μL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate. The organic layer was dried over anhydrous sodium sulfate and concentrated. Chloroform (5 mL) was added to the residue, cooled to −40 ° C., 3-chloroperbenzoic acid (content 75%, 138 mg) was added, the temperature was gradually raised to room temperature, and the mixture was stirred overnight. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99.5: 0.5 to 97: 3) to obtain the title compound (158 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (s, 1H), 8.57 (s, 2H), 8.10 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 8.3 Hz, 1H ), 7.61-7.68 (m, 2H), 7.53 (d, J = 6.3 Hz, 1H), 5.42 (d, J = 7.3 Hz, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.47 (s, 18H)
MS (ESI ^<+> ) m / z: 627 [M + H] ^< +>.

Reference Example 146 (S)-(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl-3- (tert-butoxy ) -2-((tert-butoxycarbonyl) amino) propanoate The compound obtained in Example 79 (220 mg), N- (tert-butoxycarbonyl) -O-tert-butyl-L-serine (159 mg) and N, N 1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (116 mg) was added to a solution of -dimethyl-4-aminopyridine (136 mg) in DMF (5 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 75: 25-20: 80) to give the title compound (273 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (s, 1H), 8.58 (d, J = 9.3 Hz, 1H), 8.44 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.62-7.67 (m, 2H), 7.52-7.55 (m, 1H), 5.65-5.70 (m, 1H), 5.52-5.57 ( m, 1H), 5.35-5.39 (m, 1H), 5.01 (s, 2H), 4.40-4.47 (m, 1H), 3.73-3.77 (m, 1H), 3.50-3.56 (m, 1H), 3.53 ( s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.44 (s, 9H), 0.95-1.05 (s, 9H).

(Reference Example 147) A solution of methyl 5- (methoxycarbonyl) quinoline-1-oxide quinoline-5-carboxylate (21.2 g) in chloroform (200 mL) was cooled to 0 ° C., and 3-chloroperbenzoic acid (content 75%) 31.3 g) and stirred at room temperature overnight. A sodium thiosulfate aqueous solution and a potassium carbonate aqueous solution were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (19.7 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.05 (d, J = 8.9 Hz, 1H), 8.93 (d, J = 8.9 Hz, 1H), 8.57 (d, J = 6.1 Hz, 1H), 8.38 (dd, J = 7.3, 1.2 Hz, 1H), 7.80 (dd, J = 8.9, 7.3 Hz, 1H), 7.41 (dd, J = 8.9, 6.1 Hz, 1H), 4.02 (s, 3H)
MS (ESI ^<+> ) m / z: 204 [M + H] ^< +>.

(Reference Example 148) Methyl 2-aminoquinoline-5-carboxylate A solution of the compound (2.03 g) obtained in Reference Example 147 in trifluoromethylbenzene / chloroform (30 mL / 10 mL) was cooled to 0 ° C., and tert-butylamine ( 5.25 mL) was added, p-toluenesulfonic anhydride (6.53 g) was added, and the mixture was stirred at 0 ° C. for 30 min. TFA (20 mL) was added to the reaction mixture at the same temperature, and the mixture was stirred at 85 ° C. for 2 hours and stirred at 90 ° C. for 2 hours. The reaction mixture was cooled to room temperature and concentrated. To the residue was added 2N aqueous sodium hydroxide solution, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 97: 3-90: 10) to obtain the title compound (1.26 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.05 (d, J = 9.3 Hz, 1H), 7.97 (dd, J = 7.3, 1.2 Hz, 1H), 7.84 (dt, J = 8.3, 1.1 Hz , 1H), 7.57 (dd, J = 8.3, 7.5 Hz, 1H), 6.84 (d, J = 9.3 Hz, 1H), 4.80 (br.s., 2H), 3.98 (s, 3H)
MS (ESI ^<+> ) m / z: 203 [M + H] ^< +>.

(Reference Example 149) (2-Chloroquinolin-5-yl) (morpholino) methanone
N, N-diisopropylethylamine (252 μL), HBTU (301 mg) and morpholine (69.5 μL) were added to a chloroform (5 mL) solution of 2-chloroquinoline-5-carboxylic acid (150 mg), and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with chloroform and washed with 1N aqueous sodium hydroxide solution. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 98: 2) to obtain the title compound (211 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.19 (dd, J = 8.8, 0.8 Hz, 1H), 8.08 (dt, J = 8.5, 1.0 Hz, 1H), 7.76 (dd, J = 8.5, 7.0 Hz, 1H), 7.50 (dd, J = 7.2, 1.1 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 3.81-4.01 (m, 4H), 3.47-3.64 (m, 2H), 3.16-3.34 (m, 2H)
MS (ESI ^<+> ) m / z: 277 [M + H] ^< +>.

(Reference Example 150) (2-Chloroquinolin-5-yl) (4-methylpiperazin-1-yl) methanone
To a solution of 2-chloroquinoline-5-carboxylic acid (150 mg) in chloroform (5 mL), N, N-diisopropylethylamine (252 μL) and HBTU (301 mg) were added, and the mixture was stirred at room temperature for 15 minutes. μL) was added and stirred at room temperature overnight. A 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 95: 5) to obtain the title compound (220 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.18 (dd, J = 8.8, 1.0 Hz, 1H), 8.07 (dt, J = 8.4, 1.1 Hz, 1H), 7.75 (dd, J = 8.5, 7.0 Hz, 1H), 7.49 (dd, J = 7.2, 1.1 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 3.83-4.04 (m, 2H), 3.15-3.31 (m, 2H), 2.48-2.63 (m, 2H), 2.29-2.34 (m, 1H), 2.32 (s, 3H), 2.21 (br.s., 1H)
MS (ESI ^<+> ) m / z: 290 [M + H] ^< +>.

(Reference Example 151) 2-Chloro-N, N-dimethylquinoline-5-carboxamide
To 2-hydroxyquinoline-5-carboxylic acid (1.51 g) was added phosphorus oxychloride (5.14 g), and the mixture was stirred at 120 ° C. for 3 hours. The reaction mixture was concentrated, dimethylamine hydrochloride (0.98 g) and chloroform (15 mL) were added at room temperature under an argon atmosphere, and then triethylamine (12.6 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours, dimethylamine hydrochloride (1.0 g) was added, and the mixture was stirred at room temperature for 14 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: ethyl acetate = 100: 0 to 80:20), 2-propanol (8.48 mL) was added to the obtained solid, heated to 80 ° C., and then cooled to 0 ° C. . The precipitated solid was collected by filtration and washed with 2-propanol to give the title compound (1.450 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.15 (dd, J = 8.8, 1.0 Hz, 1H), 8.06 (dt, J = 8.5, 1.0 Hz, 1H), 7.75 (dd, J = 8.5, 7.0 Hz, 1H), 7.49-7.53 (m, 1H), 7.43 (d, J = 8.8 Hz, 1H), 3.25 (s, 3H), 2.85 (s, 3H)
MS (ESI ^<+> ) m / z: 235 [M + H] ^< +>.

(Reference Example 152) 2-Amino-N, N-dimethylquinoline-5-carboxamide To the compound (1.449 g) obtained in Reference Example 151, hydrazine monohydrate (7.25 mL) and 1,4-dioxane (7.25 mL) And stirred at 82 ° C. for 24 hours. The reaction mixture was cooled to room temperature, saturated brine was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. Raney nickel (R-200, manufactured by Nikko Rica, 1.3 mL) and methanol (25 mL) were added to the residue, and the mixture was stirred at room temperature for 51.5 hours under a hydrogen atmosphere. The reaction mixture was filtered through Hyflo Super Cel (manufactured by Nacalai Tesque), and the filtrate was concentrated to obtain the title compound (1.268 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.87-7.91 (m, 1H), 7.67 (dt, J = 8.3, 1.0 Hz, 1H), 7.55 (dd, J = 8.5, 7.0 Hz, 1H) , 7.18 (dd, J = 7.2, 1.1 Hz, 1H), 6.75 (d, J = 8.8 Hz, 1H), 4.79 (br. S., 2H), 3.22 (s, 3H), 2.84 (s, 3H)
MS (ESI ^<+> ) m / z: 216 [M + H] ^< +>.

(Reference Example 153) 2-Chloroquinoline-5-carbonyl chloride
A mixture of 2-chloroquinoline-5-carboxylic acid (2.08 g), thionyl chloride (1.46 mL) and DMF (50 μL) was stirred at 60 ° C. for 6 hours. The reaction mixture was concentrated to give the title compound (2.24 g).

(Reference Example 154) Azetidin-1-yl (2-chloroquinolin-5-yl) methanone A chloroform (5 mL) suspension of the compound (452 mg) obtained in Reference Example 153 was cooled to 0 ° C. and tetrabutylammonium bromide. (129 mg), potassium carbonate (553 mg) and azetidine (126 mg) were added, and the mixture was stirred at 0 ° C. for 1 hour and then at room temperature for 24 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 60: 40-40: 60) to give the title compound (352 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.56 (dd, J = 8.8, 0.8 Hz, 1H), 8.06-8.10 (m, 1H), 7.73 (dd, J = 8.5, 7.0 Hz, 1H) , 7.60 (dd, J = 7.2, 1.1 Hz, 1H), 7.46 (d, J = 8.8 Hz, 1H), 4.32 (t, J = 7.8 Hz, 2H), 4.01 (t, J = 7.8 Hz, 2H) , 2.30-2.41 (m, 2H)
MS (ESI ⁺ ) m / z: 247 [M + H] ⁺ .

(Reference Example 155) (2-Aminoquinolin-5-yl) (azetidin-1-yl) methanone To the compound (345 mg) obtained in Reference Example 154, hydrazine monohydrate (1.36 mL), 1,4-dioxane ( 2 mL) and water (1 mL) were added and stirred at 70 ° C. for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Methanol (10 mL) and Raney nickel (WR Grace and Co. Raney 2400, 0.5 mL) were added to the residue, and the mixture was stirred at room temperature for 18 hours under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (245 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.28 (dd, J = 9.0, 0.8 Hz, 1H), 7.68-7.71 (m, 1H), 7.53 (dd, J = 8.4, 7.2 Hz, 1H) , 7.28 (dd, J = 7.2, 1.1 Hz, 1H), 6.78 (d, J = 9.3 Hz, 1H), 4.81 (br. S., 2H), 4.29 (t, J = 7.9 Hz, 2H), 3.97 (t, J = 7.7 Hz, 2H), 2.27-2.36 (m, 2H)
MS (ESI ^<+> ) m / z: 228 [M + H] ^< +>.

(Reference Example 156) (2-Chloroquinolin-5-yl) (3-fluoroazetidin-1-yl) methanone A suspension of the compound (497 mg) obtained in Reference Example 153 in chloroform (6 mL) was cooled to 0 ° C. Tetrabutylammonium bromide (129 mg), potassium carbonate (829 mg) and 3-fluoroazetidine hydrochloride (223 mg) were added, and the mixture was stirred at 0 ° C. for 10 minutes and then at room temperature for 39 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 60: 40-50: 50) to give the title compound (447 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.58 (dd, J = 9.0, 0.8 Hz, 1H), 8.10-8.13 (m, 1H), 7.74 (dd, J = 8.4, 7.2 Hz, 1H) , 7.62 (dd, J = 7.2, 1.1 Hz, 1H), 7.48 (d, J = 8.8 Hz, 1H), 5.27-5.48 (m, 1H), 4.49-4.67 (m, 1H), 4.32-4.48 (m , 1H), 4.08-4.31 (m, 2H)
MS (ESI ^<+> ) m / z: 265 [M + H] ^< +>.

Reference Example 157 (2-Aminoquinolin-5-yl) (3-fluoroazetidin-1-yl) methanone To the compound (440 mg) obtained in Reference Example 156, hydrazine monohydrate (1.62 mL), 1, 4-Dioxane (2 mL) and water (1 mL) were added, and the mixture was stirred at 60 ° C. for 36 hr. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Methanol (10 mL) and Raney nickel (Raney 2400, WR Grace and Co., 0.5 mL) were added to the residue, and the mixture was stirred at room temperature for 18 hours under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (140 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.28 (dd, J = 9.0, 0.8 Hz, 1H), 7.73 (dt, J = 8.5, 0.9 Hz, 1H), 7.52-7.57 (m, 1H) , 7.29 (dd, J = 7.3, 1.3 Hz, 1H), 6.79 (d, J = 9.3 Hz, 1H), 5.25-5.45 (m, 1H), 4.84 (br.s., 2H), 4.47-4.63 ( m, 1H), 4.29-4.45 (m, 1H), 4.04-4.27 (m, 2H)
MS (ESI ^<+> ) m / z: 246 [M + H] ^< +>.

Reference Example 158 (2-Chloroquinolin-5-yl) (3,3-difluoroazetidin-1-yl) methanone A suspension of the compound (452 mg) obtained in Reference Example 153 in chloroform (6 mL) was added at 0 ° C. Then, tetrabutylammonium bromide (129 mg), potassium carbonate (829 mg) and 3,3-difluoroazetidine hydrochloride (285 mg) were added, and the mixture was stirred at 0 ° C. for 30 minutes and then at room temperature for 42 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 65: 35-55: 45) to give the title compound (477 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.59 (dd, J = 8.8, 0.8 Hz, 1H), 8.13-8.16 (m, 1H), 7.76 (dd, J = 8.4, 7.2 Hz, 1H) , 7.65 (dd, J = 7.3, 1.3 Hz, 1H), 7.50 (d, J = 9.0 Hz, 1H), 4.60 (br. S., 2H), 4.34 (br. S., 2H)
MS (ESI ^<+> ) m / z: 283 [M + H] ^< +>.

(Reference Example 159) (2-Aminoquinolin-5-yl) (3,3-difluoroazetidin-1-yl) methanone To the compound (470 mg) obtained in Reference Example 158, hydrazine monohydrate (1.62 mL), 1,4-Dioxane (2 mL) and water (1 mL) were added, and the mixture was stirred at 50 ° C. for 60 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Methanol (10 mL) and Raney nickel (Raney 2400, WR Grace and Co., 0.5 mL) were added to the residue, and the mixture was stirred at room temperature for 18 hours under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (357 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.31 (d, J = 9.0 Hz, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.56 (dd, J = 8.4, 7.2 Hz, 1H ), 7.33 (dd, J = 7.3, 1.0 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.93 (br. S., 2H), 4.57 (br. S., 2H), 4.29 ( br. s., 2H)
MS (ESI ^<+> ) m / z: 264 [M + H] ^< +>.

(Reference Example 160) (2-Chloroquinolin-5-yl) (3-methoxyazetidin-1-yl) methanone
Add N, N-diisopropylethylamine (4.64 mL) to a mixture of 2-chloroquinoline-5-carboxylic acid (1.84 g), 3-methoxyazetidine hydrochloride (1.20 g), HBTU (3.69 g) and chloroform (80 mL). The mixture was further stirred at room temperature for 24 hours. A 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 95: 5) to obtain the title compound (2.215 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.55 (dd, J = 8.9, 0.9 Hz, 1H), 8.07-8.11 (m, 1H), 7.71-7.76 (m, 1H), 7.60 (dd, J = 7.0, 1.3 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 4.42-4.49 (m, 1H), 4.22-4.28 (m, 1H), 4.07-4.19 (m, 2H), 3.86 -3.91 (m, 1H), 3.30 (s, 3H)
MS (ESI ^<+> ) m / z: 277 [M + H] ^< +>.

(Reference Example 161) (2-hydrazinylquinolin-5-yl) (3-methoxyazetidin-1-yl) methanone To the compound (2.215 g) obtained in Reference Example 160, 80% hydrazine monohydrate (11 mL) ) And 1,4-dioxane (11 mL) were added, and the mixture was stirred at 60 ° C. for 22 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated to give the title compound (1.82 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.23 (dd, J = 9.0, 0.8 Hz, 1H), 7.77-7.81 (m, 1H), 7.52-7.57 (m, 1H), 7.29 (dd, J = 7.2, 1.1 Hz, 1H), 6.85 (d, J = 9.3 Hz, 1H), 4.40-4.46 (m, 1H), 4.20-4.26 (m, 1H), 4.11-4.16 (m, 1H), 4.04 -4.09 (m, 1H), 3.83-3.88 (m, 1H), 3.29 (s, 3H)
MS (ESI ^<+> ) m / z: 273 [M + H] ^< +>.

(Reference Example 162) (2-Aminoquinolin-5-yl) (3-methoxyazetidin-1-yl) methanone To the compound (1.82 g) obtained in Reference Example 161, methanol (36 mL) and Raney nickel (Nikko Rica R -200, 2 mL) was added and stirred at room temperature under a hydrogen atmosphere for 5 days. The reaction mixture was filtered through celite, and the filtrate was concentrated to give the title compound (1.27 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.26 (d, J = 9.0 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.51-7.56 (m, 1H), 7.29 (dd , J = 7.2, 1.1 Hz, 1H), 6.79 (d, J = 9.0 Hz, 1H), 4.85 (br. S., 2H), 4.39-4.47 (m, 1H), 4.20-4.27 (m, 1H) , 4.04-4.16 (m, 2H), 3.84-3.90 (m, 1H), 3.29 (s, 3H)
MS (ESI ^<+> ) m / z: 258 [M + H] ^< +>.

Reference Example 163 5-Methylquinolin-2-amine A mixture of the compound obtained in Reference Example 111 (194 mg) and p-methoxybenzylamine (523 μL) was stirred at 160 ° C. for 1 hour in a nitrogen atmosphere. The reaction mixture was cooled to room temperature and diluted with dichloromethane, and then dry ice was added. The precipitated solid was filtered and the filtrate was concentrated. Ethanol (6 mL), 6N hydrochloric acid (1 mL) and ASCA2 catalyst (manufactured by NE Chemcat, 40 mg) were added to the residue, and the mixture was stirred at room temperature for 24 hours under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated. TFA (3 mL) was added to the residue and stirred at room temperature for 45 minutes. The reaction mixture was cooled to 0 ° C., water and 4N aqueous sodium hydroxide solution were added, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 30: 70-10: 90) to give the title compound (121 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.08 (dd, J = 9.0, 0.8 Hz, 1H), 7.50-7.55 (m, 1H), 7.41-7.47 (m, 1H), 7.08-7.11 ( m, 1H), 6.74 (d, J = 8.8 Hz, 1H), 4.74 (br. s., 2H), 2.60 (s, 3H)
MS (ESI ^<+> ) m / z: 159 [M + H] ^< +>.

Reference Example 164 5-((methylsulfonyl) methyl) quinolin-2-amine A mixture of the compound (100 mg) obtained in Reference Example 122, sodium methanesulfinate (132 mg), methanol (4 mL) and acetonitrile (4 mL). Stir at 60 ° C. for 12 hours. The reaction mixture was cooled to room temperature, concentrated to about 1/3 volume, water (6 mL) and chloroform (2 mL) were added and stirred. The precipitated solid was collected by filtration to give the title compound (67 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 8.21 (d, J = 9.0 Hz, 1H), 7.45-7.48 (m, 2H), 7.22 (t, J = 4.3 Hz, 1H), 6.79 (d, J = 9.3 Hz, 1H), 6.45 (s, 2H), 4.87 (s, 2H), 2.98 (s, 3H).

(Reference Example 165) Ethyl 7-acetyl-3-methyl-4-(((triisopropylsilyl) oxy) methyl) benzo [b] thiophene-2-carboxylate DMF (391 mg) of the compound (391 mg) obtained in Reference Example 77 4 mL) solution was added with imidazole (182 mg) and triisopropylsilyl chloride (429 μL) and stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5-90: 10) to give the title compound (591 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.12 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 7.8 Hz, 1H), 5.46 (s, 2H), 4.40 (q, J = 7.2 Hz, 2H), 3.00 (s, 3H), 2.75 (s, 3H), 1.42 (t, J = 7.0 Hz, 3H), 1.19-1.28 (m, 3H), 1.09-1.15 (m, 18H) .

(Reference Example 166) 7-acetyl-3-methyl-4-(((triisopropylsilyl) oxy) methyl) benzo [b] thiophene-2-carboxylic acid Methanol (10 mL) of the compound (590 mg) obtained in Reference Example 165 ) 1N aqueous sodium hydroxide solution (1.97 mL) was added to the suspension, and the mixture was stirred at room temperature for 3 hours. THF (20 mL) was added to the reaction mixture, and the mixture was stirred at room temperature overnight. 1N Hydrochloric acid (1.97 mL) was added to the reaction mixture, and the mixture was concentrated. Water was added to the residue and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 94: 6) to obtain the title compound (424 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.14 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 7.8 Hz, 1H), 5.46 (s, 2H), 3.02 (s, 3H ), 2.76 (s, 3H), 1.19-1.29 (m, 3H), 1.10-1.15 (m, 18H)
MS (ESI ^<+> ) m / z: 421 [M + H] ^< +>.

Reference Example 167 7-Acetyl-N- (5- (methoxymethyl) quinolin-2-yl) -3-methyl-4-(((triisopropylsilyl) oxy) methyl) benzo [b] thiophene-2- Carboxamide Compound (80 mg) obtained in Reference Example 166, Compound (46.5 mg) obtained in Reference Example 127 and HBTU (75.0 mg) in dichloromethane (5 mL) suspension was added N, N-diisopropylethylamine (85 μL), Stir at room temperature for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 97: 3) to obtain the title compound (82.9 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (br. S., 1H), 8.53 (s, 2H), 8.15 (d, J = 7.8 Hz, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.63 (dd, J = 8.5, 7.0 Hz, 1H), 7.45 (d, J = 6.8 Hz, 1H), 5.48 (s, 2H), 4.89 (s, 2H), 3.45 (s, 3H), 2.97 (s, 3H), 2.78 (s, 3H), 1.19-1.31 (m, 3H), 1.11-1.15 (m, 18H).

(Reference Example 168) 7-acetyl-N- (5-(((tert-butyldimethylsilyl) oxy) methyl) quinolin-2-yl) -3-methyl-4-(((triisopropylsilyl) oxy) methyl ) Benzo [b] thiophene-2-carboxamide Compound (70 mg) obtained in Reference Example 166, Compound (48 mg) obtained in Reference Example 140 and HBTU (69 mg) in chloroform (4 mL) in N, N-diisopropyl suspension Ethylamine (83 μL) was added and stirred at room temperature for 3 days. The reaction mixture was diluted with chloroform and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5-75: 25) to give the title compound (87 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (br. S., 1H), 8.46-8.54 (m, 2H), 8.15 (d, J = 8.0 Hz, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4, 7.2 Hz, 1H), 7.49 (d, J = 6.8 Hz, 1H), 5.49 (s, 2H ), 5.16 (s, 2H), 2.97 (s, 3H), 2.78 (s, 3H), 1.20-1.31 (m, 3H), 1.11-1.16 (m, 18H), 0.94 (s, 9H), 0.12 ( s, 6H).

Reference Example 169 7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -3-methyl-4-(((triisopropylsilyl) oxy) Methyl) benzo [b] thiophene-2-carboxamide To a solution of the compound (105 mg) obtained in Reference Example 166 in chloroform (10 mL) was added N, N-diisopropylethylamine (109 μL) and HBTU (114 mg) at room temperature. Stir for minutes. The compound obtained in Reference Example 162 (64.7 mg) was added to the reaction mixture, and the mixture was stirred at 50 ° C. for 2 days. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99.5: 0.5 to 97: 3) to obtain the title compound (145 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (s, 1H), 8.58 (s, 2H), 8.16 (d, J = 7.8 Hz, 1H), 7.88-7.95 (m, 2H), 7.67 (dd, J = 8.4, 7.2 Hz, 1H), 7.52 (dd, J = 7.0, 1.0 Hz, 1H), 5.49 (s, 2H), 4.42-4.51 (m, 1H), 4.22-4.29 (m, 1H ), 4.15-4.20 (m, 1H), 4.03-4.10 (m, 1H), 3.84-3.90 (m, 1H), 3.30 (s, 3H), 2.98 (s, 3H), 2.79 (s, 3H), 1.19-1.31 (m, 3H), 1.11-1.18 (m, 18H)
MS (ESI ⁺ ) m / z: 660 [M + H] ⁺ .

(Reference Example 170) (4-bromo-3-fluorophenyl) ^(1,1-2 H ₂₎ methanol
4-bromo-3-fluorobenzoic acid methyl (13.9 g) in 2-propanol (50 mL) was added at room temperature ⁽² H ₄₎ 2-propanol was added dropwise to the (50 mL) solution of sodium borohydride (4.96 g), Stir at 70 ° C. for 5 hours. The reaction mixture was concentrated, saturated brine was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-60: 40) to give the title compound (3.8 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.52 (dd, J = 8.1, 7.3 Hz, 1H), 7.16 (dd, J = 9.3, 1.6 Hz, 1H), 7.02 (dd, J = 8.1, 2.0 Hz, 1H).

(Reference Example 171) 1-bromo-2-fluoro-4- (methoxy ⁽² H ₂₎ methyl) compound obtained in benzene Example 170 in dichloromethane (20 mL) solution of (3.8 g) was cooled to 0 ° C., methane After sulfonyl chloride (1.573 mL) was added dropwise, triethylamine (2.81 mL) was added dropwise and stirred at 0 ° C. for 1 hour. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. Sodium methoxide (1M methanol solution, 92 mL) was added dropwise to the residue at room temperature, and the mixture was stirred for 2 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give the title compound (3.5 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.51 (dd, J = 8.1, 7.3 Hz, 1H), 7.13 (dd, J = 9.1, 1.8 Hz, 1H), 6.99 (dd, J = 8.1, 2.4 Hz, 1H), 3.39 (s, 3H).

(Reference Example 172) 1- (3-bromo-2-fluoro-6- (methoxy ⁽² H ₂₎ methyl) phenyl) ethanone
A 2,2,6,6-tetramethylpiperidine (2.68 g) solution in THF (30 mL) was cooled to −75 ° C. under a stream of argon, and n-butyllithium (1.59 M hexane solution, 10.95 mL) was added dropwise. The mixture was stirred at the same temperature for 40 minutes. A THF (20 mL) solution of the compound (3.5 g) obtained in Reference Example 171 was added dropwise to the reaction mixture, and the mixture was stirred at the same temperature for 1 hour. DMF (1.349 mL) was added dropwise to the reaction mixture, and the mixture was stirred at the same temperature for 1 hour. Acetic acid (10 mL) and water (50 mL) were sequentially added to the reaction mixture, and the mixture was warmed to room temperature. The reaction mixture was extracted with ethyl acetate, and the organic layer was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in THF (30 mL), added dropwise to methylmagnesium bromide (1M THF solution, 38.1 mL) cooled to 0 ° C., and stirred at room temperature for 3 hours. A saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. Acetonitrile (20 mL), N-methylmorpholine-N-oxide (1.591 g) and tetrapropylammonium perruthenate (0.199 g) were added to the residue, and the mixture was stirred at room temperature for 45 minutes. The reaction mixture was washed with 0.1N hydrochloric acid, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1) to obtain the title compound (2.4 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.57 (t, J = 7.5 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 3.35 (s, 3H), 2.56-2.60 (m , 3H).

(Reference Example 173) 4- (methoxy ⁽² H ₂₎ methyl) -3-methyl-7 - ((trimethylsilyl) ethynyl) benzo [b] thiophene-2-carboxylic acid ethyl Reference Example 172 To a solution of the compound obtained in (2.4 g ) And 1,8-diazabicyclo [5.4.0] -7-undecene (4.12 mL) in DMF (50 mL) were added dropwise ethyl thioglycolate (1.10 mL) and stirred at room temperature for 2 hours. Water (400 mL) was added to the reaction mixture, and the mixture was stirred at 0 ° C. for 1 hr. The precipitated solid was collected by filtration, and the obtained solid was dissolved in ethyl acetate and washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. After the residue was dissolved in THF (30 mL), trimethylsilylacetylene (2.146 mL), tetrakis (triphenylphosphine) palladium (0) (0.221 g), triethylamine (2.66 mL) and copper (I) bromide (0.082 g) In addition, the mixture was stirred at 80 ° C. for 12 hours under an argon atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5-50: 50) to give the title compound (2.8 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.49-7.52 (m, 1H), 7.33 (d, J = 7.3 Hz, 1H), 4.41 (q, J = 6.9 Hz, 2H), 3.43 (s , 3H), 3.01 (s, 3H), 1.43 (t, J = 7.1 Hz, 3H), 0.32 (s, 9H).

(Reference Example 174) 7-acetyl-4- (methoxy ( ² H ₂ ) methyl) -3-methylbenzo [b] thiophene-2-carboxylic acid A solution of the compound (2.8 g) obtained in Reference Example 173 in chloroform (50 mL) P-Toluenesulfonic acid monohydrate (8.81 g) was added to and stirred at 70 ° C. for 12 hours. A 2N aqueous sodium hydroxide solution and a saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. To the residue were added THF (35 mL), ethanol (11.67 mL) and 4N aqueous sodium hydroxide solution (5 mL), and the mixture was stirred at room temperature for 24 hours. 4N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (1.4 g).
¹ H NMR (DMSO, 400MHz): δ (ppm) 13.40 (br. S., 1H), 8.29 (d, J = 7.7 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 3.40 (s , 3H), 2.95 (s, 3H), 2.73 (s, 3H).

(Reference Example 175) (2-chloropyridin-4-yl) ^(1,1-2 H ₂₎ methanol
To a solution of methyl 2-chloroquinoline-4-carboxylate (2.1 g) in 2-propanol (30 mL) was added ( ² H ₄ ) sodium borohydride (0.824 g) at 40 ° C., and the mixture was stirred at 55 ° C. for 1.5 hours. The reaction mixture was concentrated, saturated brine was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. To the residue was added an ethyl acetate-hexane mixture, heated, and cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (1.27 g).
¹ H NMR (MeOD, 400MHz): δ (ppm) 7.95-8.00 (m, 1H), 7.74-7.81 (m, 1H), 7.67 (s, 1H), 7.60-7.65 (m, 2H)
MS (ESI ^<+> ) m / z: 196 [M + H] ^< +>.

Reference Example 176 (R) -1-((2-Aminoquinolin-4-yl) ( ² H ₂ ) methyl) pyrrolidin-3-ol The compound (1.27 g) obtained in Reference Example 175 was added to dibenzylamine ( 2.86 mL) was added and the mixture was stirred at 111 ° C. for 48 hours. 2N hydrochloric acid was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was filtered, and the filtrate was dried over anhydrous sodium sulfate and then concentrated to obtain 930 mg of residue. 510 mg of the obtained residue was dissolved in dichloromethane (6 mL), cooled to 0 ° C., triethylamine (0.259 mL) and methanesulfonyl chloride (0.145 mL) were added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was cooled to 0 ° C., saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was cooled to 0 ° C., a solution of (R) -pyrrolidinol (265 mg) and triethylamine (0.399 mL) in THF (10 mL) was added dropwise, and the mixture was stirred at 50 ° C. for 6 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was extracted with 6N hydrochloric acid, and the aqueous layer was made basic by adding an aqueous sodium hydroxide solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. Dichloromethane (10 mL) and trifluoromethanesulfonic acid (0.746 mL) were added to the residue, and the mixture was stirred at 50 ° C. for 5 hours. The reaction mixture was cooled to 0 ° C., basified with 8N aqueous sodium hydroxide solution, and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 80:20) to obtain the title compound (0.25 g).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 7.94 (dd, J = 8.5, 1.2 Hz, 1H), 7.65-7.70 (m, 1H), 7.55 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H ), 7.24-7.30 (m, 1H), 6.81 (s, 1H), 4.73 (br.s., 2H), 4.35-4.41 (m, 1H), 2.94-3.01 (m, 1H), 2.79 (d, J = 10.1 Hz, 1H), 2.63 (dd, J = 9.9, 5.1 Hz, 1H), 2.38-2.46 (m, 1H), 2.17-2.28 (m, 1H), 1.75-1.84 (m, 1H)
MS (ESI ^<+> ) m / z: 246 [M + H] ^< +>.

(Reference Example 177) 2-Chloro-5-(( ² H ₃ ) methoxymethyl) quinoline A solution of the compound obtained in Reference Example 111 (480 mg) in DMF (10 mL) was cooled to 0 ° C., and sodium hydride (60% oil suspension (119 mg) was added, and the mixture was stirred at room temperature for 20 minutes. Iodo ( ² H ₃ ) methane (0.079 mL) was added and stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform: methanol = 10: 0 to 10: 1) to obtain the title compound (480 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.44 (dd, J = 8.9, 0.9 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.68 (dd, J = 8.5, 7.0 Hz , 1H), 7.51-7.55 (m, 1H), 7.43 (d, J = 8.8 Hz, 1H), 4.86 (s, 2H)
MS (ESI ^<+> ) m / z: 211 [M + H] ^< +>.

(Reference Example 178) 1-bromo-2-fluoro -4 - ⁽⁽² H ₃₎ methoxymethyl) sodium hydride at 0 ℃ in DMF (60 mL) solution of the compound obtained in benzene Reference Example 65 (18 g) (60 % Oil suspension, 4.92 g) was added, and the mixture was stirred at 0 ° C. for 45 minutes. Iodo ( ² H ₃ ) methane (7.69 mL) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-80: 20) to give the title compound (15 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.51 (dd, J = 8.0, 7.0 Hz, 1H), 7.12 (dd, J = 9.3, 1.8 Hz, 1H), 6.97-7.01 (m, 1H) , 4.41 (s, 2H).

(Reference Example 179) 3-bromo-2-fluoro -6 - ⁽⁽² H ₃₎ methoxymethyl) benzaldehyde
A THF solution (30 mL) of 2,2,6,6-tetramethylpiperidine (13.76 mL) was cooled to −75 ° C. under an argon stream, and n-butyllithium (1.59 M hexane solution, 46.7 mL) was added dropwise. The mixture was stirred at the same temperature for 40 minutes. A THF (110 mL) solution of the compound (15 g) obtained in Reference Example 178 was added dropwise to the reaction mixture, and the mixture was stirred at −75 ° C. for 80 minutes. DMF (5.75 mL) was added dropwise to the reaction mixture, and the mixture was stirred at -78 ° C for 1 hour. Acetic acid (10 mL) and water (100 mL) were sequentially added to the reaction mixture, and the mixture was warmed to room temperature. The mixture was extracted with ethyl acetate, and the organic layer was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was washed with a diisopropyl ether-hexane (4: 1) mixture to obtain the title compound (8.8 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 10.47 (d, J = 0.8 Hz, 1H), 7.78 (dd, J = 8.5, 7.0 Hz, 1H), 7.44 (dt, J = 8.4, 1.1 Hz , 1H), 4.78 (s, 2H).

Reference Example 180 1- (3-Bromo-2-fluoro-6-(( ² H ₃ ) methoxymethyl) phenyl) ethanone To a solution of the compound obtained in Reference Example 179 (9.3 g) in THF (200 mL) at 0 ° C. Was added dropwise methylmagnesium bromide (1.12M THF solution, 83 mL) and stirred at room temperature for 3 hours. A saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. Acetonitrile (70 mL), N-methylmorpholine-N-oxide (11.23 g) and tetrapropylammonium perruthenate (2.69 g) were added to the residue, and the mixture was stirred at room temperature for 6 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0-3: 1) to give the title compound (9.3 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.56 (dd, J = 8.3, 7.0 Hz, 1H), 7.11 (dq, J = 8.3, 0.8 Hz, 1H), 4.43 (s, 2H), 2.57 (d, J = 2.8 Hz, 3H).

Reference Example 181 Ethyl 4-(( ² H ₃ ) methoxymethyl) -3-methyl-7-((trimethylsilyl) ethynyl) benzo [b] thiophene-2-carboxylate Compound obtained in Reference Example 180 (9.3 g ) And 1,8-diazabicyclo [5.4.0] -7-undecene (15.92 mL) in DMF (50 mL) were added dropwise ethyl thioglycolate (4.25 mL), and the mixture was stirred at room temperature for 2 hours. Water (400 mL) was added to the reaction mixture, and the mixture was stirred at 0 ° C. for 1 hr. The precipitated solid was collected by filtration, and the obtained solid was dissolved in ethyl acetate and washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. After the residue was dissolved in THF (170 mL), trimethylsilylacetylene (8.10 mL), tetrakis (triphenylphosphine) palladium (0) (1.001 g), triethylamine (8.05 mL) and copper (I) bromide (0.414 g) were added. In addition, the mixture was stirred at 80 ° C. for 12 hours under an argon atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5-50: 50) to give the title compound (6.0 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 7.50 (d, J = 7.5 Hz, 1H), 7.33 (d, J = 7.5 Hz, 1H), 4.85 (s, 2H), 4.41 (q, J = 7.3 Hz, 2H), 3.01 (s, 3H), 1.43 (t, J = 7.2 Hz, 3H), 0.32 (s, 9H).

(Reference Example 182) Ethyl 7-acetyl-4-(( ² H ₃ ) methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylate p-toluenesulfone was added to the compound (6.0 g) obtained in Reference Example 181. Acid monohydrate (9.42 g) and chloroform (80 mL) were added, and the mixture was stirred at 70 ° C. for 12 hr. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (chloroform: ethyl acetate = 100: 0 to 5: 1) to obtain the title compound (4.4 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.07 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 4.98 (s, 2H), 4.40 (q, J = 7.0 Hz, 2H), 3.03 (s, 3H), 2.75 (s, 3H), 1.43 (t, J = 7.2 Hz, 3H)
MS (ESI ^<+> ) m / z: 310 [M + H] ^< +>.

(Reference Example 183) 7-acetyl-4-(( ² H ₃ ) methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxylic acid Ethanol (100 mL) was added to the compound (4.4 g) obtained in Reference Example 182. 4N Aqueous sodium hydroxide solution (100 mL) was added, and the mixture was stirred at 50 ° C. for 8 hr. The reaction mixture was cooled to room temperature, hydrochloric acid was added, and the precipitated solid was collected by filtration to give the title compound.
MS (ESI ^<+> ) m / z: 282 [M + H] ^< +>.

(Reference Example 184) (2-Chloro-5-yl) ^(1,1-2 H ₂₎ of the compound obtained in methanol Reference Example 110 (6.9 g) and ⁽² H ₄₎ Sodium borohydride (4.71 g) To a THF (20 mL) solution was added dropwise methanol (20 mL) at 0 ° C., and the mixture was stirred at 50 ° C. for 1 hour. The reaction mixture was concentrated, saturated brine was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was added with ethyl acetate-hexane mixture and heated, and then cooled to 0 ° C. The precipitated solid was collected by filtration to give the title compound (4.5 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.49 (dd, J = 8.9, 0.9 Hz, 1H), 7.99 (dt, J = 8.5, 1.0 Hz, 1H), 7.70 (dd, J = 8.5, 7.0 Hz, 1H), 7.57 (dd, J = 7.0, 1.0 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H)
MS (ESI ^<+> ) m / z: 196 [M + H] ^< +>.

(Reference Example 185) 2-Chloro-5- (methoxy ( ² H ₂ ) methyl) quinoline Sodium hydride (60% oil suspension) was added to a solution of the compound obtained in Reference Example 184 (1.0 g) in DMF (10 mL) at 0 ° C. 245 mg) and stirred at room temperature for 20 minutes. To the reaction mixture was added iodomethane (163 μL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform: methanol = 10: 0 to 10: 1) to obtain the title compound (1.1 g).
MS (ESI ^<+> ) m / z: 210 [M + H] ^< +>.

(Reference Example 186) (2 - ((5-4-methoxybenzyl) amino) yl) ^(1,1-2 H ₂₎ in place of the compound obtained in Reference Example 111 as a raw material in methanol Reference Example 120 The title compound was obtained by the same procedures as in Reference Example 120 using the compound obtained in Reference Example 184.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.19 (dd, J = 9.0, 0.8 Hz, 1H), 7.66-7.70 (m, 1H), 7.49 (dd, J = 8.4, 7.2 Hz, 1H) , 7.31-7.36 (m, 2H), 7.19-7.25 (m, 1H), 6.84-6.90 (m, 2H), 6.67 (d, J = 9.0 Hz, 1H), 4.62-4.69 (m, 2H), 3.80 (d, J = 0.8 Hz, 3H)
MS (ESI ^<+> ) m / z: 297 [M + H] ^< +>.

(Reference Example 187) (2-Amino-yl) ^(1,1-2 H ₂₎ the compound obtained in Reference Example 186 in place of the compound obtained in Reference Example 120 as a starting material in methanol Reference Example 121 And the title compound was obtained in the same manner as in Reference Example 121.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.22 (dd, J = 9.0, 0.8 Hz, 1H), 7.62-7.66 (m, 1H), 7.50 (dd, J = 8.5, 7.0 Hz, 1H) , 7.21-7.25 (m, 1H), 6.76 (d, J = 9.0 Hz, 1H), 4.74-4.80 (m, 2H)
MS (ESI ^<+> ) m / z: 177 [M + H] ^< +>.

Reference Example 188 7-acetyl-4-(( ² H ₃ ) methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide Reference instead of the compound obtained in Reference Example 74, which is the starting material in Reference Example 102 The title compound was obtained by the same procedures as in Reference Example 102 using the compound obtained in Example 183.
¹ H NMR (DMSO, 400 MHz): δ (ppm) 8.25 (d, J = 7.8 Hz, 1H), 7.86 (br. S., 1H), 7.60-7.69 (m, 2H), 4.96 (s, 2H) , 2.77 (s, 3H), 2.74 (s, 3H)
MS (ESI ^<+> ) m / z: 281 [M + H] ^< +>.

(Reference Example 189) benzyl 3-hydroxyazetidine-1-carboxylate
Add water (5 mL), methanol (5 mL) and sodium carbonate (1161 mg) to 3-hydroxyazetidine hydrochloride (500 mg), cool to 0 ° C., add benzyloxycarbonyl chloride (782 μL), and continue at 0 ° C. for 1 hour. After stirring, the mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 92: 8) to obtain the title compound (900 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.28-7.38 (m, 5H), 5.09 (s, 2H), 4.57-4.65 (m, 1H), 4.20-4.26 (m, 2H), 3.85- 3.91 (m, 2H), 2.50 (dd, J = 6.1, 1.4 Hz, 1H).

(Reference Example 190) 3- ⁽² H ₃₎ methoxyazetidine-1-carboxylic acid benzyl Reference Example 189 To a solution of the compound obtained in (900 mg) in DMF (4 mL) of sodium hydride at 0 ℃ in solution (60% oil suspension, 208 mg) was added and stirred for 20 minutes. To the reaction mixture was added iodo ( ² H ₃ ) methane (405 μL), and the mixture was stirred at 0 ° C. for 30 minutes and then at room temperature for 2 hours. The reaction mixture was diluted with ethyl acetate and washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 98: 2) to obtain the title compound (798 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 7.28-7.38 (m, 5H), 5.10 (s, 2H), 4.12-4.20 (m, 3H), 3.87-3.95 (m, 2H)
MS (ESI ^<+> ) m / z: 225 [M + H] ^< +>.

(Reference Example 191) 3- ⁽² H ₃₎ methoxyazetidine compound obtained in the hydrochloride Reference Example 190 (768 mg) in methanol (6 mL) was added 6N hydrochloric acid (685μL) and 10% palladium / carbon (Nacalai Tesque, 60 mg) was added, and the mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (419 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 9.08 (br. S., 2H), 4.20-4.28 (m, 1H), 4.04-4.15 (m, 2H), 3.72-3.82 (m, 2H).

(Reference Example 192) (2-chloro-yl) (3- ⁽² H ₃₎ methoxy-1-yl) methanone
N, N-diisopropylethylamine (1.01 μL) and HBTU (694 mg) were added to a chloroform (10 mL) solution of 2-chloroquinoline-5-carboxylic acid (345 mg) at room temperature, and the mixture was stirred at room temperature for 30 minutes. The compound (210 mg) obtained in Reference Example 191 was added to the reaction mixture, and the mixture was stirred overnight at room temperature. N, N-diisopropylethylamine (129 mg), HBTU (76 mg) and the compound obtained in Reference Example 191 (63 mg) were added, and the mixture was stirred at room temperature for 2 hours. A 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99.5: 0.5 to 97: 3) to obtain the title compound (423 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.55 (dd, J = 9.0, 0.8 Hz, 1H), 8.09 (dt, J = 8.5, 0.9 Hz, 1H), 7.73 (dd, J = 8.4, 7.2 Hz, 1H), 7.60 (dd, J = 7.3, 1.3 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 4.42-4.49 (m, 1H), 4.22-4.28 (m, 1H), 4.07-4.18 (m, 2H), 3.86-3.91 (m, 1H)
MS (ESI ⁺ ) m / z: 280 [M + H] ⁺ .

(Reference Example 193) (2-Aminoquinolin-5-yl) (3- ( ² H ₃ ) methoxyazetidin-1-yl) methanone 80% hydrazine monohydrate was added to the compound (423 mg) obtained in Reference Example 192. (2.0 mL) and 1,4-dioxane (2.0 mL) were added, and the mixture was stirred at 80 ° C. for 11 hours. The reaction mixture was cooled to room temperature, saturated brine was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. Methanol (10 mL) and Raney nickel (R-200 manufactured by Nikko Rica, 2.0 mL) were added to the residue, and the mixture was stirred at room temperature for 20 hours under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 98: 2-91: 9) to give the title compound (204 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.26 (d, J = 8.5 Hz, 1H), 7.69-7.73 (m, 1H), 7.53 (dd, J = 8.4, 7.2 Hz, 1H), 7.28 (dd, J = 7.2, 1.1 Hz, 1H), 6.78 (d, J = 9.0 Hz, 1H), 4.79 (s, 2H), 4.40-4.46 (m, 1H), 4.20-4.26 (m, 1H), 4.03-4.16 (m, 2H), 3.83-3.89 (m, 1H)
MS (ESI ^<+> ) m / z: 261 [M + H] ^< +>.

(Example 1)
4,7-Diacetyl-3-methyl-N- (quinolin-2-yl) benzo [b] thiophene-2-carboxamide

To a solution of the compound (50 mg) obtained in Reference Example 5 in dimethylformamide (5 mL), 2-aminoquinoline (26 mg), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (52 mg) and N, N-dimethyl-4-aminopyridine (40 mg) was added, and the mixture was stirred at 40 ° C. for 15 hr. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 89:11) to obtain the title compound (7.5 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 8.49 (br.s., 1H), 8.27 (d, J = 8.9 Hz, 1H), 8.11-8.16 (m, 1H), 8.00-8.04 (m, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.69-7.75 (m, 1H), 7.46-7.54 (m, 2H), 2.81 (s, 3H ), 2.75 (s, 3H), 2.68 (s, 3H)
MS (ESI ^<+> ) m / z: 403 [M + H] ^< +>.

(Example 2)
4,7-Diacetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 5 (0.500 g), the compound obtained in Reference Example 8 (0.366 g) and PyBOP (0.942 g) in dichloromethane (18 mL) was added N, N-diisopropylethylamine (630 μL). And stirred at room temperature for 70 hours. The compound (0.366 g) obtained in Reference Example 8 and N, N-diisopropylethylamine (315 μL) were added to the reaction mixture, and the mixture was stirred at 32 ° C. for 48 hours. Chloroform (50 mL) and water (50 mL) were added to the reaction mixture, and the obtained organic layer was dried over anhydrous magnesium sulfate and concentrated. 2-Propanol (3.0 mL) was added to the residue and heated to 85 ° C., and then cooled to room temperature. The precipitated solid was collected by filtration and washed with 2-propanol to give the title compound (0.665 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.84 (br. S., 1H), 8.68-8.72 (m, 1H), 8.59 (br. S., 1H), 8.12 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.62 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.41-7.50 (m, 2H), 2.81 (s, 3H), 2.74 (s, 3H), 2.64 (s, 3H), 2.29 (br. s., 1H), 1.91 (s, 6H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 3)
4,7-Diacetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

To the compound (46.1 mg) obtained in Example 2, 2-propanol (2 mL) and hydrogen chloride (4N 1,4-dioxane solution, 200 μL) were added, and the mixture was concentrated. To the residue was added 2-propanol (1 mL), heated to 60 ° C., and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (31.7 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 9.04 (s, 1H), 8.86-8.91 (m, 1H), 8.12-8.19 (m, 2H), 7.86-7.92 (m, 1H), 7.67- 7.74 (m, 1H), 7.46 (d, J = 7.7 Hz, 1H), 3.71 (s, 1H), 2.79 (s, 3H), 2.76 (s, 3H), 2.74 (s, 3H), 1.96 (s , 6H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 4)
4,7-Diacetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrobromide obtained in Example 2 To the compound (46.1 mg) was added 2-propanol (2 mL) and 47% hydrobromic acid (50 μL), and the mixture was concentrated. 2-Propanol (1 mL) was added to the residue and heated to 60 ° C., and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (34.4 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.06 (s, 1H), 8.87-8.92 (m, 1H), 8.19-8.24 (m, 1H), 8.14 (d, J = 7.3 Hz, 1H) , 7.91 (t, J = 7.7 Hz, 1H), 7.69-7.75 (m, 1H), 7.46 (d, J = 7.3 Hz, 1H), 2.79 (s, 3H), 2.77 (s, 3H), 2.76 ( s, 3H), 2.52 (s, 1H), 1.96 (s, 6H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 5)
4,7-Diacetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hemisulfate

To the compound obtained in Example 2 (46.1 mg), 2-propanol (2 mL) and concentrated sulfuric acid (20 μL) were added, followed by concentration. 2-Propanol (1 mL) was added to the residue, followed by hexane (1 mL). The precipitated solid was collected by filtration to give the title compound (35.5 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.88 (s, 1H), 8.78-8.82 (m, 1H), 8.17-8.22 (m, 1H), 8.14 (d, J = 7.7 Hz, 1H) , 7.86-7.93 (m, 1H), 7.69-7.75 (m, 1H), 7.45 (d, J = 7.7 Hz, 1H), 2.79 (s, 3H), 2.76 (s, 3H), 2.67 (s, 3H ), 1.94 (s, 6H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 6)
4,7-Diacetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide methanesulfonate

To the compound (46.1 mg) obtained in Example 2, 2-propanol (2 mL) and methanesulfonic acid (40 μL) were added and then concentrated. 2-Propanol (1 mL) was added to the residue, followed by hexane (1 mL). The precipitated solid was collected by filtration to give the title compound (40 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.78-8.82 (m, 2H), 8.11-8.18 (m, 2H), 7.91 (t, J = 7.7 Hz, 1H), 7.72 (t, J = 7.9 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 2.91 (s, 6H), 2.80 (s, 3H), 2.77 (s, 3H), 2.66 (s, 3H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 7)
4,7-Diacetyl-3-ethyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 13 (290 mg), the compound obtained in Reference Example 8 (202 mg) and PyBOP (572 mg) in dichloromethane (5 mL) was added N, N-diisopropylethylamine (344 μL) at room temperature. Stir for 108 hours. Dichloromethane and water were added to the reaction mixture, and the resulting organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30-20: 80) to give the title compound (313 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.66-8.74 (m, 2H), 8.54-8.66 (m, 1H), 8.14 (d, J = 7.7 Hz, 1H), 7.82-7.94 (m, 1H), 7.62-7.69 (m, 1H), 7.43-7.51 (m, 2H), 3.13-3.24 (m, 2H), 2.81 (s, 3H), 2.77 (s, 3H), 2.17 (br. S. , 1H), 1.91 (s, 6H), 1.19-1.25 (m, 3H)
MS (ESI ^<+> ) m / z: 475 [M + H] ^< +>.

(Example 8)
4,7-Diacetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

Similar to Example 7 using the compound obtained in Reference Example 16 (52 mg), the compound obtained in Reference Example 8 (40 mg), PyBOP (115 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (69 μL). The title compound (57 mg) was obtained by the method.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.93-9.04 (m, 2H), 8.60-8.77 (m, 2H), 8.16-8.21 (m, 1H), 8.07-8.11 (m, 1H), 7.85-7.95 (m, 1H), 7.67 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.48 (ddd, J = 8.5, 6.9, 1.2 Hz, 1H), 2.83 (s, 3H), 2.82 ( s, 3H), 2.21 (s, 1H), 1.91 (s, 6H)
MS (ESI ^<+> ) m / z: 447 [M + H] ^< +>.

(Example 9)
7-acetyl-4- (1-hydroxyethyl) -N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

The compound obtained in Reference Example 24 (20 mg), the compound obtained in Reference Example 8 (14 mg), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (19 mg) and 1-hydroxy-7-azabenzo A solution of triazole (13 mg) in DMF (10 mL) was stirred at room temperature for 10 hours. The reaction mixture is concentrated, and the residue is subjected to silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10), basic silica gel column chromatography (hexane: ethyl acetate = 60: 40 to 0: 100) and silica gel column chromatography. The title compound (19.4 mg) was obtained by sequential purification by chromatography (ethyl acetate-hexane (1: 1) mixture: methanol = 100: 0 to 93: 7).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.73 (m, 1H), 8.59 (br. S., 1H), 8.13 (d, J = 8.1 Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.61-7.68 (m, 1H), 7.44-7.51 (m, 1H), 5.98-6.06 (m, 1H), 2.95 (s, 3H), 2.77 (s, 3H), 1.89-1.95 (m, 6H), 1.62 (d, J = 6.5 Hz, 3H)
MS (ESI ^<+> ) m / z: 463 [M + H] ^< +>.

(Example 10)
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methyl-4-propionylbenzo [b] thiophene-2-carboxamide

Compound (87 mg) obtained in Reference Example 28, compound (45 mg) obtained in Reference Example 8, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (86 mg), 1-hydroxy-7-azabenzo The title compound (21.9 mg) was obtained in the same manner as in Example 9 using triazole (61 mg) and DMF (20 mL).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.09 (br. S., 1H), 8.65 (dd, J = 8.7, 1.0 Hz, 1H), 8.50 (br. S., 1H), 8.06 ( d, J = 7.7 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.50-7.58 (m, 1H), 7.32-7.39 (m, 2H), 2.92-3.02 (m, 2H), 2.78 (s, 3H), 2.53 (s, 3H), 1.89 (s, 6H), 1.29 (t, J = 7.3 Hz, 3H)
MS (ESI ^<+> ) m / z: 475 [M + H] ^< +>.

(Example 11)
4,7-Diacetyl-3-methyl-N- (4-methylquinolin-2-yl) benzo [b] thiophene-2-carboxamide

Similar to Example 7 using the compound (100 mg), 4-methylquinolin-2-amine (58 mg), PyBOP (281 mg), dichloromethane (30 mL) and N, N-diisopropylethylamine (97 μL) obtained in Reference Example 5. By the method, the title compound (16.5 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.77 (br. S., 1H), 8.33 (br. S., 1H), 8.13 (d, J = 7.7 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.81-7.89 (m, 1H), 7.63-7.72 (m, 1H), 7.42-7.53 (m, 2H), 2.81 (s, 3H), 2.77 (s, 3H), 2.75 (s, 3H), 2.67 (s, 3H)
MS (ESI ^<+> ) m / z: 417 [M + H] ^< +>.

(Example 12)
4,7-Diacetyl-N- (4-methoxyquinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Compound obtained in Reference Example 5 (40 mg), compound obtained in Reference Example 29 (26 mg), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (42 mg), 1-hydroxy-7-azabenzo The title compound (35 mg) was obtained in the same manner as in Example 9 using triazole (30 mg) and DMF (15 mL).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (br. S., 1H), 8.09-8.14 (m, 2H), 7.69-7.75 (m, 1H), 7.62-7.68 (m, 1H) , 7.47 (d, J = 7.7 Hz, 1H), 7.41 (t, J = 7.5 Hz, 1H), 4.15 (s, 3H), 2.81 (s, 3H), 2.75 (s, 3H), 2.69 (s, 3H)
MS (ESI ^<+> ) m / z: 433 [M + H] ^< +>.

(Example 13)
4,7-Diacetyl-N- (4- (1-hydroxyethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

The compound obtained in Reference Example 5 (97 mg), the compound obtained in Reference Example 37 (60 mg), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (102 mg), 1-hydroxy-7-azabenzo The title compound (54 mg) was obtained in the same manner as in Example 9 using triazole (73 mg) and DMF (15 mL).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.64 (br. S., 1H), 8.13 (d, J = 7.7 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.89 ( d, J = 7.7 Hz, 1H), 7.64-7.72 (m, 1H), 7.43-7.54 (m, 2H), 5.59-5.70 (m, 1H), 2.80 (s, 3H), 2.75 (s, 3H) , 2.67 (s, 3H), 1.72 (d, J = 6.5 Hz, 3H)
MS (ESI ^<+> ) m / z: 447 [M + H] ^< +>.

(Example 14)
4,7-Diacetyl-N- (4- (hydroxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 5 (108 mg), the compound obtained in Reference Example 39 (62 mg), PyBOP (270 mg), dichloromethane (30 mL) and N, N-diisopropylethylamine (92 mg), the same as in Example 7. The title compound (17.1 mg) was obtained by the method.
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.52 (br.s., 1H), 8.22 (d, J = 7.7 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.88 (d , J = 8.1 Hz, 1H), 7.68-7.75 (m, 1H), 7.50-7.60 (m, 2H), 5.19 (s, 2H), 2.83 (s, 3H), 2.79 (s, 3H), 2.64 ( s, 3H)
MS (ESI ^<+> ) m / z: 433 [M + H] ^< +>.

(Example 15)
4,7-Diacetyl-3-methyl-N- (4-((N-methylacetamido) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

The compound obtained in Reference Example 5 (48 mg), the compound obtained in Reference Example 40 (41 mg), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (52 mg), 1-hydroxy-7-azabenzo The title compound (69 mg) was obtained in the same manner as in Example 9 using triazole (37 mg) and DMF (5 mL).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (br. S., 1H), 8.37 (br. S., 1H), 8.14 (d, J = 7.7 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.84-7.90 (m, 1H), 7.66-7.72 (m, 1H), 7.46-7.53 (m, 2H), 5.11 (s, 2H), 3.06 (s, 3H), 2.81 (s, 3H), 2.75 (s, 3H), 2.67 (s, 3H), 2.26 (s, 3H)
MS (ESI ^<+> ) m / z: 488 [M + H] ^< +>.

(Example 16)
N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methyl-7-propionylbenzo [b] thiophene-2-carboxamide

The same as Example 7 using the compound (62 mg) obtained in Reference Example 46, the compound (51 mg) obtained in Reference Example 8, PyBOP (143 mg), dichloromethane (2.5 mL) and N, N-diisopropylethylamine (86 μL). By the method, the title compound (62 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.67-8.75 (m, 2H), 8.64 (br. S., 1H), 8.19 (d, J = 6.9 Hz, 1H), 8.12 (dd, J = 8.1, 0.8 Hz, 1H), 7.85-7.93 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.21 (q, J = 7.3 Hz, 2H), 2.86 ( s, 3H), 2.17 (s, 1H), 1.92 (s, 6H), 1.35 (t, J = 7.3 Hz, 3H)
MS (ESI ^<+> ) m / z: 433 [M + H] ^< +>.

(Example 17)
7-Butyryl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 48 (78.7 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg) and dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In a similar manner, the title compound (22 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.75 (m, 2H), 8.64 (br. S., 1H), 8.19 (d, J = 6.9 Hz, 1H), 8.11 (dd, J = 8.1, 0.8 Hz, 1H), 7.85-7.93 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.15 (t, J = 7.3 Hz, 2H), 2.86 ( s, 3H), 2.18 (br.s., 1H), 1.83-1.96 (m, 8H), 1.04-1.11 (m, 3H)
MS (ESI ^<+> ) m / z: 447 [M + H] ^< +>.

(Example 18)
N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -7-isobutyryl-3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 50 (78.7 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In a similar manner, the title compound (89 mg) was obtained.
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.67-8.77 (m, 2H), 8.63 (br. S., 1H), 8.21 (d, J = 7.3 Hz, 1H), 8.12 (dd, J = 7.9, 1.0 Hz, 1H), 7.84-7.92 (m, 1H), 7.60-7.68 (m, 2H), 7.43-7.49 (m, 1H), 3.73-3.84 (m, 1H), 2.86 (s, 3H ), 2.23 (br. S., 1H), 1.91 (s, 6H), 1.34 (d, J = 6.9 Hz, 6H)
MS (ESI ^<+> ) m / z: 447 [M + H] ^< +>.

(Example 19)
7- (Cyclopropylcarbonyl) -N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 52 (78.1 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and By the same method, the title compound (84 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.67-8.74 (m, 2H), 8.63 (br. S., 1H), 8.37 (d, J = 7.3 Hz, 1H), 8.13 (d, J = 8.1 Hz, 1H), 7.83-7.92 (m, 1H), 7.61-7.69 (m, 2H), 7.43-7.49 (m, 1H), 2.84-2.93 (m, 4H), 2.19 (br. S., 1H), 1.91 (s, 6H), 1.37-1.43 (m, 2H), 1.13-1.19 (m, 2H)
MS (ESI ^<+> ) m / z: 445 [M + H] ^< +>.

(Example 20)
N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methyl-7-pentanoylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 54 (82.9 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In a similar manner, the title compound (88 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.74 (m, 2H), 8.64 (br. S., 1H), 8.19 (d, J = 7.7 Hz, 1H), 8.12 (d, J = 8.1 Hz, 1H), 7.86-7.94 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.17 (t, J = 7.5 Hz, 2H), 2.86 (s, 3H), 2.13 (s, 1H), 1.92 (s, 6H), 1.79-1.89 (m, 2H), 1.42-1.54 (m, 2H), 1.00 (t, J = 7.3 Hz, 3H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 21)
7- (Cyclobutylcarbonyl) -N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 56 (82.3 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In a similar manner, the title compound (65 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.69-8.75 (m, 2H), 8.65 (br. S., 1H), 8.11 (d, J = 8.1 Hz, 1H), 8.03 (d, J = 7.3 Hz, 1H), 7.86-7.95 (m, 1H), 7.64-7.70 (m, 1H), 7.57-7.62 (m, 1H), 7.45-7.51 (m, 1H), 4.16-4.27 (m, 1H ), 2.86 (s, 3H), 2.50-2.63 (m, 2H), 2.35-2.47 (m, 2H), 2.13-2.24 (m, 2H), 1.96-2.06 (m, 1H), 1.92 (s, 6H )
MS (ESI ^<+> ) m / z: 459 [M + H] ^< +>.

(Example 22)
N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methyl-7-pivaloylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 58 (82.9 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (258 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In a similar manner, the title compound (48 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.74 (m, 2H), 8.65 (br. S., 1H), 8.36 (d, J = 7.3 Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.63-7.69 (m, 1H), 7.55-7.61 (m, 1H), 7.43-7.50 (m, 1H), 2.86 (s, 3H), 2.12 (s, 1H), 1.92 (s, 6H), 1.54 (s, 9H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 23)
N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methyl-7- (3-methylbutanoyl) benzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 60 (82.9 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In the same manner, the title compound (63 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.69-8.74 (m, 2H), 8.65 (br. S., 1H), 8.18 (d, J = 7.7 Hz, 1H), 8.12 (d, J = 8.1 Hz, 1H), 7.86-7.95 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.51 (m, 1H), 3.04 (d, J = 6.9 Hz, 2H), 2.86 (s, 3H), 2.36-2.48 (m, 1H), 2.13 (br.s., 1H), 1.92 (s, 6H), 1.07 (d, J = 6.5 Hz, 6H)
MS (ESI ^<+> ) m / z: 461 [M + H] ^< +>.

(Example 24)
7- (2-Ethylbutanoyl) -N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 62 (87.1 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In a similar manner, the title compound (55 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.76 (m, 2H), 8.65 (s, 1H), 8.22 (d, J = 7.7 Hz, 1H), 8.14 (d, J = 7.7 Hz , 1H), 7.87-7.93 (m, 1H), 7.61-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.48-3.55 (m, 1H), 2.87 (s, 3H), 2.12 (s , 1H), 1.86-1.98 (m, 8H), 1.63-1.74 (m, 2H), 0.92 (t, J = 7.5 Hz, 6H)
MS (ESI ^<+> ) m / z: 475 [M + H] ^< +>.

(Example 25)
7- (Cyclopentylcarbonyl) -N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 64 (86.5 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (258 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 μL), Example 7 and In a similar manner, the title compound (71 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.75 (m, 2H), 8.64 (br. S., 1H), 8.22 (d, J = 7.3 Hz, 1H), 8.12 (d, J = 7.7 Hz, 1H), 7.85-7.94 (m, 1H), 7.59-7.69 (m, 2H), 7.43-7.50 (m, 1H), 3.88-3.99 (m, 1H), 2.86 (s, 3H), 2.13 (s, 1H), 2.00-2.09 (m, 4H), 1.91 (s, 6H), 1.67-1.87 (m, 4H)
MS (ESI ^<+> ) m / z: 473 [M + H] ^< +>.

(Example 26)
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 74 (55.7 mg), the compound obtained in Reference Example 8 (40.5 mg) and PyBOP (114 mg) in dichloromethane (2 mL), N, N-diisopropylethylamine (68.8 μL) was added. And stirred at room temperature for 3 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was sequentially purified by basic silica gel column chromatography (hexane: dichloromethane = 30: 70-0: 100) and silica gel column chromatography (hexane: ethyl acetate = 70: 30-20: 80) to give the title compound (49 mg) Got.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.78 (m, 2H), 8.62 (br. S., 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.60-7.68 (m, 2H), 7.43-7.49 (m, 1H), 5.00 (s, 2H), 3.53 (s, 3H), 2.99 (s, 3H), 2.78 (s, 3H), 2.22 (br.s., 1H), 1.91 (s, 6H)
MS (ESI ^<+> ) m / z: 463 [M + H] ^< +>.

(Example 27)
7-Acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

Hydrogen chloride (4N 1,4-dioxane solution, 0.016 mL) was added to a solution of the compound obtained in Example 26 (30 mg) in 2-propanol (5 mL). The mixture was concentrated, and a 2-propanol-hexane mixture was added to the resulting residue and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (30.1 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.05 (s, 1H), 8.88 (d, J = 8.5 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 7.84-7.90 (m, 1H), 7.65-7.72 (m, 1H), 7.62 (d, J = 7.3 Hz, 1H), 5.00 (s, 2H), 3.52 (s, 3H) , 3.06 (s, 3H), 2.76 (s, 3H), 1.95 (s, 6H)
MS (ESI ^<+> ) m / z: 463 [M + H] ^< +>.

(Example 28)
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrobromide

47% hydrobromic acid (3.52 μL) was added to a solution of the compound obtained in Example 26 (30 mg) in 2-propanol (5 mL). The mixture was concentrated, and a 2-propanol-hexane mixture was added to the resulting residue and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (32 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 12.19 (br. S., 1H), 9.08 (s, 1H), 8.88 (d, J = 8.1 Hz, 1H), 8.25 (d, J = 8.1 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.87-7.93 (m, 1H), 7.68-7.74 (m, 1H), 7.63 (d, J = 7.7 Hz, 1H), 5.00 (s , 2H), 3.52 (s, 3H), 3.09 (s, 3H), 2.76 (s, 3H), 2.58 (s, 1H), 1.95 (s, 6H)
MS (ESI ^<+> ) m / z: 463 [M + H] ^< +>.

(Example 29)
7-acetyl-4- (ethoxymethyl) -N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 78 (58 mg), the compound obtained in Reference Example 8 (44 mg) and PyBOP (114 mg) in dichloromethane (2 mL), N, N-diisopropylethylamine (69 μL) was added, and at room temperature. Stir for 2.5 days. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified successively by basic silica gel column chromatography (hexane: dichloromethane = 30: 70-0: 100) and silica gel column chromatography (hexane: ethyl acetate = 70: 30-20: 80) to give the title compound (55 mg) Got.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.82 (br. S., 1H), 8.69 (d, J = 8.1 Hz, 1H), 8.58 (br. S., 1H), 8.06 (d, J = 7.7 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.58-7.66 (m, 2H), 7.40-7.47 (m, 1H), 5.01 (s, 2H), 3.69 (q, J = 6.9 Hz, 2H), 2.97 (s, 3H), 2.77 (s, 3H), 2.05 (s, 1H), 1.90 (s, 6H), 1.32 (t, J = 6.9 Hz, 3H)
MS (ESI ^<+> ) m / z: 477 [M + H] ^< +>.

(Example 30)
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -3-methyl-4- (propoxymethyl) benzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 79 (61 mg), the compound obtained in Reference Example 8 (44 mg) and PyBOP (114 mg) in dichloromethane (2 mL), N, N-diisopropylethylamine (69 μL) was added, and at room temperature. Stir for 22 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30-20: 80) to give the title compound (60 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.83 (br. S., 1H), 8.69 (d, J = 8.1 Hz, 1H), 8.58 (br. S., 1H), 8.07 (d, J = 7.7 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.58-7.66 (m, 2H), 7.39-7.47 (m, 1H), 5.01 (s, 2H), 3.58 (t, J = 6.7 Hz, 2H), 2.98 (s, 3H), 2.77 (s, 3H), 2.42 (br. S., 1H), 1.90 (s, 6H), 1.66-1.75 (m, 2H), 0.98 (t , J = 7.5 Hz, 3H)
MS (ESI ^<+> ) m / z: 491 [M + H] ^< +>.

(Example 31)
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (isopropoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 80 (153 mg), the compound obtained in Reference Example 8 (111 mg) and PyBOP (286 mg) in dichloromethane (5 mL) was added N, N-diisopropylethylamine (172 μL) at room temperature. Stir for 20 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30-20: 80) to give the title compound (56 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.65-9.03 (m, 2H), 8.58 (br. S., 1H), 8.07 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.59-7.68 (m, 2H), 7.41-7.48 (m, 1H), 5.03 (s, 2H), 3.78-3.88 (m, 1H), 3.00 (s, 3H), 2.77 ( s, 3H), 2.39 (br. s., 1H), 1.91 (s, 6H), 1.30 (d, J = 6.1 Hz, 6H)
MS (ESI ^<+> ) m / z: 491 [M + H] ^< +>.

(Example 32)
7-acetyl-N- (4- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (1-methoxyethyl) -3-methylbenzo [b] thiophene-2-carboxamide

The same as Example 31 using the compound (35 mg) obtained in Reference Example 83, the compound (25 mg) obtained in Reference Example 8, PyBOP (94 mg), dichloromethane (20 mL) and N, N-diisopropylethylamine (32 μL). The title compound (16.3 mg) was obtained by the method.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73-8.81 (m, 1H), 8.71 (d, J = 8.5 Hz, 1H), 8.62 (br.s., 1H), 8.17 (d, J = 8.1 Hz, 1H), 7.89 (d, J = 8.9 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.45-7.51 (m, 1H ), 5.45-5.53 (m, 1H), 3.33 (s, 3H), 2.98 (s, 3H), 2.79 (s, 3H), 1.92 (s, 6H), 1.54-1.60 (m, 3H)
MS (ESI ^<+> ) m / z: 477 [M + H] ^< +>.

(Example 33)
7-Acetyl-N- (4- (1-hydroxyethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

The same method as in Example 31, using the compound obtained in Reference Example 74 (100 mg), the compound obtained in Reference Example 37 (68 mg), PyBOP (206 mg), dichloromethane (2 mL and N, N-diisopropylethylamine (102 μL)) After obtaining the free base of the title compound, hydrogen chloride (4N ethyl acetate solution) was added and concentrated to give the title compound (28.2 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.33-8.37 (m, 2H), 8.22-8.26 (m, 1H), 8.10 (s, 1H), 8.05 (td, J = 7.7, 1.2 Hz, 1H ), 7.84 (ddd, J = 8.4, 7.2, 1.0 Hz, 1H), 7.74 (d, J = 7.7 Hz, 1H), 5.74 (q, J = 6.4 Hz, 1H), 5.04 (s, 2H), 3.50 (s, 3H), 3.02 (s, 3H), 2.79 (s, 3H), 1.65 (d, J = 6.5 Hz, 3H)
MS (ESI ^<+> ) m / z: 449 [M + H] ^< +>.

(Example 34)
7-acetyl-N- (4-(((2-hydroxyethyl) (methyl) amino) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide Hydrochloride

Similar to Example 31 except that the compound obtained in Reference Example 74 (35 mg), the compound obtained in Reference Example 85 (32 mg), PyBOP (72 mg), dichloromethane (1 mL) and N, N-diisopropylethylamine (18 mg) were used. After obtaining the free base of the title compound by the method, hydrogen chloride (4N ethyl acetate solution) was added and concentrated to obtain the title compound (38 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.57 (s, 1H), 8.29-8.34 (m, 2H), 8.07-8.11 (m, 1H), 7.87-7.92 (m, 1H), 7.69-7.77 (m, 2H), 5.03 (s, 2H), 3.97-4.10 (m, 2H), 3.49-3.54 (m, 5H), 3.00 (s, 3H), 2.96 (s, 3H), 2.78 (s, 3H )
MS (ESI ^<+> ) m / z: 492 [M + H] ^< +>.

(Example 35)
7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 74 (70.0 mg), the compound obtained in Reference Example 86 (67.4 mg) and PyBOP (144 mg) in dichloromethane (2 mL), N, N-diisopropylethylamine (86.7 μL) was added. And stirred at room temperature for 20 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was sequentially purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 95: 5) and basic silica gel column chromatography (hexane: ethyl acetate = 50: 50 to 0: 100) to give the title compound ( 75 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (br. S., 1H), 8.52 (br. S., 1H), 8.19 (d, J = 8.1 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.87 (d, J = 8.1 Hz, 1H), 7.65-7.70 (m, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.45-7.51 (m, 1H), 5.00 (s, 2H), 4.35-4.40 (m, 1H), 4.12 (s, 2H), 3.53 (s, 3H), 2.98-3.05 (m, 4H), 2.83 (d, J = 10.1 Hz, 1H) , 2.79 (s, 3H), 2.68 (dd, J = 10.1, 4.9 Hz, 1H), 2.44-2.51 (m, 1H), 2.19-2.29 (m, 1H), 1.77-1.85 (m, 1H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

Example 36
7-acetyl-N- (4-((4-hydroxypiperidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 74 (83 mg), the compound obtained in Reference Example 87 (77 mg) and PyBOP (172 mg) in dichloromethane (3 mL) was added N, N-diisopropylethylamine (103 μL), and at room temperature. Stir for 1.5 days. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 50: 50-0: 100) to give the title compound (35 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.69 (s, 1H), 8.51 (br. S., 1H), 8.25 (d, J = 7.7 Hz, 1H), 8.10 (d, J = 7.7 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.61-7.71 (m, 2H), 7.45-7.51 (m, 1H), 5.01 (s, 2H), 3.95 (s, 2H), 3.71 -3.81 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.84-2.92 (m, 2H), 2.79 (s, 3H), 2.27-2.37 (m, 2H), 1.90-1.98 (m, 2H), 1.59-1.71 (m, 2H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 37)
7-acetyl-N- (4-((3-hydroxypiperidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

To a suspension of the compound obtained in Reference Example 74 (83 mg), the compound obtained in Reference Example 88 (77 mg) and PyBOP (172 mg) in dichloromethane (3 mL) was added N, N-diisopropylethylamine (155 μL), and at room temperature. Stir for 4.5 days. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 50: 50-0: 100) to give the title compound (70 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (s, 1H), 8.51 (br. S., 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 7.7 Hz, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.61-7.71 (m, 2H), 7.46-7.52 (m, 1H), 5.01 (s, 2H), 3.96 (s, 2H), 3.84 -3.91 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.37-2.74 (m, 4H), 1.78-1.91 (m, 1H), 1.53-1.71 (m, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 38)
(S) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide

To a suspension of the compound obtained in Reference Example 74 (83 mg), the compound obtained in Reference Example 89 (73 mg) and PyBOP (172 mg) in dichloromethane (3 mL), N, N-diisopropylethylamine (155 μL) was added, and at room temperature. Stir for 16 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 50: 50-0: 100) to give the title compound (55 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (br. S., 1H), 8.51 (br. S., 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 7.83-7.90 (m, 1H), 7.60-7.70 (m, 2H), 7.43-7.51 (m, 1H), 4.99 (s, 2H), 4.33-4.42 (m, 1H) , 4.11 (s, 2H), 3.52 (s, 3H), 2.97-3.06 (m, 1H), 2.99 (s, 3H), 2.80-2.85 (m, 1H), 2.78 (s, 3H), 2.68 (dd , J = 10.1, 4.9 Hz, 1H), 2.44-2.52 (m, 1H), 2.18-2.29 (m, 1H), 1.75-1.86 (m, 1H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

(Example 39)
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide

To a suspension of the compound obtained in Reference Example 74 (83 mg), the compound obtained in Reference Example 90 (73 mg) and PyBOP (172 mg) in dichloromethane (3 mL) was added N, N-diisopropylethylamine (155 μL), and at room temperature. Stir for 16 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified successively by basic silica gel column chromatography (hexane: ethyl acetate = 50: 50-0: 100) and silica gel column chromatography (hexane: ethyl acetate = 40: 60-0: 100) to give the title compound (57 mg )
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (s, 1H), 8.53 (br. S., 1H), 8.19 (d, J = 8.1 Hz, 1H), 8.10 (d, J = 7.7 Hz, 1H), 7.88 (d, J = 7.3 Hz, 1H), 7.61-7.71 (m, 2H), 7.46-7.52 (m, 1H), 5.01 (s, 2H), 4.34-4.41 (m, 1H) , 4.12 (s, 2H), 3.53 (s, 3H), 2.97-3.06 (m, 4H), 2.83 (d, J = 9.7 Hz, 1H), 2.79 (s, 3H), 2.67 (dd, J = 9.7 , 4.9 Hz, 1H), 2.43-2.51 (m, 1H), 2.19-2.29 (m, 1H), 2.00-2.05 (m, 1H), 1.76-1.86 (m, 1H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

(Example 40)
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide hydrochloride

A mixture of the compound obtained in Example 39 (572 mg), 2N hydrochloric acid (0.625 mL) and 2-propanol-water (8: 2) mixture (17.2 mL) was refluxed, cooled to room temperature, and the precipitated solid was collected by filtration. To give the title compound (400 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 11.48 (s, 1H), 10.84 (br. S., 1H), 8.56-8.64 (m, 1H), 8.34 (d, J = 7.7 Hz, 2H ), 7.95 (d, J = 8.5 Hz, 1H), 7.79-7.87 (m, 1H), 7.63-7.72 (m, 2H), 5.50-5.70 (m, 1H), 5.03-5.11 (m, 1H), 5.02 (s, 2H), 4.39-4.55 (m, 1H), 3.59-3.76 (m, 2H), 3.42 (s, 3H), 3.18 (d, J = 9.7 Hz, 1H), 2.85 (s, 3H) , 2.78 (s, 3H), 2.29-2.45 (m, 1H), 1.76-2.17 (m, 2H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

(Example 41)
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide p-toluenesulfonate

A mixture of the compound obtained in Example 39 (360 mg), p-toluenesulfonic acid monohydrate (138 mg), methanol (1.62) and water (167 μL) was refluxed, cooled to 0 ° C., and the precipitated solid was filtered. To give the title compound (346 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.43-11.51 (m, 1H), 10.59 (br. S., 1H), 10.07 (br. S., 1H), 8.55-8.65 (m, 1H) , 8.28-8.36 (m, 2H), 7.92-7.99 (m, 1H), 7.79-7.88 (m, 1H), 7.63-7.73 (m, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 7.7 Hz, 2H), 5.43-5.62 (m, 1H), 5.05-5.10 (m, 1H), 5.01 (s, 2H), 4.40-4.55 (m, 1H), 3.68 (br. s ., 2H), 3.47-3.56 (m, 1H), 3.42 (s, 3H), 3.38 (br. S., 1H), 3.17 (s, 2H), 3.14-3.24 (m, 1H), 2.85 (s , 3H), 2.77 (s, 3H), 2.28 (s, 3H), 1.84-2.14 (m, 1H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

(Example 42)
(R) -7-acetyl-3-ethyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) benzo [b] thiophene-2 -Carboxamide

N, N-Diisopropylethylamine (0.057 mL) was added dropwise to a solution of the compound (38 mg) obtained in Reference Example 96 and HBTU (67.1 mg) in dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes. The compound obtained in Reference Example 90 (31.6 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate (1: 1) mixture: methanol = 100: 0 to 90:10) to obtain the title compound (4.6 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.75 (br. S., 1H), 8.52 (br. S., 1H), 8.21 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 7.7 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.65-7.72 (m, 2H), 7.45-7.53 (m, 1H), 5.02 (s, 2H), 4.37 (d, J = 2.0 Hz, 1H), 4.13 (s, 2H), 3.53 (s, 3H), 3.39-3.48 (m, 2H), 2.97-3.06 (m, 1H), 2.82-2.86 (m, 1H), 2.80 ( s, 3H), 2.67 (dd, J = 10.1, 5.3 Hz, 1H), 2.42-2.52 (m, 1H), 2.19-2.30 (m, 1H), 1.76-1.87 (m, 1H), 1.40 (t, J = 7.5 Hz, 3H).

(Example 43)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (4- (pyrrolidin-1-ylmethyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

Similar to Example 39, using the compound (139 mg) obtained in Reference Example 74, the compound (114 mg) obtained in Reference Example 97, PyBOP (312 mg), dichloromethane (2.5 mL) and N, N-diisopropylethylamine (174 μL). The title compound (135 mg) was obtained by the method described above.
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.21 (br. S., 1H), 8.29-8.39 (m, 2H), 8.24 (d, J = 7.7 Hz, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.71-7.79 (m, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.52-7.61 (m, 1H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H), 2.51-2.72 (m, 4H), 1.68-1.89 (m, 4H)
MS (ESI ^<+> ) m / z: 488 [M + H] ^< +>.

(Example 44)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (4- (morpholinomethyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

Similar to Example 39, using the compound obtained in Reference Example 74 (139 mg), the compound obtained in Reference Example 98 (122 mg), PyBOP (312 mg), dichloromethane (2.5 mL) and N, N-diisopropylethylamine (174 μL). The title compound (25 mg) was obtained by the method described above.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.69 (br. S., 1H), 8.52 (br. S., 1H), 8.24 (d, J = 8.1 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.65-7.71 (m, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.46-7.52 (m, 1H), 5.01 (s, 2H), 3.96 (s, 2H), 3.73-3.77 (m, 4H), 3.53 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.57-2.62 (m, 4H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

(Example 45)
(R) -7-acetyl-N- (4-((3-fluoropyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide

N, N-Diisopropylethylamine (0.251 mL) was added dropwise to a solution of the compound (100 mg) obtained in Reference Example 74 and HBTU (186 mg) in dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes. The compound obtained in Reference Example 99 (88 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate (1: 1) mixture: methanol = 100: 0 to 90:10) to obtain the title compound (125 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.75 (br. S., 1H), 8.48 (br. S., 1H), 8.20 (d, J = 8.5 Hz, 1H), 8.06 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.63-7.68 (m, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.43-7.50 (m, 1H), 5.10-5.29 (m, 1H), 4.98 (s, 2H), 4.07-4.19 (m, 2H), 3.51 (s, 3H), 2.98 (s, 3H), 2.87-3.06 (m, 3H), 2.77 ( s, 3H), 2.62-2.70 (m, 1H), 2.03-2.26 (m, 2H)
MS (ESI ^<+> ) m / z: 506 [M + H] ^< +>.

Example 46
7-acetyl-N- (4-((4-fluoropiperidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

A mixture of the compound obtained in Reference Example 74 (56 mg), the compound obtained in Reference Example 100 (52 mg), HBTU (91 mg), dichloromethane (4 mL) and N, N-diisopropylethylamine (87 μL) was stirred at room temperature for 4 days. . Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 95: 5), and the obtained solid was washed with diethyl ether to give the title compound (30 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.69 (br. S., 1H), 8.53 (br. S., 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.87 (d, J = 6.9 Hz, 1H), 7.65-7.71 (m, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.45-7.51 (m, 1H), 5.01 (s, 2H), 4.62-4.83 (m, 1H), 3.96 (s, 2H), 3.52 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.69-2.77 (m, 2H), 2.49-2.57 (m, 2H), 1.87-2.04 (m, 4H)
MS (ESI ^<+> ) m / z: 520 [M + H] ^< +>.

(Example 47)
7-acetyl-N- (4-((3-hydroxyazetidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide dihydrochloride salt

Using the compound obtained in Reference Example 74 (27.8 mg), the compound obtained in Reference Example 101 (22.9 mg), PyBOP (62.4 mg), dichloromethane (1.0 mL) and N, N-diisopropylethylamine (34.8 μL) In the same manner as in Example 39, the free base of the title compound was obtained. Hydrogen chloride (4N ethyl acetate solution) was added to the obtained free base and then concentrated to obtain the title compound (10 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.28-8.34 (m, 2H), 8.20-8.25 (m, 1H), 8.11 (d, J = 7.7 Hz, 1H), 7.90-7.96 (m, 1H ), 7.74-7.80 (m, 1H), 7.72 (d, J = 7.7 Hz, 1H), 5.17 (s, 2H), 5.04 (s, 2H), 4.54-4.90 (m, 4H), 4.15-4.36 ( m, 1H), 3.50 (s, 3H), 2.98 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 490 [M + H] ^< +>.

Example 48
7-acetyl-N- (4-((3,3-difluoropyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Compound (60 mg) obtained in Reference Example 102, compound (61.2 mg) obtained in Reference Example 103, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (12.5 mg), cesium carbonate (85 mg) , A mixture of tris (dibenzylideneacetone) dipalladium (0) (9.9 mg) and 1,4-dioxane (5 mL) was stirred at 150 ° C. for 1 hour under an argon atmosphere. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (hexane-ethyl acetate (1: 1) mixture: methanol = 100: 0 to 90:10) to obtain the title compound (16.5 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (br. S., 1H), 8.52 (br. S., 1H), 8.18-8.24 (m, 1H), 8.10 (d, J = 7.7 Hz, 1H), 7.89 (d, J = 7.7 Hz, 1H), 7.67-7.74 (m, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.47-7.55 (m, 1H), 5.01 (s , 2H), 4.11 (s, 2H), 3.53 (s, 3H), 3.02-3.09 (m, 2H), 3.01 (s, 3H), 2.86 (t, J = 6.7 Hz, 2H), 2.79 (s, 3H), 2.25-2.40 (m, 2H)
MS (ESI ^<+> ) m / z: 524 [M + H] ^< +>.

(Example 49)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (quinolin-2-yl) benzo [b] thiophene-2-carboxamide

Compound (30 mg) obtained in Reference Example 102, 2-chloroquinoline (18 mg), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (6 mg), cesium carbonate (42 mg), tris (dibenzylidene The title compound (9 mg) was obtained in the same manner as in Example 48 using acetone) dipalladium (0) (6 mg) and 1,4-dioxane (1 mL).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.73 (brs, 1H), 8.50-8.54 (m, 1H), 8.24 (d, J = 9.0 Hz, 1H), 8.10 (d, J = 7.6 Hz , 1H), 7.88 (d, J = 6.1 Hz, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.70 (t, J = 7.3 Hz, 1H), 7.62-7.64 (m, 1H), 7.49 (t, J = 7.4 Hz, 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H).

(Example 50)
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide

Similar to Example 39, using the compound obtained in Reference Example 74 (28 mg), the compound obtained in Reference Example 105 (26 mg), PyBOP (62 mg), dichloromethane (5 mL) and N, N-diisopropylethylamine (35 μL). The title compound (14 mg) was obtained by the method.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.87 (br. S., 1H), 8.55 (d, J = 13.8 Hz, 1H), 8.09 (d, J = 8.1 Hz, 1H), 7.82- 7.94 (m, 2H), 7.67-7.75 (m, 1H), 7.63 (d, J = 7.3 Hz, 1H), 7.47-7.54 (m, 1H), 4.99 (d, J = 2.0 Hz, 2H), 4.45 -4.69 (m, 1H), 3.86-4.01 (m, 2H), 3.46-3.59 (m, 4H), 3.23-3.39 (m, 1H), 2.98 (d, J = 3.2 Hz, 3H), 2.78 (s , 3H), 1.93-2.22 (m, 2H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 51)
4,7-Diacetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

The compound obtained in Reference Example 5 (100 mg), the compound obtained in Reference Example 86 (79 mg), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (111 mg), 1-hydroxy-7-azabenzo The title compound (30 mg) was obtained in the same manner as in Example 9 using triazole (78 mg) and DMF (6 mL).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (br. S., 1H), 8.49 (br. S., 1H), 8.18 (d, J = 8.1 Hz, 1H), 8.13 (d, J = 7.7 Hz, 1H), 7.82-7.89 (m, 1H), 7.64-7.70 (m, 1H), 7.44-7.51 (m, 2H), 4.34-4.41 (m, 1H), 4.11 (s, 2H) , 2.97-3.05 (m, 1H), 2.82-2.86 (m, 1H), 2.80 (s, 3H), 2.74 (s, 3H), 2.68-2.71 (m, 1H), 2.67 (s, 2H), 2.44 -2.51 (m, 1H), 2.19-2.29 (m, 1H), 1.76-1.85 (m, 1H)
MS (ESI ⁺ ) m / z: 502 [M + H] ⁺ .

(Example 52)
4,7-Diacetyl-N- (4-((3-hydroxyazetidin-1-yl) methyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

The compound obtained in Reference Example 5 (75 mg), the compound obtained in Reference Example 101 (60 mg), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (79 mg), 1-hydroxy-7-azabenzo The title compound (14 mg) was obtained in the same manner as in Example 9 using triazole (56 mg) and DMF (5 mL).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.49 (br. S., 1H), 8.15 (d, J = 7.7 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.87 ( d, J = 7.7 Hz, 1H), 7.65-7.71 (m, 1H), 7.46-7.53 (m, 2H), 4.66-4.74 (m, 1H), 4.50 (s, 2H), 4.17-4.25 (m, 2H), 3.74-3.82 (m, 2H), 2.81 (s, 3H), 2.76 (s, 3H), 2.65 (s, 3H)
MS (ESI ^<+> ) m / z: 488 [M + H] ^< +>.

(Example 53)
7-acetyl-N- (4-chloroquinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

To a solution of the compound obtained in Reference Example 74 (171 mg) in N, N-dimethylacetamide (5 mL), HBTU (276 mg) and N, N-diisopropylethylamine (195 mg) were added under a nitrogen atmosphere and stirred for 30 minutes. 2-Amino-4-chloroquinoline (100 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 2 hours and stirred at 70 ° C. overnight. The reaction mixture was diluted with chloroform and washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1), and the resulting crude product was heated by adding an ethyl acetate-heptane mixture and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (7 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.78 (m, 2H), 8.20 (d, J = 7.3 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.70-7.79 (m, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.54-7.60 (m, 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 ( s, 3H)
MS (ESI ^<+> ) m / z: 439, 441 [M + H] ^< +>.

Example 54
7-acetyl-N- (4-aminoquinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound (192 mg), N, N-dimethylacetamide (5 mL), HBTU (310 mg), N, N-diisopropylethylamine (219 mg) and 2,4-diaminoquinoline (100 mg) obtained in Reference Example 74, In the same manner as in 53, the title compound (15 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.07 (d, J = 7.7 Hz, 1H), 7.59-7.79 (m, 5H), 7.35-7.42 (m, 1H), 5.00 (s, 2H) , 4.91 (brs, 2H), 3.52 (s, 3H), 2.99 (s, 3H), 2.78 (s, 3H)
MS (ESI ^<+> ) m / z: 420 [M + H] ^< +>.

Example 55
7-acetyl-N- (4- (dimethylamino) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Using the compound obtained in Reference Example 74 (38 mg), N, N-dimethylacetamide (2 mL), HBTU (61 mg), N, N-diisopropylethylamine (40 mg) and the compound obtained in Reference Example 106 (23 mg) In the same manner as in Example 53, the title compound (10 mg) was obtained.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.07 (d, J = 7.7 Hz, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.71-7.80 (m, 1H), 7.57-7.65 (m, 2H), 7.34-7.41 (m, 1H), 7.15-7.29 (m, 1H), 5.01 (s, 2H), 3.52 (s, 3H), 3.14 (brs, 6H), 3.02 (s, 3H ), 2.78 (s, 3H).

Example 56
7-acetyl-4- (methoxymethyl) -3-methyl-N- (4-morpholinoquinolin-2-yl) benzo [b] thiophene-2-carboxamide

A mixture of 2-amino-4-chloroquinoline (119 mg), morpholine (175 μL) and DMF (7 mL) was stirred at 140 ° C. overnight. Saturated sodium hydrogen carbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, dried over anhydrous sodium sulfate, and concentrated. To the residue were added the compound obtained in Reference Example 107 (311 mg), triethylamine (195 μL), acetonitrile (2 mL) and chloroform (2 mL), and the mixture was stirred at 60 ° C. for 4 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: ethyl acetate = 10: 90), and the obtained solid was washed with a mixed solution of ethyl acetate-dichloromethane to obtain the title compound (192 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.67 (br.s., 1H), 8.00-8.16 (m, 2H), 7.96 (d, J = 8.1 Hz, 1H), 7.80 (d, J = 7.3 Hz, 1H), 7.60-7.66 (m, 2H), 7.38-7.44 (m, 1H), 5.00 (s, 2H), 3.99-4.05 (m, 4H), 3.53 (s, 3H), 3.31- 3.37 (m, 4H), 3.01 (s, 3H), 2.78 (s, 3H)
MS (ESI ^<+> ) m / z: 490 [M + H] ^< +>.

(Example 57)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (4- (4-methylpiperazin-1-yl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

A mixture of 2-amino-4-chloroquinoline (71.4 mg), 1-methylpiperazine (133 μL) and DMF (2 mL) was stirred at 130 ° C. overnight. Saturated sodium hydrogen carbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, dried over anhydrous sodium sulfate, and concentrated. To the residue were added the compound obtained in Reference Example 107 (187 mg), triethylamine (117 μL), acetonitrile (2 mL) and chloroform (2 mL), and the mixture was stirred at 60 ° C. for 3.5 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 95: 5), and the obtained solid was washed with a hexane-ethyl acetate mixture to give the title compound (71 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.64 (br.s., 1H), 8.01-8.12 (m, 2H), 7.95 (d, J = 7.7 Hz, 1H), 7.74-7.83 (m , 1H), 7.59-7.65 (m, 2H), 7.36-7.42 (m, 1H), 5.00 (s, 2H), 3.52 (s, 3H), 3.35-3.42 (m, 4H), 3.01 (s, 3H ), 2.78 (s, 3H), 2.71-2.76 (m, 4H), 2.43 (s, 3H)
MS (ESI ^<+> ) m / z: 503 [M + H] ^< +>.

(Example 58)
(R) -N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methyl-7-pivaloylbenzo [b] thiophene-2- Carboxamide dihydrochloride

A mixture of the compound obtained in Reference Example 108 (81 mg), the compound obtained in Reference Example 90 (68 mg), HBTU (115 mg), triethylamine (106 μL) and dichloromethane (5 mL) was stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was sequentially purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 95: 5) and silica gel column chromatography (hexane: ethyl acetate = 20: 80 to 0: 100) to obtain the obtained compound. Hydrogen chloride (4N ethyl acetate solution) was added and concentrated to give the title compound (22 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.45 (d, J = 7.7 Hz, 1H), 8.39 (d, J = 8.1 Hz, 1H), 8.31 (br. S., 1H), 8.24 (d , J = 8.5 Hz, 1H), 8.02-8.08 (m, 1H), 7.84-7.91 (m, 1H), 7.69 (d, J = 7.7 Hz, 1H), 5.24 (br. S., 2H), 5.02 (s, 2H), 4.63-4.69 (m, 1H), 3.64-4.06 (m, 4H), 3.50 (s, 3H), 3.00 (s, 3H), 2.07-2.61 (m, 2H), 1.49-1.54 (m, 9H)
MS (ESI ^<+> ) m / z: 546 [M + H] ^< +>.

(Example 59)
(R) -N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -7-isobutyryl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide dihydrochloride

A mixture of the compound obtained in Reference Example 109 (80 mg), the compound obtained in Reference Example 90 (64 mg), HBTU (119 mg), triethylamine (109 μL) and dichloromethane (4 mL) was stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 20: 80-0: 100), and the resulting compound was added with hydrogen chloride (4N ethyl acetate solution) and concentrated to give the title compound (86 mg). It was.
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.44 (d, J = 8.1 Hz, 1H), 8.40 (d, J = 7.7 Hz, 1H), 8.31 (d, J = 8.5 Hz, 1H), 8.22 (br. s., 1H), 8.09-8.15 (m, 1H), 7.91-7.96 (m, 1H), 7.75 (d, J = 7.7 Hz, 1H), 5.29 (br. s., 2H), 5.05 (s, 2H), 4.64-4.70 (m, 1H), 3.54-4.09 (m, 5H), 3.51 (s, 3H), 3.03 (s, 3H), 2.02-2.63 (m, 2H), 1.28 (d , J = 6.5 Hz, 6H)
MS (ESI ^<+> ) m / z: 532 [M + H] ^< +>.

(Example 60)
(R) -7-acetyl-N- (5-((3-fluoropyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide hydrochloride

Compound (50 mg) obtained in Reference Example 102, compound (48 mg) obtained in Reference Example 113, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (10 mg), cesium carbonate (70 mg), tris The free base (71 mg) of the title compound was obtained in the same manner as in Example 48 using (dibenzylideneacetone) dipalladium (0) (8 mg) and 1,4-dioxane (2 mL). Hydrogen chloride (4N 1,4-dioxane solution, 0.033 mL) was added to the obtained compound, and a methanol-ethyl acetate-heptane mixture was further added and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (61 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.42 (brs, 1H), 10.87-11.08 (m, 1H), 8.90-8.94 (m, 1H), 8.40 (d, J = 9.3 Hz, 1H), 8.33 (d, J = 7.7 Hz, 1H), 7.98 (d, J = 7.7 Hz, 1H), 7.79-7.92 (m, 2H), 7.69 (d, J = 7.7 Hz, 1H), 5.38-5.41 (m , 1H), 5.01 (s, 2H), 4.87-5.10 (m, 2H), 3.70-3.91 (m, 2H), 3.33-3.67 (m, 2H), 3.42 (s, 3H), 2.83 (s, 3H ), 2.78 (s, 3H), 2.10-2.40 (m, 2H).

(Example 61)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5- (morpholinomethyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide hydrochloride

Compound (50 mg) obtained in Reference Example 102, Compound (48 mg) obtained in Reference Example 114, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (10 mg), cesium carbonate (70 mg), tris The free base (40 mg) of the title compound was obtained in the same manner as in Example 48 using (dibenzylideneacetone) dipalladium (0) (8 mg) and 1,4-dioxane (2 mL). Hydrogen chloride (4N 1,4-dioxane solution, 0.02 mL) was added to the obtained compound, and a methanol-ethyl acetate-heptane mixture was further added and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (32 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.41 (brs, 1H), 10.35 (brs, 1H), 8.95 (d, J = 9.8 Hz, 1H), 8.42 (d, J = 9.0 Hz, 1H) , 8.33 (d, J = 7.6 Hz, 1H), 7.99 (d, J = 5.0 Hz, 1H), 7.80-7.88 (m, 2H), 7.69 (d, J = 7.7 Hz, 1H), 5.01 (s, 2H), 4.83-4.91 (m, 2H), 3.90-4.00 (m, 2H), 3.57-3.78 (m, 2H), 3.42 (s, 3H), 3.23-3.39 (m, 4H), 2.83 (s, 3H), 2.77 (s, 3H).

(Example 62)
7-acetyl-N- (5-((dimethylamino) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide dihydrochloride

Compound (60 mg) obtained in Reference Example 102, compound (50 mg) obtained in Reference Example 115, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (14 mg), cesium carbonate (90 mg), tris The free base (66 mg) of the title compound was obtained in the same manner as in Example 48 using (dibenzylideneacetone) dipalladium (0) (11 mg) and N, N-dimethylacetamide (5 mL). Hydrogen chloride (4N 1,4-dioxane solution, 0.07 mL) was added to the obtained compound, and a methanol-ethyl acetate-heptane mixture was further added and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (59 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.38 (brs, 1H), 9.98 (brs, 1H), 8.89 (d, J = 9.2 Hz, 1H), 8.40 (d, J = 9.2 Hz, 1H) , 8.33 (d, J = 7.7 Hz, 1H), 7.98 (d, J = 7.9 Hz, 1H), 7.84 (t, J = 7.2 Hz, 1H), 7.78 (d, J = 6.6 Hz, 1H), 7.69 (d, J = 7.7 Hz, 1H), 5.01 (s, 2H), 4.81 (d, J = 5.5 Hz, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.82 (s, 3H) , 2.80 (s, 3H), 2.77 (s, 3H).

(Example 63)
(S) -7-Acetyl-N- (5-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide dihydrochloride

Compound (24 mg) obtained in Reference Example 102, compound (23 mg) obtained in Reference Example 116, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (5 mg), cesium carbonate (34 mg), tris The free base (11 mg) of the title compound was obtained in the same manner as in Example 48 using (dibenzylideneacetone) dipalladium (0) (4 mg) and N, N-dimethylacetamide (2 mL). Hydrogen chloride (4N 1,4-dioxane solution, 0.044 mL) was added to the obtained compound, and a methanol-ethyl acetate-heptane mixture was further added and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (8 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.40 (brs, 1H), 8.82-8.91 (m, 1H), 8.38-8.46 (m, 1H), 8.29-8.35 (m, 1H), 7.94-8.00 (m, 1H), 7.78-7.89 (m, 2H), 7.69 (d, J = 7.7 Hz, 1H), 5.01 (s, 2H), 4.85-4.99 (m, 2H), 4.38-4.54 (m, 1H ), 3.30-3.63 (m, 2H), 3.42 (s, 3H), 2.87-3.20 (m, 2H), 2.83 (s, 3H), 2.77 (s, 3H), 1.80-2.11 (m, 2H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

(Example 64)
(R) -7-acetyl-N- (5-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide dihydrochloride

N, N-Diisopropylethylamine (2.52 mL) and HBTU (2.745 g) were added to a suspension of the compound (1.612 g) obtained in Reference Example 74 in chloroform (20 mL), and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture was added a solution of the compound (1.409 g) obtained in Reference Example 119 in chloroform (10 mL), and the mixture was stirred at room temperature overnight. To the reaction mixture was added 2N aqueous sodium hydroxide solution, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 98: 2-90: 10) to obtain the free base (1.852 g) of the title compound. Hydrogen chloride (4N ethyl acetate solution, 2.21 mL) was added to an ethyl acetate / methanol (5 mL / 5 mL) solution of the obtained compound, followed by concentration. The residue was washed with methanol to give the title compound (1.762 g).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.39 (br. S., 1H), 10.56 (br. S., 1H), 8.89 (t, J = 9.1 Hz, 1H), 8.38-8.42 (m , 1H), 8.33 (d, J = 7.7 Hz, 1H), 7.95-7.99 (m, 1H), 7.80-7.87 (m, 2H), 7.70 (d, J = 8.1 Hz, 1H), 5.01 (s, 2H), 4.87-4.99 (m, 2H), 4.38-4.51 (m, 2H), 3.48-3.63 (m, 2H), 3.42 (s, 3H), 3.21-3.35 (m, 2H), 3.06-3.16 ( m, 1H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

Example 65
7-acetyl-N- (5-((3-hydroxyazetidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide dihydrochloride salt

N, N-Diisopropylethylamine (76 μL) and HBTU (79 mg) were added to a suspension of the compound obtained in Reference Example 74 (48.6 mg) in dichloromethane (3 mL), and the mixture was stirred at room temperature for 20 minutes. To the reaction mixture was added a solution of the compound obtained in Reference Example 123 (40 mg) in dichloromethane (5 mL), DMF (2 mL) was added, and the mixture was stirred at room temperature overnight. A 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 98.5: 1.5 to 89:11) to obtain the free base (10 mg) of the title compound. Hydrogen chloride (4N 1,4-dioxane solution, 15 μL) was added to a chloroform / methanol (0.25 mL / 0.25 mL) solution of the obtained compound, followed by concentration to obtain the title compound (11 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.38 (br.s., 1H), 8.79-8.86 (m, 1H), 8.37-8.42 (m, 1H), 8.33 (d, J = 7.7 Hz, 1H), 7.92-7.97 (m, 1H), 7.72-7.83 (m, 2H), 7.70 (d, J = 7.7 Hz, 1H), 5.01 (s, 2H), 4.90-4.95 (m, 2H), 4.69 -4.78 (m, 1H), 4.41-4.48 (m, 1H), 3.90-4.34 (m, 5H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 490 [M + H] ^< +>.

Example 66
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

N, N-Diisopropylethylamine (168 μL) and HBTU (161 mg) were added to a suspension of the compound (107.5 mg) obtained in Reference Example 74 in chloroform (3 mL), and the mixture was stirred at room temperature for 20 minutes. A chloroform (3 mL) solution of the compound (94 mg) obtained in Reference Example 124 was added to the reaction mixture, and the mixture was stirred at 40 ° C. for 10 hours. A 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 98: 2) to obtain the title compound (150 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.70 (br. S., 1H), 8.62 (d, J = 8.9 Hz, 1H), 8.48-8.55 (m, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.57-7.66 (m, 2H), 7.38 (d, J = 6.9 Hz, 1H), 5.01 (s, 2H), 4.03-4.10 (m, 3H), 3.60-3.66 (m, 2H), 3.52 (s, 3H), 3.26 (s, 3H), 3.00 (s, 3H), 3.01-3.05 (m, 2H), 2.79 (s, 3H )
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

Example 67
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

N, N-diisopropylethylamine (2.8 mL) and dichloromethane were added to a suspension of the compound (1.000 g) obtained in Reference Example 127, the compound (1.479 g) obtained in Reference Example 74 and HBTU (3.022 g) in dichloromethane (20 mL). (8 mL) was added and stirred at room temperature for 72.5 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: ethyl acetate = 90: 10-85: 15) to obtain the title compound (2.058 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.69 (s, 1H), 8.54 (s, 2H), 8.10 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H ), 7.60-7.66 (m, 2H), 7.45 (d, J = 7.3 Hz, 1H), 5.01 (s, 2H), 4.89 (s, 2H), 3.52 (s, 3H), 3.45 (s, 3H) , 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 449 [M + H] ^< +>.

Example 68
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

Hydrogen chloride (4N ethyl acetate solution, 1.3 mL) and ethanol (5.6 mL) were added to a solution of the compound obtained in Example 67 (2.057 g) in ethanol (15 mL), and the mixture was cooled to 0 ° C. The precipitated solid was collected by filtration, washed with ethanol, and dried to give the title compound (2.122 g).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.36 (br.s., 1H), 8.63 (d, J = 9.3 Hz, 1H), 8.28-8.34 (m, 2H), 7.88 (d, J = 8.3 Hz, 1H), 7.67-7.76 (m, 2H), 7.55 (d, J = 7.0 Hz, 1H), 5.01 (s, 2H), 4.88 (s, 2H), 3.42 (s, 3H), 3.38 ( s, 3H), 2.84 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 449 [M + H] ^< +>.

(Example 69)
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide methanesulfonate

Methanesulfonic acid (58 mg) was added to the compound obtained in Example 67 (270 mg), a methanol-chloroform-diisopropyl ether mixture was further added and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (309 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.26 (brs, 1H), 8.58 (d, J = 9.2 Hz, 1H), 8.31-8.33 (m, 2H), 7.83 (d, J = 8.4 Hz, 1H), 7.68-7.72 (m, 2H), 7.53 (d, J = 6.0 Hz, 1H), 5.01 (s, 2H), 4.88 (s, 2H), 3.42 (s, 3H), 3.38 (s, 3H ), 2.83 (s, 3H), 2.77 (s, 3H), 2.30 (s, 3H).

Example 70
7-acetyl-N- (5- (ethoxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

A mixture of the compound obtained in Reference Example 128 (101 mg), the compound obtained in Reference Example 74 (153 mg), HBTU (228 mg), N, N-diisopropylethylamine (0.208 mL) and chloroform (5 mL) at 50 ° C. for 24 hours. Stir. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 60: 40-40: 60) to give the title compound (146 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (br. S., 1H), 8.51-8.59 (m, 2H), 8.09 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.60-7.66 (m, 2H), 7.44-7.48 (m, 1H), 5.01 (s, 2H), 4.93 (s, 2H), 3.62 (q, J = 6.9 Hz, 2H) , 3.52 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 1.27 (t, J = 7.0 Hz, 3H)
MS (ESI ^<+> ) m / z: 463 [M + H] ^< +>.

Example 71
7-Acetyl-N- (5-((2-methoxyethoxy) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

A mixture of the compound obtained in Reference Example 130 (23.2 mg), the compound obtained in Reference Example 74 (30.6 mg), HBTU (45.5 mg), N, N-diisopropylethylamine (0.042 mL) and dichloromethane (1 mL) at room temperature. Stir for 18 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 60: 40-30: 70) to give the free base (28.6 mg) of the title compound. Hydrogen chloride (4N ethyl acetate solution, 58 μL) was added to an ethyl acetate (1 mL) solution of the obtained compound, and the mixture was concentrated to give the title compound (27.0 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 9.18 (d, J = 9.3 Hz, 1H), 8.32 (d, J = 7.5 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 7.97 -8.03 (m, 1H), 7.80-7.89 (m, 2H), 7.72 (d, J = 7.8 Hz, 1H), 5.06 (s, 2H), 5.02 (s, 2H), 3.75-3.79 (m, 2H ), 3.60-3.64 (m, 2H), 3.51 (s, 3H), 3.37 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H)
MS (ESI ^<+> ) m / z: 493 [M + H] ^< +>.

(Example 72)
7-Acetyl-N- (5-((2-hydroxyethoxy) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

Hydrogen chloride (4N 1,4-dioxane solution, 0.045 mL) was added to a solution of the compound obtained in Reference Example 133 (53 mg) in ethanol (1 mL), and the mixture was stirred at room temperature for 1 hour. Diethyl ether (1 mL) was added to the reaction mixture and cooled to 0 ° C. The precipitated solid was collected by filtration and washed with a mixed solution of ethanol-diethyl ether (1: 2) to obtain the title compound (30.4 mg).
¹ H NMR (MeOD, 400 MHz): δ (ppm) 9.22 (dd, J = 9.5, 0.8 Hz, 1H), 8.35 (d, J = 7.5 Hz, 1H), 8.18 (d, J = 8.5 Hz, 1H) , 7.98-8.03 (m, 1H), 7.89 (d, J = 9.5 Hz, 1H), 7.82-7.86 (m, 1H), 7.74 (d, J = 7.8 Hz, 1H), 5.08 (s, 2H), 5.04 (s, 2H), 3.73-3.76 (m, 2H), 3.68-3.71 (m, 2H), 3.50 (s, 3H), 3.02 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 479 [M + H] ^< +>.

(Example 73)
7-acetyl-N- (5-((difluoromethoxy) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

Compound (53 mg) obtained in Reference Example 102, compound (47 mg) obtained in Reference Example 134, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (11 mg), cesium carbonate (75 mg), tris A mixture of (dibenzylideneacetone) dipalladium (0) (9 mg) and N, N-dimethylacetamide (4 mL) was stirred at 140 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed successively with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1 to 1: 1) to obtain the free base (31 mg) of the title compound. Hydrogen chloride (4N 1,4-dioxane solution, 18 μL) was added to the obtained compound, and a methanol-diisopropyl ether mixture was further added and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (22 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.29 (brs, 1H), 8.57 (d, J = 9.2 Hz, 1H), 8.33-8.38 (m, 2H), 7.90 (d, J = 8.8 Hz, 1H), 7.47 (t, J = 7.2 Hz, 1H), 7.69 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 6.8 Hz, 1H), 6.89 (t, J = 75.6 Hz, 1H) , 5.41 (s, 2H), 5.01 (s, 2H), 2.83 (s, 3H), 2.77 (s, 3H). One peak (s, 3H) might be disappeared because of the overlap with water peak.
MS (ESI ⁺ ) m / z: 485 [M + H] ⁺ .

Example 74
7-acetyl-N- (5- (2-hydroxypropan-2-yl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Compound obtained in Reference Example 102 (87.7 mg), Compound obtained in Reference Example 135 (77.1 mg), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (18.3 mg), cesium carbonate (123 mg ), Tris (dibenzylideneacetone) dipalladium (0) (14.5 mg) and N-methylpyrrolidone (3 mL) were stirred at 135 ° C. for 40 minutes. The reaction mixture was diluted with ethyl acetate, washed with water, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30-30: 70) to give the title compound (45 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.16 (s, 1H), 9.35 (d, J = 9.7 Hz, 1H), 8.31 (d, J = 7.7 Hz, 1H), 8.25 (d, J = 9.3 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.53 (d, J = 6.1 Hz , 1H), 5.43 (s, 1H), 5.00 (s, 2H), 3.42 (s, 3H), 2.82 (s, 3H), 2.76 (s, 3H), 1.70 (s, 6H)
MS (ESI ^<+> ) m / z: 463 [M + H] ^< +>.

(Example 75)
7-acetyl-N- (5-acetylquinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

A mixture of the compound obtained in Reference Example 136 (18.6 mg), the compound obtained in Reference Example 74 (30.6 mg), HBTU (45.5 mg), triethylamine (0.042 mL) and chloroform (2 mL) was stirred at 50 ° C. for 20 hours. . Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 94: 6), and the obtained solid was washed with dichloromethane to give the title compound (25.5 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.27 (d, J = 9.3 Hz, 1H), 8.72 (s, 1H), 8.61 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.98 (dd, J = 7.4, 1.1 Hz, 1H), 7.68-7.74 (m, 1H), 7.64 (d, J = 7.5 Hz , 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 447 [M + H] ^< +>.

(Example 76)
7-acetyl-N- (5- (1-hydroxyethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

HBTU (261 mg) and N, N-diisopropylethylamine (250 μL) were added to a solution of the compound obtained in Reference Example 74 (160 mg) in chloroform (5 mL), and the mixture was stirred at room temperature for 20 minutes. To the reaction mixture was added chloroform (5 mL) of the compound (108 mg) obtained in Reference Example 137, and the mixture was stirred at room temperature overnight, and then stirred at 60 ° C. for 3 hours. A 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 97.5: 2.5) to obtain the title compound (200 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (s, 1H), 8.58-8.63 (m, 1H), 8.49-8.55 (m, 1H), 8.09 (d, J = 7.7 Hz, 1H) , 7.80 (d, J = 8.5 Hz, 1H), 7.59-7.69 (m, 3H), 5.57-5.66 (m, 1H), 5.00 (s, 2H), 3.52 (s, 3H), 3.00 (s, 3H ), 2.79 (s, 3H), 1.96-2.01 (m, 1H), 1.69 (d, J = 6.4 Hz, 3H)
MS (ESI ^<+> ) m / z: 449 [M + H] ^< +>.

Example 77
7-Acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

Ethanol (62.5 mL) and 6N hydrochloric acid (7.6 mL) were added to the compound obtained in Reference Example 141 (8.325 g), and the mixture was stirred at 60 ° C. for 25 hours. The reaction mixture was cooled to 0 ° C., and the precipitated solid was collected by filtration and washed with ethanol to obtain the title compound (6.043 g).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.39 (br. S., 1H), 8.68 (d, J = 8.5 Hz, 1H), 8.30 (m, 2H), 7.83 (d, J = 8.5 Hz , 1H), 7.67-7.77 (m, 2H), 7.58 (d, J = 7.3 Hz, 1H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 435 [M + H] ^< +>.

(Example 78)
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide methanesulfonate

Ethanol (1.35 mL) and methanesulfonic acid (64 μL) were added to the compound obtained in Reference Example 141 (0.270 g), and the mixture was stirred at 80 ° C. for 1 hour. To the reaction mixture was added 2-propanol (1.35 mL), and the mixture was stirred at the same temperature for 9 hours. The reaction mixture was cooled to 0 ° C., and the precipitated solid was collected by filtration and washed with 2-propanol to give the title compound (0.201 g).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.40 (br. S., 1H), 8.67 (d, J = 9.3 Hz, 1H), 8.33 (d, J = 7.8 Hz, 1H), 8.26 (d , J = 9.0 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.67-7.77 (m, 2H), 7.58 (d, J = 7.0 Hz, 1H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H), 2.35 (s, 3H)
MS (ESI ^<+> ) m / z: 435 [M + H] ^< +>.

(Example 79)
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

To the compound (6.656 g) obtained in Example 77, potassium carbonate (6.656 g), chloroform (430 mL), water (143 mL) and methanol (43 mL) were sequentially added and stirred. The organic layer was dried over anhydrous magnesium sulfate and concentrated. DMF was added to the residue and heated to 85 ° C., water was added, and the mixture was cooled to 0 ° C., and the precipitated solid was collected by filtration. The obtained solid was washed with a DMF-water (5: 3) mixture to obtain the title compound (5.607 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.75 (br. S., 1H), 8.57 (s, 2H), 8.10 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.61-7.67 (m, 2H), 7.49 (d, J = 6.0 Hz, 1H), 5.15 (s, 2H), 5.00 (s, 2H), 3.53 (s, 3H), 3.00 (s , 3H), 2.79 (s, 3H), 1.83 (br. S., 1H)
MS (ESI ^<+> ) m / z: 435 [M + H] ^< +>.

Example 80
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrobromide

8N Hydrobromic acid (158 μL), water (0.72 mL) and acetonitrile (1.68 mL) were added to the compound (0.5 g) obtained in Example 79, heated to 100 ° C., and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (409 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.26 (br.s., 1H), 8.62 (d, J = 8.8 Hz, 1H), 8.27-8.34 (m, 2H), 7.77-7.81 (m, 1H), 7.67-7.73 (m, 2H), 7.55 (d, J = 5.8 Hz, 1H), 5.01 (s, 2H), 4.97 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H ), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 435 [M + H] ^< +>.

Example 81
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p-toluenesulfonate

P-Toluenesulfonic acid monohydrate (6.24 g) and ethanol (60 mL) were added to the compound obtained in Reference Example 141 (6.000 g), and the mixture was stirred at 60 ° C. for 24.5 hours. The reaction mixture was cooled to 0 ° C., and the precipitated solid was collected by filtration and washed with ethanol to obtain the title compound (6.404 g).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.40 (br. S., 1H), 8.69 (d, J = 9.0 Hz, 1H), 8.33 (d, J = 7.8 Hz, 1H), 8.25 (d , J = 9.3 Hz, 1H), 7.81-7.88 (m, 1H), 7.67-7.78 (m, 2H), 7.58 (d, J = 6.8 Hz, 1H), 7.45-7.50 (m, 2H), 7.11 ( d, J = 8.5 Hz, 2H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.85 (s, 3H), 2.77 (s, 3H), 2.29 (s, 3H )
MS (ESI ^<+> ) m / z: 435 [M + H] ^< +>.

(Example 82)
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide half ethane-1,2-disulfonate

After adding ethane-1,2-disulfonic acid dihydrate (0.344 g), water (3 mL) and 2-ethoxyethanol (9 mL) to the compound obtained in Example 79 (1.200 g), the mixture was heated to 100 ° C. And cooled to 0 ° C. The precipitated solid was collected by filtration. The obtained solid was washed with 2-ethoxyethanol to give the title compound (1.307 g).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.37 (br. S., 1H), 8.67 (d, J = 9.3 Hz, 1H), 8.33 (d, J = 7.8 Hz, 1H), 8.27 (d , J = 9.0 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.67-7.76 (m, 2H), 7.57 (d, J = 7.0 Hz, 1H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H), 2.67 (s, 2H)
MS (ESI ^<+> ) m / z: 435 [M + H] ^< +>.

Example 83
(2- (7-Acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl acetate

Acetic anhydride (36 μL) and pyridine (34 μL) were added to a solution of the compound obtained in Example 79 (150 mg) in DMF (3 mL), stirred at room temperature overnight, and then stirred at 60 ° C. for 3 hours. Acetic anhydride (36 μL) and pyridine (34 μL) were added to the reaction mixture, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99.5: 0.5 to 99: 1) to obtain the title compound (50 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (br.s., 1H), 8.53-8.61 (m, 1H), 8.43 (d, J = 9.0 Hz, 1H), 8.10 (d, J = 7.5 Hz, 1H), 7.84-7.90 (m, 1H), 7.61-7.69 (m, 2H), 7.50-7.55 (m, 1H), 5.55 (s, 2H), 5.00 (s, 2H), 3.52 ( s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 2.12 (s, 3H)
MS (ESI ^<+> ) m / z: 477 [M + H] ^< +>.

(Example 84)
(S)-(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl-2-amino-3-methylbutanoate

To a solution of the compound obtained in Reference Example 142 (187 mg) in chloroform (4 mL) was added TFA (1 mL) and stirred for 1 hour. The reaction mixture was concentrated, diluted with chloroform and washed with saturated aqueous sodium bicarbonate. The organic layer was dried over anhydrous sodium sulfate and concentrated. A hexane-ethyl acetate mixture was added to the residue, and the resulting solid was collected by filtration to give the title compound (148 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (br.s., 1H), 8.55-8.62 (m, 1H), 8.43 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.62-7.69 (m, 2H), 7.52-7.56 (m, 1H), 5.54-5.64 (m, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.34 (d, J = 4.8 Hz, 1H), 3.01 (s, 3H), 2.79 (s, 3H), 1.96-2.06 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H)
MS (ESI ^<+> ) m / z: 534 [M + H] ^< +>.

Example 85
(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl-2-aminoacetate

To a solution of the compound obtained in Reference Example 143 (148 mg) in chloroform (4 mL) was added TFA (1 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (110 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (br. S., 1H), 8.55-8.61 (m, 1H), 8.43 (d, J = 8.8 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.62-7.69 (m, 2H), 7.51-7.55 (m, 1H), 5.61 (s, 2H), 5.01 (s, 2H) , 3.53 (s, 3H), 3.49 (s, 2H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 492 [M + H] ^< +>.

Example 86
(S)-(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl-2-aminopropanoate

To a solution of the compound obtained in Reference Example 144 (152 mg) in chloroform (4 mL) was added TFA (1 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (118 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.75 (br. S., 1H), 8.55-8.60 (m, 1H), 8.41 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.60-7.68 (m, 23H), 7.50-7.54 (m, 1H), 5.54-5.64 (m, 2H), 5.00 (s, 2H), 3.60 (q, J = 7.0 Hz, 1H), 3.53 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 1.33 (d, J = 7.0 Hz, 3H)
MS (ESI ^<+> ) m / z: 506 [M + H] ^< +>.

Example 87
(2- (7-Acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyldihydrogen phosphate hydrochloride

6N Hydrochloric acid (0.5 mL) was added to a solution of the compound (153 mg) obtained in Reference Example 145 in methanol (1.5 mL), and the mixture was stirred at room temperature for 3 days. Acetonitrile (4 mL) was added dropwise to the reaction mixture, and the mixture was stirred at room temperature for 3 hours. The precipitated solid was collected by filtration to give the title compound (116 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.30 (br. S., 1H), 8.63 (d, J = 9.3 Hz, 1H), 8.30-8.37 (m, 2H), 7.85-7.89 (m, 1H), 7.73 (dd, J = 8.5, 7.0 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.58-7.61 (m, 1H), 5.35 (d, J = 6.5 Hz, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 515 [M + H] ^< +>.

Example 88
(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl phosphate disodium salt

To a suspension of the compound obtained in Example 87 (408 mg) in ethanol (8.88 mL) was added 1N aqueous sodium hydroxide solution (2.22 mL), and the mixture was vibrated with ultrasonic waves. The precipitated solid was collected by filtration and washed with a water-ethanol (1: 4) mixture to obtain the title compound (360 mg).
¹ H NMR (D ₂ O, 400 MHz): δ (ppm) 8.20 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.73-7.79 (m, 1H), 7.52- 7.66 (m, 3H), 7.35 (d, J = 7.8 Hz, 1H), 5.10 (d, J = 4.8 Hz, 2H), 4.78-4.80 (m, 2H), 3.51 (s, 3H), 2.77 (s , 3H), 2.53 (s, 3H)
MS (ESI ^<+> ) m / z: 515 [M + H] ^< +>.

Example 89
4-((2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methoxy) -4-oxobutanoic acid

A solution of the compound obtained in Example 79 (700 mg), succinic anhydride (193 mg), triethylamine (0.268 mL) and N, N-dimethyl-4-aminopyridine (9.8 mg) in DMF (12 mL) at 85 ° C. Stir for hours. The reaction mixture was concentrated, an aqueous acetic acid solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was washed with water to give the title compound (781 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.28 (br. S., 1H), 8.55 (d, J = 9.0 Hz, 1H), 8.36 (d, J = 9.3 Hz, 1H), 8.32 (d , J = 7.8 Hz, 1H), 7.85-7.89 (m, 1H), 7.67-7.75 (m, 2H), 7.57-7.60 (m, 1H), 5.57 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H), 2.57-2.62 (m, 2H), 2.50-2.54 (m, 2H)
MS (ESI ^<+> ) m / z: 535 [M + H] ^< +>.

Example 90
4-((2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methoxy) -4-oxobutanoic acid sodium salt

A 1N aqueous sodium hydroxide solution (224 μL) was added to a suspension of the compound (114 mg) obtained in Example 89 in ethanol (1.12 mL), dissolved by heating, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (47 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 11.29 (br. S., 1H), 8.56 (d, J = 9.0 Hz, 1H), 8.29-8.35 (m, 2H), 7.84 (d, J = 8.5 Hz, 1H), 7.66-7.72 (m, 2H), 7.55-7.59 (m, 1H), 5.50 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H ), 2.77 (s, 3H), 2.43 (t, J = 7.2 Hz, 2H), 2.10-2.16 (m, 2H)
MS (ESI ^<+> ) m / z: 535 [M + H] ^< +>.

Example 91
(S)-(2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinolin-5-yl) methyl-2-amino-3-hydroxypropanoate

To a solution of the compound obtained in Reference Example 146 (305 mg) in chloroform (3 mL) was added TFA (3 mL), and the mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform-ethyl acetate (1: 1) mixture: methanol = 99: 1 to 89:11) to obtain the title compound (171 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (br.s., 1H), 8.55-8.62 (m, 1H), 8.41 (d, J = 9.0 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.62-7.69 (m, 2H), 7.53 (d, J = 7.0 Hz, 1H), 5.63 (s, 2H), 5.01 (s , 2H), 3.76-3.82 (m, 1H), 3.68-3.73 (m, 1H), 3.63-3.67 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H )
MS (ESI ^<+> ) m / z: 522 [M + H] ^< +>.

(Example 92)
2- (7-Acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinoline-5-carboxylate methyl

N, N-Diisopropylethylamine (1.56 mL) and HBTU (1.635 g) were added to a suspension of the compound (1.0 g) obtained in Reference Example 74 in chloroform (50 mL), and the mixture was stirred at room temperature for 15 minutes. The compound obtained in Reference Example 148 (726 mg) was added to the reaction mixture, and the mixture was stirred at 50 ° C. for 8 hours and then at 55 ° C. for 6 hours. The reaction mixture was cooled to room temperature, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 99: 1 to 97: 3) to obtain the title compound (1.59 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.39 (d, J = 9.3 Hz, 1H), 8.72 (s, 1H), 8.62 (d, J = 9.3 Hz, 1H), 8.20 (dd, J = 7.3, 1.2 Hz, 1H), 8.10 (d, J = 7.7 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.70 (dd, J = 8.3, 7.5 Hz, 1H), 7.64 (d , J = 7.7 Hz, 1H), 5.01 (s, 2H), 4.03 (s, 3H), 3.53 (s, 3H), 3.01 (s, 3H), 2.80 (s, 3H)
MS (ESI ^<+> ) m / z: 463 [M + H] ^< +>.

(Example 93)
2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamido) quinoline-5-carboxylic acid

A mixture of the compound obtained in Example 92 (41 mg), lithium chloride (18.8 mg) and pyridine (5 mL) was stirred at 170 ° C. for 20 minutes, and stirred at 190 ° C. for 1 hour and 20 minutes. The reaction mixture was concentrated, an aqueous acetic acid solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 97: 3-90: 10) to give the title compound (29 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.33 (s, 1H), 9.33 (d, J = 9.3 Hz, 1H), 8.42 (d, J = 9.5 Hz, 1H), 8.32 (d, J = 7.8 Hz, 1H), 8.17 (dd, J = 7.3, 1.3 Hz, 1H), 8.03-8.11 (m, 1H), 7.82 (dd, J = 8.4, 7.4 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 449 [M + H] ^< +>.

Example 94
2- (7-acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide) -N- (pyrrolidin-1-yl) quinoline-5-carboxamide

Obtained in Example 93 under nitrogen atmosphere in a solution of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (16 mg) and 1-hydroxybenzotriazole (9 mg) in N, N-dimethylacetamide (2 mL) Compound (25 mg) was added and stirred for 1 hour. A solution of triethylamine (17 mg) and pyrrolidin-1-amine hydrochloride (21 mg) in N, N-dimethylacetamide (2 mL) was added to the reaction mixture, and the mixture was stirred overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 1: 1) to give the title compound (6 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.78 (d, J = 9.3 Hz, 1H), 8.51-8.60 (m, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.94 (d , J = 8.0 Hz, 1H), 7.54-7.68 (m, 3H), 5.00 (s, 2H), 3.53 (s, 3H), 3.08-3.19 (m, 4H), 3.00 (s, 3H), 2.79 ( s, 3H), 1.95-2.04 (m, 4H)
MS (ESI ^<+> ) m / z: 517 [M + H] ^< +>.

Example 95
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((morpholin-4-yl) carbonyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

Compound (100 mg) obtained in Reference Example 102, compound (120 mg) obtained in Reference Example 149, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (20.9 mg), cesium carbonate (141 mg), A mixture of tris (dibenzylideneacetone) dipalladium (0) (16.5 mg) and N-methylpyrrolidone (3 mL) was stirred at 135 ° C. for 40 minutes. The reaction mixture was diluted with ethyl acetate and washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 97.5: 2.5) to obtain the title compound (64 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (s, 1H), 8.59 (d, J = 9.3 Hz, 1H), 8.28 (d, J = 9.0 Hz, 1H), 8.11 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.70 (dd, J = 8.4, 7.2 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.41 (dd, J = 7.0, 1.3 Hz, 1H), 5.01 (s, 2H), 3.83-4.04 (m, 4H), 3.51-3.62 (m, 2H), 3.53 (s, 3H), 3.25 (br.s., 2H) , 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

Example 96
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((4-methylpiperazin-1-yl) carbonyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

Compound (95.7 mg) obtained in Reference Example 102, Compound (100 mg) obtained in Reference Example 150, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (20.0 mg), cesium carbonate (135 mg) , A mixture of tris (dibenzylideneacetone) dipalladium (0) (16 mg) and N-methylpyrrolidone (2.5 mL) was stirred at 135 ° C. for 40 minutes. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: chloroform = 30: 70-0: 100) to give the title compound (21 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (s, 1H), 8.58 (d, J = 9.0 Hz, 1H), 8.27 (d, J = 9.0 Hz, 1H), 8.11 (d, J = 7.5 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.69 (dd, J = 8.5, 7.0 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.41 (dd, J = 7.0, 1.0 Hz, 1H), 5.01 (s, 2H), 4.08 (br.s., 1H), 3.86 (br.s., 1H), 3.53 (s, 3H), 3.24 (br.s., 2H), 3.01 (s, 3H), 2.79 (s, 3H), 2.51-2.66 (m, 2H), 2.33 (s, 3H), 2.28-2.32 (m, 1H), 2.22 (br. S., 1H )
MS (ESI ^<+> ) m / z: 533 [M + H] ^< +>.

Example 97
2- (7-Acetyl-4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide) -N, N-dimethylquinoline-5-carboxamide

N, N-diisopropylethylamine (3.1 mL) was added to a suspension of the compound (1.267 g) obtained in Reference Example 152, the compound (1.638 g) obtained in Reference Example 74, and HBTU (3.348 g) in dichloromethane (33.3 mL). The mixture was stirred for 95 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed successively with dilute aqueous acetic acid solution and saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: ethyl acetate = 90: 10 to 20:80) to obtain a crude product. Ethyl acetate (10.5 mL) was added to the obtained crude product and heated to 70 ° C., and then cooled to 0 ° C. The precipitated solid was collected by filtration. The obtained solid was washed with ethyl acetate to give the title compound (2.256 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (s, 1H), 8.56 (d, J = 9.3 Hz, 1H), 8.22 (d, J = 9.3 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.61-7.72 (m, 2H), 7.42 (dd, J = 7.2, 1.1 Hz, 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.27 (s, 3H), 3.01 (s, 3H), 2.85 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 476 [M + H] ^< +>.

Example 98
7-acetyl-N- (5-((azetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Triethylamine (125 μL) was added to a suspension of the compound (68.2 mg) obtained in Reference Example 155, the compound (92 mg) obtained in Reference Example 74 and HBTU (137 mg) in chloroform (3 mL), and the mixture was stirred at 50 ° C. for 22 hours. . Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 95: 5) to obtain the title compound (119 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.75 (br. S., 1H), 8.56-8.62 (m, 2H), 8.10 (d, J = 7.5 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.62-7.70 (m, 2H), 7.51 (dd, J = 7.2, 1.1 Hz, 1H), 5.01 (s, 2H), 4.34 (t, J = 7.8 Hz, 2H), 3.98 (t, J = 7.7 Hz, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.31-2.40 (m, 2H)
MS (ESI ^<+> ) m / z: 488 [M + H] ^< +>.

Example 99
7-acetyl-N- (5-((3-fluoroazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Triethylamine (125 μL) was added to a suspension of the compound obtained in Reference Example 157 (73.6 mg), the compound obtained in Reference Example 74 (92 mg) and HBTU (137 mg) in chloroform (4.5 mL) and stirred at 50 ° C. for 20 hours. did. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 40: 60 to 10:90) to obtain a crude product. The obtained crude product was dissolved in dichloromethane (6 mL), and hexane (6 mL) was added. The precipitated solid was collected by filtration to give the title compound (116 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (s, 1H), 8.60 (s, 2H), 8.11 (d, J = 7.8 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H ), 7.62-7.71 (m, 2H), 7.53 (dd, J = 7.0, 1.0 Hz, 1H), 5.27-5.48 (m, 1H), 5.01 (s, 2H), 4.53-4.68 (m, 1H), 4.34-4.49 (m, 1H), 4.07-4.29 (m, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 506 [M + H] ^< +>.

(Example 100)
7-acetyl-N- (5-((3,3-difluoroazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Triethylamine (125 μL) was added to a suspension of the compound obtained in Reference Example 159 (79 mg), the compound obtained in Reference Example 74 (92 mg) and HBTU (137 mg) in chloroform (4.5 mL), and the mixture was stirred at 50 ° C. for 20 hours. . Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 95: 5) and basic silica gel column chromatography (hexane: dichloromethane = 40: 60 to 20:75) to give the title compound (92 mg). It was.
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.75 (s, 1H), 8.62 (s, 2H), 8.11 (d, J = 7.8 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H ), 7.63-7.72 (m, 2H), 7.56 (dd, J = 7.2, 1.1 Hz, 1H), 5.01 (s, 2H), 4.22-4.73 (m, 4H), 3.53 (s, 3H), 3.01 ( s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 524 [M + H] ^< +>.

(Example 101)
7-acetyl-N- (5-((3-hydroxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

N, N-diisopropylethylamine (210 μL) and HBTU (122 mg) were added to a suspension of the compound (120 mg) obtained in Example 93 in chloroform (30 mL), and the mixture was stirred at room temperature for 20 minutes. 3-hydroxyazetidine hydrochloride (58.6 mg) was added to the reaction mixture, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 90:10) to give the title compound (78 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (s, 1H), 8.56-8.62 (m, 2H), 8.10 (d, J = 7.5 Hz, 1H), 7.93 (d, J = 8.3 Hz , 1H), 7.66 (td, J = 8.8, 7.4 Hz, 2H), 7.50-7.54 (m, 1H), 5.01 (s, 2H), 4.76 (d, J = 4.8 Hz, 1H), 4.53-4.62 ( m, 1H), 4.09-4.20 (m, 2H), 3.87-3.94 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.23-2.30 (m, 1H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

Example 102
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

A mixture of the compound obtained in Reference Example 162 (1.27 g), the compound obtained in Reference Example 74 (1.38 g), HBTU (2.82 g), N, N-diisopropylethylamine (2.63 mL) and chloroform (60 mL) at room temperature. After stirring for 1.5 hours, the mixture was stirred at 40 ° C. for 17.5 hours. A 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 95: 5), and the obtained solid was washed with ethanol to obtain the title compound (1.78 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (s, 1H), 8.59 (s, 2H), 8.10 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H ), 7.62-7.70 (m, 2H), 7.52 (dd, J = 7.0, 1.0 Hz, 1H), 5.01 (s, 2H), 4.44-4.51 (m, 1H), 4.23-4.29 (m, 1H), 4.15-4.21 (m, 1H), 4.04-4.10 (m, 1H), 3.85-3.91 (m, 1H), 3.53 (s, 3H), 3.30 (s, 3H), 3.01 (s, 3H), 2.79 ( s, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 103)
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

Hydrogen chloride (4N 1,4-dioxane solution, 2.66 mL) was added dropwise to a suspension of the compound (5.0 g) obtained in Example 102 in methanol (20 mL) at room temperature, and the mixture was stirred at room temperature for 10 minutes, then 50 ° For 10 minutes. The reaction mixture was cooled to room temperature and stirred overnight. The reaction mixture was cooled to 4 ° C., and the precipitated solid was collected by filtration to give the title compound (2.817 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 11.97 (br. S., 1H), 9.11 (d, J = 9.5 Hz, 1H), 8.91 (d, J = 9.5 Hz, 1H), 8.29 ( d, J = 8.5 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.91 (dd, J = 8.4, 7.4 Hz, 1H), 7.71 (dd, J = 7.3, 1.0 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 5.00 (s, 2H), 4.45-4.52 (m, 1H), 4.26-4.33 (m, 1H), 4.16-4.23 (m, 2H), 3.96-4.02 ( m, 1H), 3.52 (s, 3H), 3.33 (s, 3H), 3.06 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 104)
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide benzenesulfone Acid salt

Benzenesulfonic acid monohydrate (412 mg) was added to a suspension of the compound (1.10 g) obtained in Example 102 in methanol (5.5 mL) at room temperature, heated to 70 ° C., cooled to room temperature, and stirred overnight. did. The reaction mixture was cooled to 4 ° C., and the precipitated solid was collected by filtration to give the title compound (1.176 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 9.11-9.18 (m, 1H), 8.87 (d, J = 9.8 Hz, 1H), 8.43-8.51 (m, 1H), 8.09 (d, J = 7.5 Hz, 1H), 7.83-7.93 (m, 3H), 7.69-7.74 (m, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.25-7.35 (m, 5H), 4.95 (s, 2H ), 4.44-4.53 (m, 1H), 4.26-4.33 (m, 1H), 4.15-4.22 (m, 2H), 3.94-4.01 (m, 1H), 3.49 (s, 3H), 3.33 (s, 3H ), 2.93 (s, 3H), 2.78 (s, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 105)
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide methanesulfone Acid salt

Methanesulfonic acid (207 μL) was added to a suspension of the compound (1.5 g) obtained in Example 102 in acetonitrile (4.5 mL) at room temperature, heated to 40 ° C., cooled to room temperature, and stirred overnight. The reaction mixture was cooled to 0 ° C., and the precipitated solid was collected by filtration to give the title compound (1.0 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 12.58 (br. S., 1H), 9.14 (d, J = 9.0 Hz, 1H), 8.94 (d, J = 9.5 Hz, 1H), 8.48 ( d, J = 8.8 Hz, 1H), 8.11 (d, J = 7.5 Hz, 1H), 7.88-7.94 (m, 1H), 7.69-7.74 (m, 1H), 7.64 (d, J = 7.8 Hz, 1H ), 5.01 (s, 2H), 4.45-4.52 (m, 1H), 4.26-4.33 (m, 1H), 4.16-4.24 (m, 2H), 3.95-4.01 (m, 1H), 3.51 (s, 3H ), 3.33 (s, 3H), 3.00 (s, 3H), 2.98 (s, 3H), 2.76 (s, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 106)
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p- Toluene sulfonate

P-Toluenesulfonic acid monohydrate (409 mg) was added to a suspension of the compound (1.012 g) obtained in Example 102 in ethanol (5.0 mL) at room temperature, heated to 90 ° C., and then cooled to room temperature. Stir overnight. The reaction mixture was cooled to 4 ° C., and the precipitated solid was collected by filtration. The obtained solid was washed with ethanol to give the title compound (1.175 g).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 12.67 (br. S., 1H), 9.10-9.17 (m, 1H), 8.86 (d, J = 9.8 Hz, 1H), 8.43-8.50 (m , 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.86-7.93 (m, 1H), 7.69-7.75 (m, 3H), 7.63 (d, J = 7.8 Hz, 1H), 7.02-7.07 ( m, 2H), 4.95 (s, 2H), 4.44-4.52 (m, 1H), 4.27-4.33 (m, 1H), 4.16-4.23 (m, 2H), 3.97 (d, J = 5.8 Hz, 1H) , 3.49 (s, 3H), 3.33 (s, 3H), 2.93 (s, 3H), 2.78 (s, 3H), 2.29 (s, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 107)
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide bromide Hydronate

To a suspension of the compound (400 mg) obtained in Example 102 in methanol (20 mL) was added 48% hydrobromic acid (90 μL) at room temperature, and the mixture was stirred for 10 minutes. The reaction mixture was concentrated and 2-propanol (25 mL) was added and stirred. The reaction mixture was concentrated, ethanol (25 mL) was added and stirred for 30 minutes. The reaction mixture was concentrated, 2-propanol (25 mL) was added, and the mixture was stirred overnight at room temperature. The precipitated solid was collected by filtration to give the title compound (328 mg).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 8.57 (d, J = 9.3 Hz, 1H), 8.31-8.37 (m, 2H), 7.96 (d, J = 8.5 Hz, 1H), 7.79-7.75 ( m, 1H), 7.69 (d, J = 7.5 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 5.02 (s, 2H), 4.34-4.38 (m, 1H), 4.24-4.29 (m , 1H), 4.10-4.14 (m, 1H), 3.98-3.95 (m, 1H), 3.79-3.85 (m, 1H), 3.42 (s, 3H), 3.21 (s, 3H), 2.83 (s, 3H ), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 518 [M + H] ^< +>.

(Example 108)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-methylquinolin-2-yl) benzo [b] thiophene-2-carboxamide

Triethylamine (166 μL) was added to a suspension of the compound obtained in Reference Example 163 (63.3 mg), the compound obtained in Reference Example 74 (122 mg) and HBTU (182 mg) in chloroform (4 mL) and stirred at 50 ° C. for 23 hours. . Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (hexane: dichloromethane = 55: 45-40: 60), and the obtained solid was washed with ethyl acetate to give the title compound (102 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.72 (br. S., 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 9.3 Hz, 1H), 8.09 ( d, J = 7.5 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.54-7.60 (m, 1H), 7.30 (d, J = 7.0 Hz, 1H), 5.01 (s, 2H), 3.52 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.70 (s, 3H)
MS (ESI ^<+> ) m / z: 419 [M + H] ^< +>.

(Example 109)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

N, N-Diisopropylethylamine (122 μL) and HBTU (116.5 mg) were added to a suspension of the compound (77.7 mg) obtained in Reference Example 74 in chloroform (2 mL), and the mixture was stirred at room temperature for 20 minutes. The compound (66 mg) obtained in Reference Example 164 was added to the reaction mixture, and the mixture was stirred at 60 ° C. for 4.5 hours. The reaction mixture was cooled to room temperature, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 97.5: 2.5) to obtain the title compound (90 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.29 (br. S., 1H), 8.76 (d, J = 9.3 Hz, 1H), 8.30-8.35 (m, 2H), 7.90 (d, J = 8.3 Hz, 1H), 7.77 (dd, J = 8.4, 7.2 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.61 (dd, J = 7.3, 1.0 Hz, 1H), 5.09 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 3.05 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 497 [M + H] ^< +>.

(Example 110)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide hydrochloride

To a suspension of the compound obtained in Example 109 (76 mg) in methanol / ethyl acetate (2 mL / 2 mL) was added hydrogen chloride (4N ethyl acetate solution, 77 μL), and the mixture was concentrated. The obtained solid was washed with ethyl acetate to give the title compound (78 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.31 (br.s., 1H), 8.78 (d, J = 9.3 Hz, 1H), 8.29-8.34 (m, 2H), 7.91 (d, J = 8.8 Hz, 1H), 7.75-7.81 (m, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 7.3 Hz, 1H), 5.09 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 3.05 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 497 [M + H] ^< +>.

(Example 111)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide methanesulfonate

Methanesulfonic acid (39 μL) and dichloromethane (5 mL) were added to a suspension of the compound (290 mg) obtained in Example 109 in methanol (10 mL). Diethyl ether (40 mL) was added to the reaction mixture, and the precipitated solid was collected by filtration and washed with diethyl ether (5 mL) to give the title compound (311 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 9.20 (d, J = 9.5 Hz, 1H), 8.34 (d, J = 7.8 Hz, 1H), 8.25 (d, J = 8.5 Hz, 1H), 8.05 (dd, J = 8.5, 7.5 Hz, 1H), 7.94 (d, J = 9.5 Hz, 1H), 7.90 (dd, J = 7.3, 0.8 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H) , 5.14 (s, 2H), 5.03 (s, 2H), 3.50 (s, 3H), 3.11 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.69 (s, 3H)
MS (ESI ^<+> ) m / z: 497 [M + H] ^< +>.

(Example 112)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (5-((methylsulfonyl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide hydrobromide

48% hydrobromic acid (4.26 mL) was added to a chloroform (6.4 L) solution of the compound obtained in Example 109 (16.64 g) at room temperature, and the mixture was stirred for 1 hour. The reaction mixture was concentrated, ethanol (400 mL) was added to the residue, and the mixture was stirred at room temperature for 1 hr. The solid was collected by filtration and washed with ethanol (100 mL) to give the title compound (18.69 g).
¹ H NMR (DMSO, 400 MHz): δ (ppm) 8.81 (d, J = 9.3 Hz, 1H), 8.29-8.34 (m, 2H), 7.94 (d, J = 8.5 Hz, 1H), 7.82-7.78 ( m, 1H), 7.69 (d, J = 7.5 Hz, 1H), 7.63 (d, J = 7.5 Hz, 1H), 5.10 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 3.06 (s, 3H), 2.85 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 497 [M + H] ^< +>.

(Example 113)
7-acetyl-4- (hydroxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Acetic acid (13 μL) and tetrabutylammonium fluoride (1M THF solution, 220 μL) were added to a THF (6 mL) solution of the compound obtained in Reference Example 167 (85.0 mg), and the mixture was stirred at room temperature overnight. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was heated by adding an ethyl acetate-hexane mixture and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (57.0 mg).
¹ H NMR (CDCl ₃ , 400MHz): δ (ppm) 8.15-8.47 (m, 3H), 7.67-7.82 (m, 2H), 7.54-7.66 (m, 1H), 7.34-7.47 (m, 1H), 5.12-5.16 (m, 1H), 5.14 (s, 2H), 4.81-4.87 (m, 2H), 3.36 (s, 3H), 3.28 (s, 3H), 1.98 (s, 3H).

(Example 114)
7-acetyl-4- (hydroxymethyl) -N- (5- (hydroxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Acetic acid (18 μL) and tetrabutylammonium fluoride (1M THF solution, 315 μL) were added to a dichloromethane / THF (2 mL / 2 mL) solution of the compound (87 mg) obtained in Reference Example 168 at room temperature, and the mixture was stirred at room temperature overnight. Tetrabutylammonium fluoride (1M THF solution, 315 μL) was added to the reaction mixture, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform: methanol = 97.5: 2.5 to 90:10) to obtain the title compound (35 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.18 (br.s., 1H), 8.60 (d, J = 9.0 Hz, 1H), 8.28-8.34 (m, 2H), 7.74-7.79 (m, 2H), 7.67-7.72 (m, 1H), 7.52-7.56 (m, 1H), 5.61 (t, J = 5.3 Hz, 1H), 5.40 (t, J = 5.5 Hz, 1H), 5.13-5.17 (m , 2H), 4.94-4.99 (m, 2H), 2.85 (s, 3H), 2.76 (s, 3H)
MS (ESI ^<+> ) m / z: 421 [M + H] ^< +>.

(Example 115)
7-acetyl-4- (hydroxymethyl) -N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Acetic acid (18.8 μL) and tetrabutylammonium fluoride (1M THF solution, 330 μL) were added to a THF (10 mL) solution of the compound obtained in Reference Example 169 (145 mg), and the mixture was stirred at room temperature for 1 hour. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The obtained solid was washed with a mixed solution of ethyl acetate-hexane (1: 1) to obtain the title compound (82 mg).
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.27 (s, 1H), 8.56 (d, J = 9.3 Hz, 1H), 8.31-8.40 (m, 2H), 7.94 (d, J = 8.3 Hz, 1H), 7.74-7.79 (m, 2H), 7.60-7.63 (m, 1H), 5.61 (t, J = 5.4 Hz, 1H), 5.15 (d, J = 5.3 Hz, 2H), 4.33-4.39 (m , 1H), 4.23-4.29 (m, 1H), 4.09-4.15 (m, 1H), 3.94-3.99 (m, 1H), 3.79-3.84 (m, 1H), 3.21 (s, 3H), 2.84 (s , 3H), 2.76 (s, 3H)
MS (ESI ^<+> ) m / z: 504 [M + H] ^< +>.

(Example 116)
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) ( ² H ₂ ) methyl) quinolin-2-yl) -4- (methoxy ( ² H ₂ ) methyl)- 3-Methylbenzo [b] thiophene-2-carboxamide

A solution of the compound (286 mg) obtained in Reference Example 174, HBTU (486 mg) and N, N-diisopropylethylamine (0.445 mL) in DMF (10 mL) was stirred for 20 minutes, and then the compound (250 mg) obtained in Reference Example 176 was obtained. The mixture was further stirred at room temperature for 24 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to give the title compound (240 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.77 (br. S., 1H), 8.50 (br. S., 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.63-7.70 (m, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.44-7.50 (m, 1H), 4.34-4.40 (m, 1H), 3.51 (s, 3H), 2.98 (s, 3H), 2.96-3.05 (m, 1H), 2.83 (d, J = 9.7 Hz, 1H), 2.78 (s, 3H) , 2.66-2.71 (m, 1H), 2.44-2.52 (m, 1H), 2.19-2.29 (m, 1H), 1.75-1.86 (m, 1H)
MS (ESI ⁺ ) m / z: 508 [M + H] ⁺ .

(Example 117)
7-acetyl-4- (methoxymethyl) -N- (5-(( ² H ₃ ) methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Compound (90 mg) obtained in Reference Example 102, compound (68.4 mg) obtained in Reference Example 177, copper (I) iodide (61.8 mg), potassium carbonate (135 mg), N, N′-dimethylethylenediamine (57.2 mg) ) And N, N-dimethylacetamide (3 mL) were stirred at 162 ° C. for 3 hours under an argon atmosphere. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 80:20) to obtain a crude product. Ethyl acetate was added to the obtained crude product and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (60 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68-8.77 (m, 1H), 8.53 (br. S., 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.82-7.86 (m , 1H), 7.60-7.67 (m, 2H), 7.42-7.47 (m, 1H), 7.33-7.38 (m, 1H), 5.00 (s, 2H), 4.88 (s, 2H), 3.52 (s, 3H ), 3.00 (s, 3H), 2.78 (s, 3H)
MS (ESI ^<+> ) m / z: 452 [M + H] ^< +>.

(Example 118)
7-acetyl -4 - ⁽⁽² H ₃₎ methoxymethyl)-N-(5-(methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide

Triethylamine (258 μL) and HBTU (324 mg) were added to a 1,2-dichloroethane solution (7 mL) of the compound (200 mg) obtained in Reference Example 183 at room temperature, and the mixture was stirred at room temperature for 1 hour. The compound (134 mg) obtained in Reference Example 127 was added to the reaction mixture, and the mixture was stirred at 40 ° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane (1: 1) mixture: methanol = 100: 0 to 90:10) to give the title compound (140 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.71 (s, 1H), 8.54 (s, 2H), 8.09 (d, J = 7.5 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H ), 7.60-7.66 (m, 2H), 7.45 (d, J = 6.5 Hz, 1H), 5.01 (s, 2H), 4.89 (s, 2H), 3.45 (s, 3H), 3.00 (s, 3H) , 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 452 [M + H] ^< +>.

(Example 119)
7-Acetyl-N- (5- (hydroxy ( ² H ₂ ) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

The title compound was obtained in the same manner as in Example 71 by using the compound obtained in Reference Example 187 instead of the compound obtained in Reference Example 130 as a starting material in Example 71.
¹ H NMR (DMSO, 400MHz): δ (ppm) 11.38 (br. S., 1H), 8.67 (d, J = 9.3 Hz, 1H), 8.33 (d, J = 7.8 Hz, 1H), 8.28 (d , J = 9.3 Hz, 1H), 7.81-7.85 (m, 1H), 7.68-7.76 (m, 2H), 7.55-7.59 (m, 1H), 5.01 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H)
MS (ESI ^<+> ) m / z: 437 [M + H] ^< +>.

(Example 120)
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4-(( ² H ₃ ) methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide

Compound (200 mg) obtained in Reference Example 188, compound (138 mg) obtained in Reference Example 111, copper (I) iodide (136 mg), potassium carbonate (296 mg), N, N′-dimethylethylenediamine (126 mg) and N , N-dimethylacetamide (3 mL) was stirred at 162 ° C. for 3 h under argon atmosphere. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 80:20) to obtain a crude product. Ethyl acetate was added to the obtained crude product and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (19 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.76 (br. S., 1H), 8.56 (s, 2H), 8.09 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.60-7.66 (m, 2H), 7.48 (d, J = 7.0 Hz, 1H), 5.11-5.18 (m, 2H), 5.00 (s, 2H), 2.99 (s, 3H), 2.79 (s, 3H)
MS (ESI ⁺ ) m / z: 438 [M + H] ⁺ .

(Example 121)
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4-(( ² H ₃ ) methoxymethyl) -3-methylbenzo [b] thiophene- 2-carboxamide

N, N-Diisopropylethylamine (59 μL) and HBTU (61 mg) were added to a chloroform (3 mL) solution of the compound (38 mg) obtained in Reference Example 183, and the mixture was stirred at room temperature for 20 minutes. The compound (35 mg) obtained in Reference Example 162 was added to the reaction mixture, and the mixture was stirred at 40 ° C. overnight. The reaction mixture was cooled to room temperature, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99: 1 to 96: 4) to obtain the title compound (54 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.73 (s, 1H), 8.59 (s, 2H), 8.10 (d, J = 7.5 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H ), 7.62-7.70 (m, 2H), 7.49-7.54 (m, 1H), 5.01 (s, 2H), 4.45-4.51 (m, 1H), 4.23-4.29 (m, 1H), 4.15-4.21 (m , 1H), 4.03-4.10 (m, 1H), 3.85-3.90 (m, 1H), 3.30 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI ⁺ ) m / z: 521 [M + H] ⁺ .

(Example 122)
7-acetyl-N- (5-((3- ( ² H ₃ ) methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene- 2-carboxamide

N, N-Diisopropylethylamine (67 μL) and HBTU (70 mg) were added to a chloroform (4 mL) solution of the compound (42.8 mg) obtained in Reference Example 74 at room temperature, and the mixture was stirred at room temperature for 20 minutes. The compound obtained in Reference Example 193 (40 mg) was added to the reaction mixture, and the mixture was stirred at 60 ° C. for 12 hours. The reaction mixture was cooled to room temperature, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99.5: 0.5 to 96: 4) to obtain the title compound (73 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (s, 1H), 8.58 (s, 2H), 8.10 (d, J = 7.5 Hz, 1H), 7.93 (d, J = 8.5 Hz, 1H ), 7.62-7.70 (m, 2H), 7.51 (dd, J = 7.0, 1.0 Hz, 1H), 5.01 (s, 2H), 4.44-4.52 (m, 1H), 4.22-4.29 (m, 1H), 4.14-4.20 (m, 1H), 4.03-4.10 (m, 1H), 3.84-3.91 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI ⁺ ) m / z: 521 [M + H] ⁺ .

(Example 123)
7- Acetyl -N- (5 - ((3- ( 2 H 3) methoxy-1-yl) carbonyl) quinolin-2-yl) -4- (methoxy ⁽² H ₂₎ methyl) -3-methylbenzo [b] thiophene-2-carboxamide

N, N-Diisopropylethylamine (67 μL) and HBTU (70 mg) were added to a solution of the compound (43 mg) obtained in Reference Example 174 in chloroform (4 mL) at room temperature, and the mixture was stirred at room temperature for 20 minutes. The compound (40 mg) obtained in Reference Example 193 was added to the reaction mixture, and the mixture was stirred at 60 ° C. for 15 hours. The reaction mixture was cooled to room temperature, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 99.5: 0.5 to 96: 4) to obtain the title compound (69 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.74 (s, 1H), 8.58 (s, 2H), 8.10 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 8.5 Hz, 1H ), 7.62-7.70 (m, 2H), 7.52 (dd, J = 7.2, 1.1 Hz, 1H), 4.44-4.51 (m, 1H), 4.22-4.30 (m, 1H), 4.14-4.20 (m, 1H ), 4.03-4.10 (m, 1H), 3.84-3.90 (m, 1H), 3.52 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI ^<+> ) m / z: 523 [M + H] ^< +>.

(Example 124)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (4- (piperazin-1-ylmethyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

(1) 4- (Piperazin-1-ylmethyl) quinolin-2-amine
To a solution of 4- (bromomethyl) -2-chloroquinoline (1.28 g) and triethylamine (836 μL) in acetonitrile (10 mL) was added tert-butylpiperazine-1-carboxylate (931 mg), and the mixture was stirred at room temperature for 3 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. 4-methoxybenzylamine (3.27 mL) was added to the residue, and the mixture was stirred at 100 ° C. for 20 hours under an argon atmosphere. The reaction mixture was dissolved in dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. Toluene (1.62 mL) and methanesulfonic acid (1.62 mL) were added to the residue, and the mixture was stirred at 80 ° C. for 20 hr. 4N sodium hydroxide was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was washed with ethyl acetate to give the title compound (530 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.01 (d, J = 8.5 Hz, 1H), 7.46-7.54 (m, 2H), 7.19-7.25 (m, 1H), 6.88 (s, 1H), 3.79 (s, 2H), 3.29-3.32 (m, 4H), 2.82-2.87 (m, 4H), 2.52 (br. S., 4H)
MS (ESI ^<+> ) m / z: 243 [M + H] ^< +>.
(2) tert-Butyl 4-((2-aminoquinolin-4-yl) methyl) piperazine-1-carboxylate To a solution of the compound obtained in (1) (145 mg) and triethylamine (88 μL) in dichloromethane (3 mL) Di-tert-butyl dicarbonate (229 mg) was added and stirred at room temperature for 2 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated to give the title compound (253 mg).
MS (ESI ^<+> ) m / z: 343 [M + H] ^< +>.
(3) 7-acetyl-4- (methoxymethyl) -3-methyl-N- (4- (piperazin-1-ylmethyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide obtained in Reference Example 74 N, N-diisopropylethylamine (209 μL) was added to a suspension of the compound (167 mg), the compound obtained in (2) (253 mg) and PyBOP (375 mg) in dichloromethane (3 mL), and the mixture was stirred at room temperature for 20 hours. . TFA (1.5 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 6 hours. The reaction mixture was diluted with dichloromethane and extracted with 0.5N hydrochloric acid. The aqueous layer was basified with 4N aqueous sodium hydroxide solution and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was washed with a dichloromethane-hexane (1: 1) mixture to obtain the title compound (113 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.48 (br.s., 1H), 8.26 (d, J = 7.3 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.86 ( d, J = 8.1 Hz, 1H), 7.61-7.70 (m, 2H), 7.46-7.51 (m, 1H), 5.01 (s, 2H), 3.94 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.93 (t, J = 4.9 Hz, 4H), 2.79 (s, 3H), 2.56 (br. s., 4H)
MS (ESI ^<+> ) m / z: 503 [M + H] ^< +>.

(Example 125)
7-acetyl-4- (methoxymethyl) -3-methyl-N- (4-((4-methylpiperazin-1-yl) methyl) quinolin-2-yl) benzo [b] thiophene-2-carboxamide

(1) 4-((4-Methylpiperazin-1-yl) methyl) quinolin-2-amine
1-Methylpiperazine (555 μL) was added to a solution of 4- (bromomethyl) -2-chloroquinoline (1.28 g) and triethylamine (836 μL) in acetonitrile (10 mL), and the mixture was stirred at room temperature for 3 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. 4-methoxybenzylamine (3.27 mL) was added to the residue, and the mixture was stirred at 100 ° C. for 20 hours under an argon atmosphere. The reaction mixture was dissolved in dichloromethane and dry ice was added. The precipitated solid was collected by filtration, and the filtrate was concentrated. Toluene (1.62 mL) and methanesulfonic acid (1.62 mL) were added to the residue, and the mixture was stirred at 80 ° C. for 20 hr. 4N sodium hydroxide was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was washed with ethyl acetate to give the title compound (356 mg).
¹ H NMR (MeOD, 400MHz): δ (ppm) 8.01 (d, J = 7.7 Hz, 1H), 7.46-7.54 (m, 2H), 7.19-7.25 (m, 1H), 6.86 (s, 1H), 3.82 (d, J = 0.8 Hz, 2H), 2.34-2.75 (m, 8H), 2.28 (s, 3H)
MS (ESI ^<+> ) m / z: 257 [M + H] ^< +>.
(2) 7-acetyl-4- (methoxymethyl) -3-methyl-N- (4-((4-methylpiperazin-1-yl) methyl) quinolin-2-yl) benzo [b] thiophen-2- Carboxamide N, N-diisopropylethylamine (174 μL) was added to a suspension of the compound (139 mg) obtained in Reference Example 74, the compound (128 mg) obtained in (1) above and PyBOP (312 mg) in dichloromethane (2.5 mL). And stirred at room temperature for 20 hours. The reaction mixture was diluted with dichloromethane and extracted with 0.5N hydrochloric acid. The aqueous layer was basified with 4N aqueous sodium hydroxide solution and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by basic silica gel column chromatography (dichloromethane: methanol = 100: 0 to 90:10) to obtain the title compound (133 mg).
¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) 8.68 (br. S., 1H), 8.50 (br. S., 1H), 8.24 (d, J = 8.1 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.61-7.70 (m, 2H), 7.45-7.50 (m, 1H), 5.00 (s, 2H), 3.97 (s, 2H ), 3.52 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.63 (br. S, 4H), 2.49 (br. S., 4H), 2.30 (s, 3H)
MS (ESI ^<+> ) m / z: 517 [M + H] ^< +>.

  In the following Test Examples 1 and 2, the compounds synthesized in Example 39, Example 68, Example 77, and Example 106 were used.

Example 39:
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide

In addition, this compound can also be described with the following names:
7-acetyl-N- (4-{[(3R) -3-hydroxypyrrolidin-1-yl] methyl} quinolin-2-yl) -4- (methoxymethyl) -3-methyl-1-benzothiophene-2 -Carboxamide.

Example 68:
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

In addition, this compound can also be described with the following names:
7-acetyl-4- (methoxymethyl) -N- [5- (methoxymethyl) quinolin-2-yl] -3-methyl-1-benzothiophene-2-carboxamide hydrochloride.

Example 77
7-Acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride

In addition, this compound can also be described with the following names:
7-acetyl-N- [5- (hydroxymethyl) quinolin-2-yl] -4- (methoxymethyl) -3-methyl-1-benzothiophene-2-carboxamide hydrochloride.

Example 106:
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p- Toluene sulfonate

In addition, this compound can also be described with the following names:
7-acetyl-N- {5-[(3-methoxyazetidin-1-yl) carbonyl] quinolin-2-yl} -4- (methoxymethyl) -3-methyl-1-benzothiophene-2-carboxamide tosyl Acid salt.

(Test Example 1)
Suppressive effect on spontaneous locomotor activity in rats induced by repeated PCP administration: Effect of single administration CD (SD) male rats (6 weeks old at the start of the study) supplied by Charles River Japan Co., Ltd. were used for the study It was. PCP (2 mg / kg) was repeatedly subcutaneously administered once a day for 5 days, and the test substance was orally administered about 1 hour before PCP administration only on the 5th day. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. Four measurement fields (40 cm long x 40 cm wide, 40 cm high, Muromachi Kikai Co., Ltd.) were placed side by side, and the spontaneous momentum of rats was measured using behavior analysis software (ANY-maze 4.72, Stoelting Co.). .
Repeated subcutaneous administration of PCP (2 mg / kg) once a day for 5 days significantly increased the locomotor activity of rats (about 10 times that of the vehicle group). Anti-psychotic haloperidol (1 mg / kg) (Figure 1), risperidone (0.3, 1 mg / kg) (Figure 2), quetiapine fumarate (Figure 2) 100 mg / kg) (Fig. 3) and aripiprazole (100 mg / kg) (Fig. 4) pre-administered significant inhibitory effects. Example 39 (10, 30 mg / kg) (Figure 5), Example 68 (3 mg / kg) (Figure 6), Example 77 (1, 3 mg / kg) (Figure 7), Example 106 ( Pre-administration of 1, 3 mg / kg (Fig. 8) also showed a significant inhibitory effect as with antipsychotic drugs.

(Test Example 2)
Suppressive effect on spontaneous locomotor activity in rats induced by repeated PCP administration: Effects of combined administration CD (SD) male rats (6 weeks old at the start of the study) supplied by Charles River Japan Co., Ltd. were used for the study It was. PCP (2 mg / kg) was repeatedly subcutaneously administered once a day for 5 days. On the fifth day, the antipsychotic and the compound of the present invention were orally administered about 1 hour before the PCP administration. Rat locomotor activity was measured for 60 minutes immediately after PCP administration. Four measurement fields (40 cm long x 40 cm wide, 40 cm high, Muromachi Kikai Co., Ltd.) were placed side by side, and the spontaneous momentum of rats was measured using behavior analysis software (ANY-maze 4.72, Stoelting Co.). . A combination of 1/3 of the lowest effective dose that showed an inhibitory effect on the spontaneous motor momentum induced by PCP, ie haloperidol (0.3 mg / kg), risperidone (0.1 mg / kg) , Combination use of quetiapine fumarate (30 mg / kg) or aripiprazole (30 mg / kg) and Example 39 (3 mg / kg) (Fig. 9), Example 68 (1 mg / kg) ( Figure 10), spontaneous use of rats induced by repeated administration of PCP by combination with Example 77 (0.3 mg / kg) (Figure 11) or combination with Example 106 (0.3 mg / kg) (Figure 12) Increased momentum was significantly suppressed.

(Formulation example)
A compound is obtained by mixing 5 g of compound, 90 g of lactose, 34 g of corn starch, 20 g of crystalline cellulose and 1 g of magnesium stearate with a blender and then tableting with a tableting machine.

  The compound represented by the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof is effective for schizophrenia when combined with an existing antipsychotic drug based on its potent PDE10A inhibitory activity, It is useful as a medicine.

Claims (13)

A medicament for the treatment of schizophrenia, characterized in that a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug are administered in combination: .
(Where
R ¹ is a hydrogen atom or a C1-C3 alkyl group,
R ² is a hydrogen atom, a C1-C3 alkylcarbonyl group, a hydroxy C1-C3 alkyl group or a C1-C3 alkoxy C1-C3 alkyl group,
R ³ is a C1-C6 alkyl group or a C3-C6 cycloalkyl group,
R ⁴ and R ⁵ are each independently selected from a hydrogen atom, a C1-C6 alkyl group optionally substituted with one substituent selected from substituent group α, or a substituent group α. (Azetidin-1-yl) carbonyl group optionally substituted by one substituent,
Substituent group α is a group consisting of a hydroxy group, a C1-C6 alkoxy group, a methylsulfonyl group, a hydroxypyrrolidine group, and a hydroxypiperidine group,
Provided that at least one of R ⁴ and R ⁵ is a hydrogen atom)   The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent are contained as active ingredients of different formulations, and are administered at the same time or at different times. The medicament according to claim 1, wherein   The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic agent are contained in a single preparation. Medicine.   The medicament according to claim 1, which is a kit preparation comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and at least one antipsychotic drug.   Any one selected from 1 to 4 for a patient undergoing treatment with a pharmaceutical composition containing a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient The medicine according to one item.   The medicine according to any one of claims 1 to 4, which is intended for a patient who is receiving treatment with an antipsychotic drug. R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, and R ⁴ and R ⁵ are each independently a hydrogen atom , A C1-C3 alkyl group which may be substituted with one substituent selected from substituent group α, or may be substituted with one substituent selected from substituent group α ( Azetidin-1-yl) carbonyl group, and the substituent group α is a group consisting of a hydroxy group, a C1-C3 alkoxy group, and a hydroxypyrrolidine group, provided that at least one of R ⁴ and R ⁵ is a hydrogen atom. The medicament according to any one of claims 1 to 6, selected from claims 1 to 6. R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, R ⁴ is a hydrogen atom, and R ⁵ is one A C1-C3 alkyl group substituted with a hydroxy group, a C1-C3 alkyl group substituted with one C1-C3 alkoxy group, or a 3-position substituted with one C1-C3 alkoxy group The medicament according to any one of claims 1 to 6, which is (azetidin-1-yl) carbonyl group. R ¹ is a C1-C3 alkyl group, R ² is a C1-C3 alkoxy C1-C3 alkyl group, R ³ is a C1-C3 alkyl group, and R ⁴ is one (3-hydroxypyrrolidine-1 - yl) a C1~C3 alkyl group substituted with a group the medicament according to any one of R ⁵ is selected from claims 1 to 6 is a hydrogen atom. A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof,
(R) -7-acetyl-N- (4-((3-hydroxypyrrolidin-1-yl) methyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2- Carboxamide,
7-acetyl-N- (5-((3-methoxyazetidin-1-yl) carbonyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide p- Toluene sulfonate,
7-acetyl-4- (methoxymethyl) -N- (5- (methoxymethyl) quinolin-2-yl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride, or
7-acetyl-N- (5- (hydroxymethyl) quinolin-2-yl) -4- (methoxymethyl) -3-methylbenzo [b] thiophene-2-carboxamide hydrochloride selected from 1 to 6 The medicament according to any one of the above. Antipsychotic drugs
4- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -1- (4-fluorophenyl) butan-1-one,
3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -2-methyl-6,7,8,9-tetrahydro-4H -Pyrido [1,2-a] pyrimidin-4-one,
Cis-N- [4- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] butyl] cyclohexane-1,2-dicarboximide,
(9RS) -3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -9-hydroxy-2-methyl-6,7 , 8,9-Tetrahydro-4H-pyrido [1,2-a] pyrimidin-4-one,
5- [2- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] ethyl] -6-chloro-1,3-dihydro-2H-indol-2-one,
Trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz [2,3: 6,7] oxepino [4,5-c] pyrrole,
(3aR, 4S, 7R, 7aS) -2-{(1R, 2R) -2- [4- (1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl] cyclohexylmethyl} hexahydro-4, 7-methano-2H-isoindole-1,3-dione,
2- (4-ethyl-1-piperazinyl) -4- (4-fluorophenyl) -5,6,7,8,9,10-hexahydrocycloocta [b] pyridine,
2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol,
2-methyl-4- (4-methylpiperazin-1-yl) -10H-thieno [2,3-b] [1,5] benzodiazepine,
8-chloro-11- (4-methylpiperazin-1-yl) -5H-dibenzo [b, e] [1,4] diazepine,
7- [4- [4- (1-benzothiophen-4-yl) piperazin-1-yl] butoxy] quinolin-2 (1H) -one, or
7- [4- [4- (2,3-dichlorophenyl) -1-piperazinyl] butoxy] -3,4-dihydro-2 (1H) -quinolinone or a pharmaceutically acceptable salt thereof. The medicament according to any one of 10 selected from 10. Antipsychotic drugs
4- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -1- (4-fluorophenyl) butan-1-one,
3- {2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl] ethyl} -2-methyl-6,7,8,9-tetrahydro-4H -Pyrido [1,2-a] pyrimidin-4-one,
2- [2- (4-dibenzo [b, f] [1,4] thiazepine-11-ylpiperazin-1-yl) ethoxy] ethanol hemi-fumarate, or
11. Any one selected from 1 to 10 which is 7- [4- [4- (2,3-dichlorophenyl) -1-piperazinyl] butoxy] -3,4-dihydro-2 (1H) -quinolinone. The medicament according to 1. A method for treating schizophrenia, comprising administering a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof in combination with at least one antipsychotic agent.
(Where
R ¹ is a hydrogen atom or a C1-C3 alkyl group,
R ² is a hydrogen atom, a C1-C3 alkylcarbonyl group, a hydroxy C1-C3 alkyl group or a C1-C3 alkoxy C1-C3 alkyl group,
R ³ is a C1-C6 alkyl group or a C3-C6 cycloalkyl group,
R ⁴ and R ⁵ are each independently selected from a hydrogen atom, a C1-C6 alkyl group optionally substituted with one substituent selected from substituent group α, or a substituent group α. (Azetidin-1-yl) carbonyl group optionally substituted by one substituent,
Substituent group α is a group consisting of a hydroxy group, a C1-C6 alkoxy group, a methylsulfonyl group, a hydroxypyrrolidine group, and a hydroxypiperidine group,
Provided that at least one of R ⁴ and R ⁵ is a hydrogen atom)